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Abstract
This thesis presents a critical evaluation of the clinical and microbiological
background to the study of infection in the intensive therapy unit (ITU), the
development and importance of the B-lactam antibiotics and the mechanisms and
genetics of resistance to them, with emphasis on the commonest and continually
evolving cause of 6-lactam resistance, the 13-lactamases.
A selective parenteral and enteral antisepsis regimen (SPEAR) comprising
three components: selective decontamination of the digestive tract (SDD), systemic
cefotaxime and intensive microbiological surveillance was applied to patients in a
local medical/surgical ITU, with encouraging results. After the formal trial the
decision was made to continue with SPEAR. Although clinical problems with
antimicrobial resistance were not encountered, this routine use of prophylactic
systemic cefotaxime prompted fears of promoting resistance not only to cefotaxime
but to the B-lactam antibiotics in general by:
• the selection in the B-lactamase-inducible species of aerobic Gram-negative
bacilli (AGNB) of stably derepressed mutants which hyperproduce
chromosomal AmpC B-lactamases and
• the selection of plasmid-mediated extended-spectrum B-lactamases (ESBLs).
Both types of enzymes attack multiple B-lactam antibiotics.
The objective was to investigate those AGNB from surveillance flora showing
resistance to cefotaxime with reference to plasmid-mediation and B-lactamase
characterization using molecular biology techniques.
• One hundred and seventy-five of 200 isolates collected over a period of two
years and ten months fulfilled the criteria for the study.
• Plasmids were detected in 78 of 175 isolates by agarose gel electrophoresis
with sizes ranging from 2 kb to 214 kb.
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• Transconjugation experiments were carried out on all isolates. Both test and
control systems were used.
• B-Lactamases were detected in 144 of 175 isolates by isoelectric focusing.
• All isolates were tested for susceptibility to a battery of B-lactam antibiotics
chosen to facilitate the recognition of the resistance patterns associated with
particular 6-lactamase types. Disk diffusion and agar dilution methods were
used.
• All isolates were tested for the production ofESBLs. Potential ESBLs were
found in four isolates and their relevance is discussed.
• There was evidence of chromosomal B-lactamase derepression in 65 of 175
isolates.
This is the first such study ofAGNB from the surveillance flora of patients
exposed simultaneously to cefotaxime and an effective SDD regimen in an ITU.
• Its results were favourable to SPEAR.
• Intensive microbiological surveillance should remain an integral part of that
triple regimen.
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Aims of the Study
to investigate the cefotaxime resistance mechanisms of aerobic Gram-
negative bacilli isolated from surveillance flora of patients undergoing a
selective parenteral and enteral antisepsis regimen (SPEAR) in an intensive
therapy unit.
to assess the implications of such resistance mechanisms for the
continuation of SPEAR which comprised selective decontamination of the
digestive tract, systemic cefotaxime and intensive microbiological
surveillance.
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Chapter 1 Clinical and Scientific Background
1.1 Introduction
"
so many of our outstanding technical achievements and brilliant examples
of dogged devotion to day-to-day care still fail because of our fundamental inability
to control the infectious process. For some 30 years we have sought with increasing
sophistication, cost, and possible danger, the magic bullet - a new and perfect
antimicrobial agent. As each new agent has evolved and been tested, it is ever
clearer that the microbial adjustment to the new therapy is so rapid that we have
only changed the uniform of our enemy while maintaining a stable battle line." [1]
Infection is one of the most serious problems in the management of intensive care
patients. Infection-related morbidity and mortality remain unacceptably high. Once
a cycle of infection, reduced host defence and organ failure becomes established
conventional management is clearly inadequate and mortality exceeds 50% [2],
Until 1984 the prevention and control of infection in the intensive therapy unit
(ITU) was managed by combining detailed clinical and microbiological
surveillance, antibiotic policies and isolation procedures. In theory surveillance
allowed early detection of infection or pre-infection states and identified the causal
organisms, the antibiotic policies restricted drug use thereby minimising selection
pressure for resistance and isolation procedures prevented the transmission of
infection within the units.
Disenchanted by the legacy of the conventional approach to infection in intensive
care patients a Dutch team in Groningen [3] developed a preventative approach
based on the observation that many infections are endogenous i.e. caused by
potentially pathogenic microorganisms colonizing the patient's own digestive tract.
Stressing the importance of endogenously-derived infection by aerobic Gram-
negative bacilli (AGNB) and the protective role of the anaerobic intestinal flora in
colonization resistance, Stoutenbeek et al. [3] applied selective decontamination of
the digestive tract (SDD), a familiar concept in the management of cancer patients,
to the novel setting of the ITU. It should be emphasized that this first application of
SDD to patients in the ITU was in fact part of a prophylactic triple regimen which
combined three distinct elements: SDD applied throughout the duration of stay in
the ITU, systemic administration of the third-generation cephalosporin cefotaxime
directed against early endogenous infection and intensive microbiological
monitoring throughout the admission.
SDD was achieved with a mixture of tobramycin, polymyxin E and amphotericin
B applied as a sticky paste to the oropharynx and as a fluid by nasogastric tube to
the stomach and more distal intestinal tract even in the absence of peristalsis. The
aim of the SDD regimen was to eliminate or markedly reduce the number of
potentially pathogenic AGNB and yeasts in the gastrointestinal tract thereby directly
reducing the risk of endogenous infection with these organisms. The highly selective
action of the antibiotics used in such SDD regimens allows retention of the
predominantly anaerobic flora of the gastrointestinal tract. This retained flora
prevents colonization with organisms resistant to the antibiotics used for SDD, a
phenomenon termed "colonization resistance" [4,5]. The systemic administration of
cefotaxime was directed against early endogenous infection and was discontinued as
soon as the microbiological monitoring showed that the patient was free of
potentially pathogenic microorganisms [3].
In 1981 Stoutenbeek and colleagues had started a pilot study on infection
prevention by SDD, initially without additional systemic antibiotic prophylaxis but
"As this appeared not optimal, a systemic colonization resistance-indifferent
antibiotic such as Cefotaxim was added to the regimen, assuming that the
combination with SDD prevents emergence of resistance" [3].
The use of this prophylactic triple regimen achieved a marked reduction in the
colonization of the oropharynx and rectum with AGNB and a reduction in the
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incidence of unit-acquired infection. Problems with antibiotic resistance were not
encountered. In fact environmental studies [6] suggested a beneficial secondary
effect on the bacterial ecology of the ITU with a consequent reduction in the risk of
exogenous infection with AGNB. Although impressive, the results of these studies
applied only to a highly selected group of patients, i.e. 63 multiple trauma patients
who were neither infected nor receiving antibiotics at the time of admission and
whose duration of stay in the ITU was for five days or longer.
Intrigued by the Dutch findings a Scottish team [7] applied a similar selective
parenteral and enteral antisepsis regimen (SPEAR) to all 324 patients admitted to a
non-specialized medical/surgical ITU in Glasgow, Scotland over a period of eight
months. This prospective trial studied a control group of 161 patients who were
managed traditionally followed by a test group of 163 patients managed with
SPEAR. As in the Groningen regimen the three components of SPEAR comprised
SDD, systemic cefotaxime and intensive microbiological monitoring.
Intravenous cefotaxime was used as a supplement to SDD during the first four
days to provide additional broad-spectrum cover for the early period of admission.
During this time SDD is only partially established, intubation and other invasive
procedures are very common and subclinical infection undiagnosed at admission
may become manifest.
The SPEAR group of patients in the Glasgow study showed a striking and
consistent reduction in the colonization of the oropharynx, stomach and rectum with
AGNB and a statistically significant reduction (24% to 10% p=0.006) in the
incidence of unit-acquired infection. Mortality in certain categories of patient was
also reduced but statistical significance could be reached only in relation to trauma
patients. Problems of drug resistance were not encountered [7].
Although the results of the study strongly suggested that SPEAR represented a
substantial advance in the control of unit-acquired infection in a general ITU [7], the
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widespread application of such a regimen has remained controversial because of
concern about the emergence of serious drug resistance [8-12],
In particular the prospect of the routine use of prophylactic cefotaxime (an
extended-spectrum B-lactam) in ITUs prompted fears of promoting resistance not
only to cefotaxime itself but to many other 8-lactam antibiotics [8]. Cefotaxime is a
third-generation cephalosporin which possesses broad-spectrum high potency
antimicrobial activity and stability to a wide range of B-lactamases [13 {p90}].
Although problems with resistance were not encountered clinically during the
Scottish SPEAR trial [7], it is known that selection processes within the normal
flora often precede the emergence of clinically important multiply-resistant bacteria
[10]. Problems may arise from the complex selection pressures in an ITU which
affect not only the individual patient but the patient's total microbiological
environment.
After completion of the trial in Glasgow the decision was made to continue
SPEAR. Intensive microbiological surveillance remained an integral part of the
regimen. This surveillance entailed the routine microbiological examination of
tracheal and gastric aspirates, urine, and swabs from the throat and rectum of every
patient within four hours of admission to the ITU and three times weekly throughout
the patient's stay in the unit in order to monitor resistance. Two hundred consecutive
isolates of AGNB from the surveillance flora showing resistance to any component
of SPEAR were stored on nutrient agar slopes in darkness at room temperature.
B-Lactams such as cefotaxime favour the selection of stably derepressed mutants
in certain species ofAGNB. These mutants produce high levels of chromosomal
AmpC B-lactamases and have reduced susceptibility to multiple B-lactams [14].
Such multiply resistant organisms have spread widely in some hospitals and this
trend has been correlated closely with the extent of use of third-generation
cephalosporins [15-18]. Plasmid-mediated extended-spectrum B-lactamases (ESBLs)
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attack not only cefotaxime but most B-lactams. Their potential for spread among
AGNB and dissemination outside the ITU is well known [19-24].
The aim of the present work was to investigate the resistance mechanisms of
those AGNB showing resistance to cefotaxime, with reference to plasmid-mediation
and 13-lactamase characterization and to assess their implications for SPEAR.
One hundred and seventy-five of the 200 consecutive isolates collected over a
period of two years and ten months (5/8/88 to 20/5/91) were appropriate for
inclusion in the present study. This is the first such study of AGNB isolated from the
surveillance flora of patients exposed simultaneously to systemic cefotaxime and an
effective SDD regimen in a general ITU. The results will have important
implications for the long-term validation of SPEAR.
1.2 The ITU and the importance of infection
Specialised patient-care units providing a focus for the technological rescue of
critically ill patients have been evolving since their introduction in the late 1950s
[25] and have become one of the hallmarks of modern medicine. These ITUs are
characterized by small groups of severely ill patients with compromised host
defences, the routine use ofmultiple medical devices and treatments with inherent
side effects and high ratios of specially trained medical and nursing personnel. They
may be subspecialized into neonatal, paediatric, cardiac, respiratory, medical,
surgical or neurological or may have mixed facilities such as in a general
medical/surgical unit depending on the needs and expertise in the individual
hospitals.
Infection has always been a serious problem in the management of intensive care
patients. In contrast to general wards with an average nosocomial infection rate of 5-
10% the incidence of such infections in ITUs is usually much higher [26].
Awareness of the situation intensified in the middle 1970s through the 1980s [26-
30] when an overall incidence of infection of 18%-36% in general medical/surgical
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ITUs was reported frequently [28,31,32]. There was a high incidence of unit-
acquired infection; the proportion of infected patients increased with duration of
stay and could exceed 90% in patients remaining in the unit for longer than seven
days [3,28,30],
1.3 Intensive care patients
A patient requiring intensive care may be defined as one who is severely ill and
who requires support of one or more vital functions until a disease process is
arrested or ameliorated. Patients may be admitted directly from the community or
may be transferred from other wards in the same hospital or from other hospitals.
Nowadays it is possible to support seriously ill patients who would previously
have died. Patients with major organ failure are kept alive with dialysis, ventilation,
transfusions and other sophisticated interventional procedures. Such patients are
highly susceptible to infection due in part to compromised host defences which
often accompany the underlying disease or trauma. The Study on the Efficacy of
Nosocomial Infection Control (SENIC) project [33] confirmed that the risk of
nosocomial infection is positively associated with the severity of the underlying
illness. Broken skin and mucosal surfaces are immediately colonized as part of the
mechanism of injury, allowing microorganisms to bypass otherwise healthy skin and
mucosa. Colonization with nosocomial organisms occurs quickly in the intensive
care settings necessary for the treatment of patients with multiple trauma and
correlates well with the severity of injury and presence of invasive devices [34,35].
Once colonized, wounds, drains and catheters are resistant to microbial clearance by
host immune defences. Intensive care patients need various forms of instrumentation
to monitor vital functions and support failing organ systems. The epithelial barrier
of the skin and mucous membranes is the most important component of normal
antibacterial defences. Vascular cannulae mechanically breach skin barriers and
provide a direct portal of entry for microorganisms into the bloodstream. Tubes and
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catheters inserted into airways and into the gastrointestinal and urinary tracts
circumvent local defence mechanisms. Epithelial colonization develops rapidly
following admission to an ITU [36]. The critically injured patient loses the
protective colonization immunity provided by normal intestinal tract flora as injury,
ischaemia, impaired motility, pH changes, fasting and antibiotics disrupt the normal
microenvironment. Agents such as antacids and cimetidine (a histamine type 2
blocker or "H2 blocker") given to reduce gastric secretions in the prophylaxis of
stress ulcer and haemorrhage alter both the qualitative and quantitative bacterial
flora of the stomach. Alterations in this important chemical barrier have implications
for both respiratory and gastrointestinal infections. Traumatic injury produces a
hypermetabolic state that results in a relative nutritional deficiency, potentially
compromising wound healing and host immunity [1].
1.4 The importance of AGNB in ITU infections
In all ITUs septicaemia, pneumonia, infections of the skin and subcutaneous
tissue, upper respiratory tract, urinary tract and wound infections are the most
common nosocomial infections [26]. However nosocomial infections of the
respiratory tract are particularly worrying as they not only complicate and extend
hospitalization times but also tend to be lethal [37]. They have been reported to
account for 37% to 66% of ITU infections and there are often intractable difficulties
in both diagnosis and treatment [30,38,39],
A wide range ofmicroorganisms is associated with ITU infections. However
several studies emphasise the importance ofAGNB [27,28] especially in unit-
acquired infections [30,32,38-43]. The microorganisms include Escherichia coli,
Klebsiella, Proteus, Enterobacter, Citrobacter and Serratia species, Pseudomonas
aeruginosa, Acinetobacter species, Morganella morganii and Stenotrophomonas
(Xanthomonas) maltophilia [32,34,44]. Within this context AGNB is a useful
collective term for these organisms.
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1.5 The conventional approach to ITU infection
Until the middle 1980s it was generally recommended that antibiotic prophylaxis
should not be used routinely in patients in an ITU because apart from being
ineffective it might encourage the emergence of resistance in nosocomial AGNB
[27,45]. Detailed clinical and microbiological surveillance was used to detect early
infection and identify the causal organisms. Systemic antibiotics were given when
there was clinical evidence of infection and the spread of resistant organisms was
limited by isolation procedures.
1.6 The novel approach to ITU infection
1.6.1 The importance of endogenous infection in the ITU setting
Although the importance of the digestive tract flora as a source of infection had
been demonstrated in leukaemic and granulocytopaenic patients [46-48] and also in
ITU patients [36,37,49], this aspect had been overshadowed previously in the ITU
setting by the importance of exogenous infections [27,41].
In 1983, in a novel approach to infection control in the ITU, Dutch workers [50]
focused attention on the importance of endogenous infection. In agreement with
other workers [51,52] they recognized that the patient's own aerobic digestive tract
flora in the oropharynx, stomach and intestines was the major source of all
infections with the other major organ systems such as the respiratory tract, urinary
tract and skin being the target organs.
1.6.2 Colonization and infection
Colonization had been defined by Northey and colleagues in 1974 [34] as the
appearance of a microorganism in, or on, a patient without clinical signs of disease.
They also defined infection as the presence and multiplication of organisms in, or
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on, a patient with some clinical signs or symptoms of disease such as an elevated
temperature or a wound with a purulent exudate.
The patient's own endogenous flora may change profoundly following admission
to a hospital environment and the patient may be colonized by endemic hospital
strains of pathogens which may subsequently cause infection. Therefore many
apparently endogenous infections are really exogenous in origin [27].
The Dutch team [3] who first applied the concepts of SDD to ITU patients
defined colonization as the presence of the same species of potentially pathogenic
microorganism in an organ system for more than 3 days (> 2 positive samples)
without signs of infection. They defined infection according to the criteria described
above [34].
Infection was termed endogenous when it was caused by microorganisms that
were part of the patient's oropharyngeal or gastrointestinal flora [53] and they
defined the sequence of events in the pathogenesis of endogenous infection as
acquisition of potentially pathogenic microorganisms, followed by oral or
gastrointestinal colonization which was recognized as a prerequisite for infection by
these microorganisms. Primary endogenous infection was distinguished from
secondary endogenous infection. According to van Saene [53] and colleagues
admission flora is involved in primary endogenous infection, while microorganisms
acquired during a hospital stay are associated with secondary endogenous infection.
Although the microorganisms involved in secondary endogenous infection are
acquired in hospital ("exogenous" microorganisms), the infection is called
endogenous because oral and gastrointestinal colonization form an essential stage in
the development of infection. An exogenous infection was defined by the Dutch
workers as an infection caused by microorganisms not present in the patient's oral
and gastrointestinal flora, e.g. lower airway infections associated with ventilation
equipment and humidifiers [53]. According to the above criteria ITU-acquired
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infection may be either secondary endogenous infection or exogenous infection, but
never primary endogenous infection.
1.6.3 Effect of illness on oropharyngeal colonization
A breakthrough in the understanding of the pathogenesis of ITU infections
occurred when Johanson reported in his pivotal paper in 1969 [54] that serious
illness itself predisposed to oropharyngeal carriage ofAGNB. He noted that the
prevalence of AGNB among the oropharyngeal bacterial flora was low in
physiologically normal subjects despite hospital exposure but rose markedly in
patients with illnesses of varying severity. This increased prevalence did not
correlate with antibiotic administration or inhalation therapy and did not depend on
duration of hospitalization but correlated best with the clinical severity of illness. He
contended that increased exposure to these organisms alone did not adequately
explain the findings but that pharyngeal clearance mechanisms were impaired in
these patients. As most bacterial pneumonias begin with the aspiration of bacteria
present in the upper respiratory tract, he concluded that this alteration in the
pharyngeal flora of ill patients might represent an important initial step in the
pathogenesis of pneumonia due to AGNB. The importance of the progression from
abnormal colonization on a surface to overt tissue infection is exemplified by the
well documented colonization of the oropharynx, stomach and trachea with AGNB
prior to the development of lower respiratory tract infection with these organisms
[37,55,56]. Increased oropharyngeal colonization with AGNB is also related to old
age and to antibiotic use [57].
1.6.4 Influence of pH on gastric colonization
In critically ill patients a gastric pH >4 has been shown to be the major risk factor
for gastric colonization with AGNB [29]. One reason why such patients may have a
gastric pH >4 is the use of H2 blockers or antacids as prophylaxis against stress
- 10-
ulceration and haemorrhage [58]. Driks and colleagues [56] showed a nosocomial
pneumonia rate twice as high in an antacid/H2 receptor-antagonist group compared
with a group receiving sucralfate which preserves the natural gastric acid barrier
against bacterial overgrowth. However critically ill patients may have a gastric pH >
4 even in the absence of antacid or H2 receptor-antagonist therapy [56,59].
1.6.5 Colonization resistance and the role of the indigenous anaerobic flora
In contrast to aerobes, anaerobic bacteria are rarely described as a cause of unit-
acquired infection [41] although they may be important in sepsis present on
admission [28]. In fact anaerobic bacteria as part of the indigenous flora are thought
to play a major role in the host's colonization resistance which can be defined as the
host's capacity to prevent colonization and infection with aerobic bacteria. As the
digestive tract is the main reservoir ofAGNB (the cause ofmost episodes of ITU
infection) its resistance to colonization is of great importance. The principle of
colonization resistance, which concerns the barriers that must be overcome before
microorganisms can colonize body surfaces, was formulated by van der Waaij
[4,5,60] on the basis of findings in mice and monkeys.
In 1971 van der Waaij and colleagues [4] investigated the occurrence of intestinal
colonization after oral administration of various doses of three different species of
AGNB in mice. Much higher oral doses of bacteria were required to achieve
colonization for two weeks or longer in animals with a "conventional" microflora
than in those whose microflora had been altered by prolonged oral antibiotic
treatment. Van der Waaij and colleagues [4] used the term "colonization resistance"
to describe this phenomenon and expressed the term quantitatively as the logarithm
of the oral dose of an organism resulting in colonization of the intestinal tracts of
50% of the experimental animals for at least 2 weeks. The concept of colonization
resistance was defined by van der Waaij [61] in broader terms as the resistance
which a potentially pathogenic microorganism encounters when it tries to colonize a
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"landing site" on the mucosa of one of the three tracts (respiratory, alimentary and
urinary) that have an open communication with the exterior. In the respiratory and
the urinary tracts the colonization resistance determining forces - mucus, IgA
secretion, cell desquamation and mechanical cleansing forces such as ciliary
movement and bladder emptying - are entirely of host origin. In the digestive tract,
however, the indigenous anaerobic microflora plays a key role, although
colonization resistance-determining host factors comparable to those in the other
two systems are also present. They include saliva flow and the presence of
antimicrobial components such as peroxidase and lactoferrin in saliva, integrity of
the mucosa, mechanical cleansing by muscular action and swallowing, peristalsis,
mucus, desquamation of mucosal cells and secretory IgA.
1.6.6 Selective decontamination of the digestive tract
Following the work of van der Waaij and colleagues [4,5,60-63] it became
widely accepted that the indigenous anaerobic flora of the digestive tract plays a
crucial role in preventing intestinal colonization with potential pathogens [64], The
indigenous anaerobic flora is susceptible to a number of antibiotics. It is possible
that colonization by potentially pathogenic bacteria (AGNB) can occur only when
such bacteria find a "foothold" in the mucosa vacated by the protective anaerobes
[61]. Severe illness and/or broad-spectrum antibiotic treatment may result in an
increase in the size and number of these footholds by their adverse effect on the
anaerobic bacteria. The adherence of larger numbers ofpotentially pathogenic
bacteria (colonization) appears to be associated with detectable penetration of the
mucosal lining and migration into the lymphatic system (translocation) [65]. As a
result empirical antimicrobial therapy was used to eliminate intestinal AGNB known
to be potential pathogens while maintaining the anaerobic microflora in the
management of immunosuppressed patients [47,48,66]. The technique was
originally described as SDD [60].
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It was against this background that the Dutch team in Groningen [3] carried out
the first clinical trial of SDD supplemented with parenteral cefotaxime in the novel
setting of the ITU and started the vigorous controversy which persists today
[11,43,67,68].
1.7 The B-Iactam antibiotics
1.7.1 Introduction
One of the most important group of antibiotics both historically and medically is
the B-lactam group to which cefotaxime belongs. Lactam, from lact(one) and
am(ide), is the chemical term for any of a group of inner amides derived from amino
acids, having the characteristic group -CONH-. A lactam is a cyclic amide: "6"
indicates that the amine group used to form the amide is on the second carbon from
the carbonyl (C=0) end. The B-lactam structure is therefore a four-membered ring.
Such a small ring is normally a strained structure of low inherent stability. This
explains why some of the penicillins readily undergo acid or base hydrolysis [69].
The B-lactam antibiotics include the penicillins, cephalosporins, cephamycins,
monocyclic B-lactams (monobactams) and carbapenems. These antibiotics are called
B-lactams because they contain the B-lactam ring system. Their antibacterial activity
depends on the integrity of the B-lactam ring structure; once disrupted, antibacterial
activity is lost. It was recognized in 1949 [70] that the lability of one link in the
penicillin molecule was the single most important factor in all of the reactions of
that substance. That link was the amide link of the B-lactam ring structure. In the
best-known B-lactam agents, the penicillins and cephalosporins, the B-lactam ring is
fused to a five-membered thiazolidine ring or six-membered dihydrothiazine ring
respectively (Figure 1).
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Figure la The basic structure of a penicillin.
COOH
Figure lb The basic structure of a cephalosporin.
- 14-
The antimicrobial activity of the B-lactam antibiotics results at least in part from
their ability to interfere with the synthesis of the peptidoglycan component in the
bacterial cell wall. Peptidoglycan has a mesh structure with polysaccharide strands
cross-linked by peptide bridges and has a vital role in maintaining the strength of the
cell wall. B-Lactam antibiotics inhibit the penicillin-binding proteins (PBPs) which
structurally resemble and are probably derived from serine proteases [71]. These
PBPs are transpeptidases, carboxypeptidases and endopeptidases that catalyse the
cross-linking of the peptidoglycan [72,73]. PBPs are capable of binding to B-lactams
because the highly stressed amide group of the B-lactam ring is conformationally
similar to the D-alanyl-D-alanine bond of the peptidoglycan pentapeptide [74,75].
As a result the PBPs react with the B-lactams instead of their natural substrates and
yield stable covalent esters that lack catalytic activity. The mechanisms are complex
and many subtleties are incompletely understood. In simplistic terms the B-lactams
prevent the formation of peptide bridges causing a weakened wall to be produced.
They may also activate cell wall degrading enzymes called autolysins [76,77].
1.7.2 Penicillins
Penicillin was discovered in 1928 and isolated in 1929 from Penicillium notatum
by Alexander Fleming [78], In 1940 the systematic study of the chemistry and
production of penicillin by Florey, Chain and associates began in Oxford and in
1941 the first clinical trials were instigated. As Britain was in the throes ofWorld
War II the commercial production of penicillin was initiated in the USA. There
followed a unique, international collaborative effort to ascertain the chemical
constitution ofpenicillin and to devise methods for its synthesis [79].
According to Johnson and colleagues [70] the first evidence interpreted
specifically in favour of the B-lactam structure was that discovered by the Merck
group in 1944 when they succeeded in removing the sulphur from benzylpenicillin.
The properties of the resulting desthiopenicillin strongly suggested its B-lactam
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structure [80], This was followed by cogent theoretical advocacy of the B-lactam
structure by Johnson and colleagues [70]. Finally, the results ofX-ray
crystallography studies at Oxford and Greenwich in 1945 and 1946, as documented
by Crowfoot and colleagues [81], provided indisputable evidence for the existence
of the four-ring 13-lactam structure. In 1945 Fleming, Florey and Chain shared the
Nobel Prize for their pioneering work on penicillin.
The penicillin nucleus, 6-aminopenicillanic acid (6-APA) was itself produced
first as a natural product [82] but was subsequently obtained more easily from
penicillin G by removal of the side chain, either by chemical or enzymatic means
[83]. Its isolation enabled the synthesis of a variety of penicillin compounds by
coupling the free 6-amino group of the penicillanic acid to free carboxyl groups of
different radicals.
1.7.3 Cephalosporins
The cephalosporins originate from the work of Giuseppe Brotzu, a Professor of
Bacteriology in the University of Cagliari, Sardinia in the mid-1940's. Brotzu
hypothesized that the apparent clearing of microorganisms from the water in the
vicinity of a sewage outlet in the harbour at Cagliari might result from the inhibitory
effect of substances produced by another microorganism. His search led to the
isolation of a fungus, Cephalosporium acremonium, the first microbial source of a
cephalosporin [84],
In 1948, unable to proceed further with this work, Brotzu sent a culture of the
organism to Sir Howard Florey at Oxford where workers led by Professor Edward P
Abraham proceeded to identify several fermentation products of Cephalosporium
acremonium which possessed antimicrobial activity. In 1953 they identified
cephalosporin C [85] which became the foundation upon which current
cephalosporin antimicrobials are constructed.
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Cephalosporin C is a 6-lactam compound in which the B-lactam ring is fused to a
six-membered dihydrothiazine ring, in contrast to the penicillins where the
comparable unit is a five-membered thiazolidine ring. The knowledge that
substitution of different side chains at the 6-acylamino site of the 6-APA resulted in
semisynthetic penicillins of increased potency set the stage for attempts to modify
cephalosporin C and thereby enhance its potency [86]. The structure of
cephalosporin C, and its relationship to penicillin, was established [87] shortly after
the discovery and isolation of 6-APA and at about the same time as the introduction
of the first of the semisynthetic penicillins. Acid hydrolysis of the side chain of
cephalosporin C yielded a nucleus, 7-aminocephalosporanic acid (7-ACA) from
which the cephalosporins have been derived as semisynthetic compounds in a
manner analogous to that of the semisynthetic penicillins.
1.7.4 Classification of cephalosporins
The most widely used classification system combines the parenteral and oral
cephalosporins into generations based on their spectrum ofmicrobiological activity
[88]. The first-generation compounds have a relatively narrow spectrum of activity
focused primarily on the Gram-positive cocci but with some activity against Gram-
negative bacteria. The second-generation cephalosporins have variable activity
against Gram-positive cocci but have increased activity against Gram-negative
bacteria. The cephamycins (7-a-methoxycephalosporins) were produced from
Streptomyces species [84]. In spite of relatively increased activity against Gram-
negative aerobic and anaerobic bacilli the cephamycins are included in the second
generation. Third-generation cephalosporins (e.g. cefotaxime and ceftazidime) are
those with very marked activity against aerobic Gram-negative bacteria. Some of




Cefotaxime is a third-generation cephalosporin resulting from the addition of an
aminothiazole group to the acyl side chain at position 7 and the addition of an
iminomethoxy group to the a-site of this side chain (Figure 2).
The important structural feature of this aminothiazolyloxime-cephalosporin is the
conjunction in the acetyl side-chain of the aminothiazolyl ring and the a-syn-
methoxyimino group [89]. Oxime derivatives exist as two geometrical isomers, the
syn form and the anti form. In the cephalosporin series it was known that whereas
the syn oxyimino derivatives retained the antibiotic properties of the parent molecule
and had increased resistance to the deactivating action of the 13-lactamases, the
corresponding anti oximes had inferior antibiotic properties when compared to the
parent molecule. This was found to be the case with cefotaxime which is the syn
oxime derivative. The aminothiazolylmethoxy side chain confers stability to many
of the 13-lactamases ofGram-negative bacteria while retaining high activity against
streptococci and to a lesser degree against methicillin-susceptible Staphylococcus
aureus [88].
1.7.6 Resistance to the B-lactam antibiotics
Resistance to the 13-lactam antibiotics can be mediated through three mechanisms:
decreased ability of the antibiotic to reach its PBP target, alteration of a PBP target
that is essential for cell survival, or production of 13-lactamases that inactivate the
antibiotics [88].
In Gram-negative bacteria the outer membrane, in addition to concentrating 13-
lactamases within the periplasm, also contributes to resistance because it acts as a










Figure 2 The structural formula of cefotaxime.
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G-Lactam compounds that conform to the structure and charge requirements of
the porin channels can penetrate into the bacterial cell and, if they are unaffected by
any B-lactamase that is present, bind to target PBPs [91,92]. The activity of B-
lactams that intrinsically penetrate slowly may be limited if they are susceptible to
hydrolysis or to removal by high concentrations of B-lactamases in the periplasmic
space. Mutations that alter porin protein structure may render a strain that was
initially susceptible to a given B-lactam antibiotic, resistant. It is thought unlikely
that porin permeability barriers alone should result in the resistance ofGram-
negative bacteria to B-lactam antibiotics [93]. Nevertheless the rate of penetration of
a B-lactam antibiotic through the outer membrane is intrinsically linked to resistance
mediated by B-lactamases [94].
Although multiple mechanisms often work in concert, B-lactamase destruction of
antibiotic is undoubtedly the most important [95], B-Lactamases are enzymes that
hydrolyze the B-lactam ring of the B-lactam antibiotics rendering them inactive.
1.8 "Penicillin- and cephalosporin-destroying enzymes" and B-lactamases
An enzyme from bacteria capable of destroying penicillin was described by
Abraham and Chain in 1940 [96], before the widespread use of penicillin in the
treatment of bacterial infections. In fact Fleming had been the first to note, in 1929,
that certain groups of bacteria such as the "coli-typhoid" group were not inhibited by
penicillin [78]. In 1940 Abraham and Chain [96] pursued Fleming's observation by
crushing a suspension of Escherichia coli "B. coli" in amill to produce an extract
which destroyed the growth-inhibiting properties of penicillin. Heat and papain
digestion inactivated the extract leading the investigators to conclude that the active
component was an enzyme which they named penicillinase. The paper ended with
an apocryphal statement:
"The fact that a number of bacteria contain an enzyme acting on penicillin points
to the possibility that this substance may have a function in their metabolism" [96].
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At that time the chemical structure ofpenicillin had not yet been worked out and
the nature of the reaction catalysed by penicillinase was unknown. In 1943 the 13-
lactam structure was proposed [97] and later the existence of the 13-lactam ring was
found to be indisputable [70]. In 1944 it had been concluded that penicillinase
converted penicillin to penicilloic acid [97]. Interest in penicillinase developed
rapidly. Nearly all of the early work concerned Gram-positive bacteria such as
Bacillus species and staphylococci. Until the 1960s most attention focused on
staphylococcal penicillinase as the prevalence of penicillin-resistant staphylococci
rapidly reached epidemic proportions in hospitals where penicillin was used widely,
then gradually spread into the community [98].
Reviewing penicillinase in 1960 Pollock [99] thought it reasonable to suppose
that the majority, if not all, of the preparations referred to as "penicillinase" owed
their activity to an enzyme which should be regarded as a "penicillin-13-lactamase"
catalysing the hydrolysis of penicillins to penicilloic acid in a reaction similar to
their chemical breakdown by dilute alkali i.e. hydrolysis of the amide bond in the 13-
lactam ring of the penicillin molecule. Almost immediately after cephaloridine came
into clinical use in 1964 it was realised that certain 13-lactamases (e.g. from indole-
positive Proteus species and Enterobacter species) were more active against
cephalosporins than against penicillins. This finding was predictable in view of the
work by Newton and Abraham on the degradation of the natural product
cephalosporin C [100]. The nomenclature became confusing as enzyme preparations
were termed variously penicillinases, cephalosporinases and 13-lactamases.
Citri and Pollock [101] rationalised the situation in 1966 by defining 13-lactamase
as an enzyme which hydrolyzed the amide bond in the 13-lactam ring of 6-APA or 7-
ACA and/or in their A-acyl derivatives (penicillins being A-acyl derivatives of 6-
APA and cephalosporins being A-acyl derivatives of 7-ACA). While acknowledging
that the ability to hydrolyze cephalosporin relative to benzylpenicillin might be one
of the distinctive properties of an enzyme, they thought that the general term 13-
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lactamase appeared to be appropriate even in the extreme cases when only one of
these substrates was measurably hydrolyzed [101].
While these early discoveries about 13-lactamases were being made knowledge of
bacterial genetics was also expanding. It was soon recognised that bacterial genetics
and antimicrobial resistance mechanisms were inextricably linked.
1.9 Genetics of antibiotic resistance
1.9.1 Introduction
Genetic variability allows microbial evolution to occur. Antimicrobial agents
exert strong selection pressures on bacterial populations favouring those organisms
that are capable of resisting them [102,103]. Genetic variability may occur by a
variety of mechanisms: 1) Point mutations may occur in a nucleotide base pair.
These mutations may alter the target site of an antimicrobial agent, interfering with
its activity. 2) Whole-scale rearrangement of large segments of deoxyribonucleic
acid (DNA) from one location on the bacterial chromosome to another may occur as
a single event. These rearrangements are frequently created by specialised genetic
elements known as transposons or insertion sequences which have the capacity to
move independently from the rest of the bacterial chromosome [103]. 3) Bacteria
may acquire foreign DNA carried by plasmids, bacteriophages or transposable
genetic elements. Inheritance of these extrachromosomal elements contributes to an
organism's ability to withstand selection pressures imposed by antimicrobial agents
[104] and endows bacteria with a seemingly unlimited capacity to develop resistance
to antimicrobial agents. Once an antibiotic resistance gene evolves, this resistance
determinant may spread to other bacteria by transformation, transduction,
conjugation or transposition. Favoured clones of bacteria may then proliferate in the
flora of patients who receive antibiotics [105]
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1.9.2 Plasmids
Plasmids are extrachromosomal genetic elements usually made of circular
double-stranded DNA molecules that range in size from less than 10 kilobase pairs
(kb) to greater than 400 kb and are very common in bacteria. They are autonomous,
self-reproducing elements that require an origin for replication and regions that
facilitate their stable maintenance in host bacteria [106], Conjugative plasmids
require additional genes that can initiate self-transfer [107]. It has been shown that
extrachromosomal genetic elements were present in bacteria prior to the advent of
antibiotics [104] but the introduction of antibiotics into clinical medicine has created
selection pressures which favour the dissemination of antibiotic resistance by mobile
genetic elements (e.g. plasmids, transposons and other mobile genes). Rapid
increases in the spread of antibiotic resistance within and between species often
correlate with the dissemination of specific resistance (R) genes.
The generic term "plasmid" was introduced by Lederberg in 1952 [108] for any
extrachromosomal genetic particle. He intended to clarify the classification of agents
that until then had been:
"thought of disjunctively as parasites, symbionts, organelles, or genes It was
important to have a new term, bereft of confusing baggage The term plasmid
was then invented as a hybrid of cytoplasm or plasmagene and '-id', as in plastid,
chromatid, or id (Weissmann, Freud, Latin 'it')." [109].
From about 1970 plasmids became important agents in molecular genetic
research and biotechnology. They were also recognized as playing a pivotal role in
the evolution ofmicrobial resistance and pathogenicity. The first plasmid to be
identified was the Escherichia coli fertility factor F which was discovered because
of its ability to mediate transfer of chromosomal markers from one strain of
Escherichia coli to another. Sexual differentiation was attributed to possession of a
transmissible factor called F (for fertility) with F+ cells acting as donors of
information and F" cells as recipients [110]. The physical nature of F was unknown
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at that time. It could spread through bacterial populations but was not apparently
part of the bacterial chromosome [110,111]. In enterobacteria the identification of F
was followed by the discovery of two other major groups of plasmids, the
colicinogenic (Col) plasmids and the infectious drug-resistance plasmids [112].
The probability that plasmids were composed ofDNA was suggested by the
finding that F factors, R factors and Col factors could be inactivated by the decay of
radioactive 32P incorporated in their host cells [113-115]. Direct demonstration that
the F factor was made ofDNA came from the work ofMarmur and colleagues [116]
who isolated it on a caesium chloride density gradient. This laid the basis for future
quantitative studies.
1.9.3 Transposons
Transposable elements are discrete sequences ofDNA that can move from one
genetic locus to another, on the same or on a different replicon, by a process of
recombination called transposition [102], The term "transposable element" was used
originally to define mobile genetic elements in wheat [117]. The size of these
elements can vary markedly and many different properties can be transposable.
Transposable elements retain their structural integrity during transposition and the
recombination does not require DNA base sequence homology between the donor
and recipient genetic loci i.e. the recombination is independent of the bacterial rec-A
system. This usually results in whole-scale modifications of large sequences ofDNA
as a single event [102,118]. When a transposable element contains an accessory
gene, encoding some marker, it is called a transposon. The transposable markers
may be antibiotic resistance determinants, toxins and other virulence factors, or
metabolic functions. According to Kopecko [102], cataloguing of the properties of
many transposons detected on plasmids obtained from a large variety of different
bacteria clearly demonstrated the fact that plasmids were evolving through a process
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of exchange of discrete transposable units. Transposable elements have been found
in many species of bacteria, Gram-positive as well as Gram-negative.
1.9.4 Conjugation
Conjugation is the process whereby DNA is transferred from one bacterial cell to
another by a mechanism that requires cell to cell contact [119]. The information
required for transfer is encoded on transfer-proficient plasmids which may also be
able to promote the transmission ofmobilizable plasmids and even chromosomal
genes. Conjugation gives the subset of genes usually located on plasmids an
evolutionary advantage. As conjugation is essentially a replication process it allows
plasmids to replicate more frequently than the chromosomal genes and enables them
to transfer to alternative bacterial hosts [120]. If cells which receive the plasmid are
favoured by natural selection, the plasmid will spread rapidly. This is illustrated by
the world-wide appearance of antibiotic-resistant bacteria.
Apparently conjugation can be divided on both physiological and genetic bases
into two parts: the recognition of recipient cells by donor cells that leads to mating
pair formation and the subsequent physical transfer of plasmid DNA [120].
Conjugative plasmids from Gram-negative bacteria control the formation of an
extracellular pilus which has an essential role in the recognition of recipient cells
and the establishment of cell-to-cell contact. Bradley [121] differentiated three
major groups of sex pili according to their morphology on electron microscopy.
After the initial contact between the tip of the pilus and the recipient cell the pilus
retracts. Pilus dissassembly is thought to be crucial in establishing contact between
the donor and recipient cell surfaces and the formation of a DNA transport pore
[122 {p98}]. Initiation ofDNA transfer takes place at a specific site on the DNA
called the origin of transfer [123]. Plasmids usually specify a surface (or entry)
exclusion system that prevents the unproductive transfer of the plasmid to a cell that
already possesses a copy [120].
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1.9.5 Infectious drug resistance and the link with plasmids or "R factors"
Resistance to antibacterial agents transferable by conjugation, i.e. from one cell
to another by direct contact, was discovered in the Enterobacteriaceae in Japan in
1959 [124-128] and later reported in Britain in 1962 [129] and in Germany in 1963
[130]. "Contagious" drug resistance was often multiple, rendering organisms
simultaneously resistant to several (as many as seven) unrelated antibacterial drugs
of therapeutic importance [131].
After the World War II the use of antibacterial drugs to combat infection became
increasingly common. It was the epidemiology of drug resistance in shigellae that
led Japanese bacteriologists to postulate that multiple drug resistance might be
transferred from one bacterial species to another. In the early 1960's the greater part
of scientific knowledge, both in epidemiology and in the fundamental analysis of
infectious drug resistance, came from Japanese workers [131].
From 1956 onwards shigellae resistant to streptomycin, tetracycline,
chloramphenicol and sulphonamides were isolated with increasing frequency in
Japan. In dysentery outbreaks, some of the shigellae isolated were sensitive to all
drugs tested, while others of the same serotype were multiply resistant. Patients
excreting drug-sensitive shigellae, when treated with only one antibacterial drug,
subsequently excreted multiply-resistant shigellae. In some studies multiply-resistant
Escherichia coli were also isolated from the patients with dysentery [126], No
acceptable explanation of these findings was forthcoming until Akiba [132]
suggested that transfer ofmultiple drug resistance from resistant Escherichia coli to
sensitive shigellae might occur in the patients' intestinal tracts. This transfer was
finally demonstrated in mixed culture independently by Ochiai and colleagues in
1959 [124] and by Akiba and colleagues in 1960 [125], Although the commonest
transmissible resistance pattern in Japan was against streptomycin, tetracycline,
chloramphenicol, and sulphonamide, combinations of resistance to three or two of
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these drugs, as well as single drug resistance, were also found to be transferable.
After these researchers [124,125] succeeded in discovering the transfer ofmultiple
drug resistance in vitro, they attempted unsuccessfully to transfer the resistance with
cell-free filtrates of resistant donor cultures. They therefore concluded, according to
Watanabe in his review of the Japanese language literature [128], that cell-to-cell
contact (or conjugation) was essential for the transfer. This finding had been
confirmed by Mitsuhashi and colleagues [126]. The transfer ofmultiple drug
resistance was not found to alter the basic diagnostic biochemical or serological
markers of the organisms [124,125].
The analogy had been drawn between the agents of such transferable drug
resistance and the sex factor F ofEscherichia coli K12 [126]. A few years earlier
Lederberg and colleagues [110] and Hayes [111] had found that F, the causative
agent of gene transfer between strains of Escherichia coli, was unlikely to be part of
the chromosome and could spread through bacterial populations. Mitsuhashi and
colleagues [133] reported that multiple drug resistance could be transferred among
the substrains of Escherichia coli K12 irrespective of their sexuality (presence or
absence of F factor), indicating that the F factor ofK12 was not required for the
transfer ofmultiple drug resistance. This fact was confirmed by Watanabe and
Fukasawa [127] who found also that the responsible resistance factors were
transferred in mixed culture independently of the host chromosome, using F~ strains
ofEscherichia coli K12 with various chromosomal markers. Multiple drug
resistance could therefore be regarded as a kind of "infective inheritance", a
phenomenon which was first described in microorganisms by Griffith [134].
"Infectious resistance" to streptomycin, tetracycline and sulphonamide was found in
15 of 306 cultures ofSalmonella typhimurium, phage type 27, which had been
isolated during an outbreak of gastroenteritis in a London hospital in 1959 [129].
This work was in fact the first Western description of transmissible antimicrobial
resistance.
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The infectious agents which mediated the resistance came to be known as R
factors and were shown to be extrachromosomal genetic elements, consisting of
DNA [128,135]. In his review in 1963 Watanabe [128] classified R factors as
episomes, acknowledging that by definition a chromosomally integrated state had to
be demonstrated for their inclusion in this category as originally defined [136],
Watanabe suggested that R factors had arisen in enteric bacteria by the attachment
of part of the host's genome to a sex factor, the resistance transfer factor (RTF)
[128].
It had been found that R factors could be transferred in vitro between cells of
many genera: all genera of the Enterobacteriaceae [137] as well as other Gram-
negative bacilli such as Vibrio species [138], Serratia species [139] and Pasteurella
species [140] and evidence for in vivo R factor-mediated resistance in Britain,
Europe and elsewhere began to accumulate [131]. In 1965 Datta [131] contended
that although R factors were frequently referred to in published works as episomes,
they had not been proved to be chromosomally integrated and thought it preferable
to refer to R factors as plasmids [108].
In 1965 Anderson and Datta [141] reported that several strains of Salmonella
typhimurium phage type la isolated in England in 1962 from humans and pigs were
resistant to ampicillin and penicillin. This was the first published observation of
such resistance in wild strains of Salmonella species. Resistance to ampicillin was
always part of a multiple resistance pattern and was readily transferable to
Escherichia coli. Resistance to tetracycline was invariably associated with resistance
to ampicillin and feeding materials for pigs commonly included penicillins and
tetracyclines. Anderson and Datta [141] suggested that the use of these antibiotics as
feeding additives in livestock might have been responsible for the emergence of
resistance to penicillins and tetracyclines in the Salmonella strains. As resistance to
ampicillin was associated with the production of a penicillin-destroying enzyme, the
inference was that the acquisition of an R factor resulted in the production of the
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enzyme. Anderson and Datta [141] drew the analogy between these Gram-negative
bacilli and Staphylococcus aureus, in which penicillinase production, according to
Harmon and Baldwin [142], seemed to be controlled by an extrachromosomal
genetic element.
1.9.6 Plasmids or "R factors" and the link with B-lactamases
The finding that the genetic information for resistance to penicillins, including
ampicillin, could be carried on R factors was described independently in Britain
[141], Greece and Switzerland [143]. This was to have far-reaching consequences as
it predicted that ampicillin resistance would spread not only among strains of
Escherichia coli but also to other genera. In 1965 Datta and Kontomichalou [143]
were able to report that this penicillin-destroying enzyme was penicillinase because
it liberated penicilloic acid on incubation with benzylpenicillin. The evidence was
therefore presented that the genetic information for the biosynthesis of penicillinase
was carried on an R factor [143]. One of the R factors studied was RTCM carried by
Escherichia coli strain TEM which had been isolated by Kontomichalou [143] from
a patient called Temoniera [98] in Athens in 1963. Escherichia coli strain TEM
synthesised relatively large amounts of penicillinase and provided a convenient
opportunity to attempt for the first time the study of a purified rather than a crude
preparation of a penicillinase from a Gram-negative species [144]. The gene
responsible for penicillinase synthesis in Escherichia coli strain TEM was also
found to be carried on an extrachromosomal R factor [143].
A number of B-lactamases from Gram-positive species, Bacillus cereus [145],
Bacillus licheniformis [146], and Staphylococcus aureus [147,148], had been
purified and their properties examined but until 1966 no penicillinase from Gram-
negative species had been purified to any extent [144], The enzyme from
Escherichia coli strain TEM showed little resemblance to the penicillinases of the
Gram-positive species. The fact that the penicillinase from Escherichia coli strain
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TEM could be liberated from the bacteria under conditions in which the cytoplasmic
membrane was protected [149] suggested that penicillinase might be one of the
periplasmic enzymes of Escherichia coli [144].
Datta and Richmond [144] thought it likely that penicillinase genes in Gram-
negative species could either be chromosomal or carried on R factors and in view of
the infectivity ofR factors among the Enterobacteriaceae cautioned that no
penicillinase should be regarded as species-specific until its synthesis was proved to
be controlled by chromosomal genes These discoveries accelerated interest in the 13-
lactamases ofGram-negative bacilli and the search for B-lactam antibiotics resistant
to these 13-lactamases became a major thrust of the pharmaceutical industry.
1.10 fi-Lactamases ofGram-negative bacteria from the 1960s onwards
1.10.1 Introduction
Resistance to 13-lactam antibiotics is due mainly to the production of 13-
lactamases, enzymes that inactivate these antibiotics by splitting the amide bond of
the 13-lactam ring. 13-Lactamases of Gram-negative bacteria are cell-associated
enzymes located in the periplasmic space that lies between the inner cytoplasmic
membrane and outer lipopolysaccharide membrane. Therefore these 13-lactamases
are concentrated and strategically placed to protect the target PBPs (located on the
outer surface of the inner cytoplasmic membrane of the cell envelope) from
exposure to 13-lactam antibiotics. Most of the enzymes, like the PBPs themselves,
belong to a family of serine proteases. 13-Lactamases of Gram-negative bacteria may
be encoded either by chromosomal genes or by transferable genes located on
plasmids or transposons. These enzymes may be constitutive (always active) or
inducible (capable of being activated by another agent), with affinity for penicillins
or cephalosporins or both types of compounds.
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1.10.2 Classification of (3-lactamases
The first attempts to classify the B-lactamases from Gram-negative bacteria were
made by Ayliffe [150] soon after ampicillin was first introduced into clinical use.
Both enzymes studied initially were "penicillinases" but soon afterwards Fleming
and colleagues [151] described a B-lactamase predominantly active against
cephalosporins. Since then such a wide variety of different B-lactamase profiles
were detected in various species of enterobacteria and pseudomonads that a simple
classification into penicillinases and cephalosporinases was no longer of much
value. Indeed there seemed to be an almost continuous spectrum of properties
extending from extreme cephalosporinases on one hand to enzymes predominantly
active against penicillins on the other [152].
1.10.2.1 Richmond and Sykes (1973)
One of the first widely used classification schemes, proposed by Richmond and
Sykes in 1973 [152], grouped the B-lactamases of Gram-negative bacteria into five
main classes by an extension of the scheme suggested previously by Jack and
colleagues [153] and Richmond and colleagues [154] which had recognised four
main classes. The enzymes were classified mainly on the basis of substrate profile
and inhibition studies and provided the first broadly useful frame of reference [152],
Class I enzymes, subdivided into types a, b, c and d, were predominantly
cephalosporinases (with a high rate of hydrolysis of cephalosporins) and included
the chromosomally determined B-lactamases ofmost of the Enterobacteriaceae and
pseudomonads. Class II enzymes, subdivided into types a and b were penicillinases,
active mainly against penicillins. Class III enzymes, having only one subtype "a",
showed broad-spectrum activity (approximately equal activity against penicillins
and cephalosporins) and were sensitive to inhibition by cloxacillin but resistant to
inhibition by /wra-chloromercuribenzoate (pCMB). Class IV enzymes, subdivided
into types a, b and c were also broad-spectrum enzymes but resistant to inhibition by
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cloxacillin and sensitive to inhibition by pCMB. Class V enzymes, the fifth group
suggested by Richmond and Sykes and subdivided into types a, b, c and d were
penicillinases able to hydrolyze cloxacillin and resistant to pCMB inhibition. The
heterogeneity within some of these classes and the problems of determining
parameters such as enzyme inhibition by /?CMB using crude enzyme preparations
made it difficult to utilise this classification, especially when additional information
on properties such as inducibility of enzyme production or location (chromosome or
plasmid) of the 13-lactamase genes was lacking.
1.10.2.2 Sykes and Matthew (1976)
In 1976 Sykes and Matthew [155] catalogued all the 13-lactamases described to
date. Recognising that the diversity of 13-lactamases would become as extensive as
that of bacteria, they thought that a formally divided classification scheme had
become unrealistic. Instead they grouped 13-lactamases first into those that were
normally mediated by the bacterial chromosome or by a transmissible R plasmid and
second by substrate profile, hoping that this grouping would be useful clinically.
The chromosomal enzymes were subdivided into those that were primarily
penicillinases, primarily cephalosporinases, or broad-spectrum 13-lactamases
corresponding to Classes II, I and IV respectively of Richmond and Sykes [152].
The R plasmid-mediated 13-lactamases were subdivided into the broad-spectrum
"TEM type" of enzyme and other enzymes that hydrolyzed isoxazolyl 13-lactam
substrates, corresponding to Classes III and V respectively of Richmond and Sykes
[152], By 1975, using isoelectric focusing, 13-lactamases had been found in 354
strains ofGram-negative bacteria from 19 genera [156]. Because of the extensive
work by Matthew and colleagues [156,157] isoelectric focusing became one of the
most critical means of characterising 13-lactamases. A major feature of the Sykes and
Matthew compilation [155] was the inclusion of the isoelectric point (pi) for many
of the clinically important 13-lactamases.
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1.10.2.3 Ambler (1980)
Until 1980 classifications of B-lactamases had been based on their functional
characteristics. In 1980 Ambler [158] pointed out that structural information, as well
as being able to provide evidence about the origin of the B-lactamases, was
necessary for the elucidation of their mechanism of action and proposed yet another
new nomenclature based on molecular structure. At that time only four amino acid
sequences of B-lactamases were known. A single class of serine enzyme was
designated, the class A B-lactamases that included the Staphylococcus aureus PCI
penicillinase, in contrast to the class B metallo-enzyme from Bacillus cereus. The
class C B-lactamases were described by Jaurin and Grundstrom [159] in 1981. The
class D oxacillin-hydrolyzing 6-lactamases were segregated from the other serine
enzymes in the late 1980s [160,161].
There has always been controversy over the physiological role of 6-lactamases in
the life history of the bacteria which produce them [96,152,155,162]. Homology
was found between the amino acid sequence around the penicillin-binding sites of
the D-alanine carboxypeptidases of the Gram-positive bacteria Bacillus
stearothermophilus and Bacillus subtilis and the active site serine of these class A 6-
lactamases, supporting the hypothesis that these B-lactamases might be derived from
PBPs involved in peptidoglycan synthesis [163,164], Hybridization techniques using
DNA probes were increasingly used during the 1980s to study the molecular basis
for B-lactamase diversity [165].
1.10.2.4 Bush (1989)
Deficiencies in the available B-lactamase classification schemes became apparent
during the 1980s and a modification of the Richmond and Sykes scheme was
proposed by Bush in 1988 [165]. A major reorganization took place. Using substrate
and inhibitor profiles in addition to physical characteristics a compilation of
distinguishing B-lactamase data was provided for both chromosomal and plasmid-
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mediated enzymes [166-168]. Unlike many earlier schemes the Bush scheme did not
use the location of the gene encoding the B-lactamase as a primary classification
factor. This reflected the appreciation of the mobility of 6-lactamase genes, with
chromosomal genes finding their way to plasmids and vice versa.
1.10.2.5 Bush-Jacoby-Medeiros (1995)
In 1995 Bush, Jacoby and Medeiros [169] presented an updated version of the
Bush scheme in which the functional characteristics of B-lactamases based on
substrate preference among penicillin, oxacillin, carbenicillin, cephaloridine,
expanded-spectrum cephalosporins and imipenem were correlated with molecular
structure as first proposed by Ambler [158], in a dendrogram for those enzymes
with known amino acid sequences.
1.10.3 Action of B-lactamases
A few B-lactamases utilise zinc ions to disrupt the B-lactam ring but a far greater
number operate via the serine ester mechanism [170] as shown in Figure 3. The
enzyme first associates noncovalently with the antibiotic to yield the noncovalent
Michaelis complex. The B-lactam ring is then attacked by the free hydroxyl on the
side chain of a serine residue at the active site of the enzyme, yielding a covalent
acyl ester. Hydrolysis of the ester finally liberates active enzyme and the
hydrolyzed, inactive drug. This mechanism is followed by enzymes ofmolecular




















Figure 3 The action of a serine B-lactamase [170,171].
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1.10.4 Distribution of B-lactamases in Gram-negative bacteria
1.10.4.1 Chromosomal enzymes
Matthew and Harris [157] found that nearly all Gram-negative bacteria produced
some chromosomally-determined B-lactamase and that the G-lactamases produced by
strains from one genus always had different pis from those produced by strains from
another genus. This was true even when the genera were fairly closely related
taxonomically and produced enzymes with similar specificities e.g. Citrobacter,
Enterobacter and Serratia whose enzymes are primarily cephalosporinases inhibited
by cloxacillin and methicillin. Matthew and Harris [157] also found that different
species from the same genus always produced different B-lactamases and that the B-
lactamases were species-specific. The pis did not appear to be related to the
biochemical properties of the enzymes, such as the substrate profiles or
susceptibility to B-lactam inhibitors that formed the basis of the Richmond and
Sykes (1973) classification [152]. Enzymes might have similar biochemical
properties and differ greatly in isoelectric focusing; alternatively they might have
very different biochemical properties and yet focus close to one another [157].
Although Matthew and Harris [157] suggested that nearly all Gram-negative
bacteria coded for a species-specific chromosomally-mediated B-lactamase, several
different chromosomal enzymes from the same strain have since been identified
[166].
The regulation of the B-lactamase gene varies in Gram-negative bacteria.
Escherichia coli and shigellae, usually have only insignificant levels of uninducible
molecular class C enzymes, often called AmpC types [172,173]. Other species
produce chromosomal B-lactamases copiously, whether constitutively or inducibly
[155,166-168,173]. Examples include isolates of klebsiellae in which molecular
class A enzymes are constitutive; Enterobacter cloacae, Enterobacter aerogenes,
Citrobacterfreundii, Morganella morganii, Serratia species, Providencia species,
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Pseudomonas aeruginosa and other fluorescent pseudomonads, which have
inducible class C enzymes; Citrobacter diversus, Proteus vulgaris, and Burkholderia
{Pseudomonas) cepacia, which have inducible class A enzymes and
Stenotrophomonas {Xanthomonas) maltophilia, which has an inducible class B
carbapenem-hydrolysing 6-lactamase and an unsequenced Bush group 2e
cephalosporinase.
1.10.4.2 Plasmid-mediated B-lactamases
Over 75 plasmid-mediated B-lactamases were recorded in Gram-negative bacteria
by Bush and colleagues [169] for their classification scheme in 1995, although many
of these enzymes were sequence variants of a few prevalent types. Since then the
numbers have dramatically increased [174]. In general plasmid-mediated 13-
lactamases are distinct from the chromosomal types but a few overlaps exist. In
particular the SHV-1 13-lactamase which is common as a plasmid-mediated type
[175] is also a typical chromosomal 13-lactamase of Klebsiella pneumoniae [170].
Another example is the PSE-4 13-lactamase of Pseudomonas aeruginosa which is
almost always encoded by chromosomally inserted transposons [176]. Plasmid-
borne genes encoding class C 13-lactamases with high sequence homology to the
chromosomal B-lactamases of Citrobacterfreundii (BIL-1, CMY-2, LAT-1),
Pseudomonas aeruginosa (MOX-1) and multiple Gram-negative bacilli (FOX-1)
have been noted since 1988 [177]. It is possible that all plasmid-mediated 6-
lactamases have chromosomal origins [178].
a) "TEM-type" 13-lactamase
Datta and Kontomichalou [143] recognized two different types of R factor-
mediated 6-lactamases and one of these, determined by the R factor RXEM,
subsequently termed R6K [179], was later referred to as the "TEM-type" B-
lactamase [180]. Production of the TEM-type enzyme was later shown to be
mediated by many different R factors [180].
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b) TEM-1 and TEM-2 B-lactamases
The enzymes previously described as "TEM type" [143,180], although uniform in
their biochemical and serological reactions, were noted to be of two types by
isoelectric focusing. One type, exemplified by the enzyme encoded by the plasmid
R6K, previously designated RTEM [179], predominated. It was specified by R factors
of nearly all compatibility groups and was referred to as type TEM-1 [181]. The
other, exemplified by the enzyme encoded by the plasmid RP4, was less common
and was determined by aminority ofplasmids within three groups. It was called
TEM-2 [181].
c) OXA B-lactamases
The other J3-lactamase recognised by Datta and Kontamichalou [143] was
determined by R1818, later termed R46 [182]. Cells carrying R46 differed from those
which produced the TEM-like enzyme in having a lower absolute level of 13-
lactamase activity against benzylpenicillin. The R46 J3-lactamase also differed from
the TEM-like enzyme in hydrolyzing methicillin at a significant rate. Subsequently
the R46 enzyme was shown to hydrolyze oxacillin more rapidly than
benzylpenicillin [183]. It was shown later that several R factors determined the
production of the 13-lactamases which resembled that ofR46 and that these were less
common than the TEM-type enzymes [180]. These oxacillin-hydrolysing enzymes
had been divisible by biochemical tests into two main classes one of which
contained two subclasses [184]. This classification was confirmed by isoelectric
focusing and the enzymes were designated OXA-1, OXA-2 and OXA-3 [181].
d) SHV-1, HMS-1 and PSE-1 - PSE-4 B-lactamases
By 1979 six additional Gram-negative plasmid-mediated 13-lactamases had been
recognized as distinct enzymes [175]. The enzyme designated SHV-1, denoting
"sulphydryl-variable", by Matthew and colleagues [185] but first mentioned by
Pitton [186] was shown to have a substrate profile broadly similar to that of the
TEM 13-lactamases, but differed from the latter in having a greater rate of hydrolysis
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of ampicillin. The most remarkable property of SHV-1 was thought to be its unique
response to inhibition by the sulphydryl group reagent /?CMB, in that the hydrolysis
of cephaloridine but not that of benzylpenicillin was inhibited [185]. It has since
been found that a serine hydroxyl, not a sulphydryl, is the active site residue of
SHV-1 [170]. The gene for SHV-1 was known to be transposon-borne [187].
The enzyme HMS-1 (Hedges, Matthew, Smith) [185] had a substrate profile
resembling that of SHV-1 but it was found to hydrolyze cephaloridine at about three
times the relative rate of SHV-1. In addition, HMS-1 differed from SHV-1 and from
both TEM B-lactamases in that it was sensitive to inhibition by /?CMB whether the
substrate was benzylpenicillin or cephaloridine [175]. The other four enzymes PSE-
1, PSE-2, PSE-3 and PSE-4 were determined by plasmids initially thought to be
Pseudomonas-specific and showed the property ofhydrolysing carbenicillin at least
as fast as benzylpenicillin [175].
e) Extended-Spectrum B-Lactamases
ESBLs are plasmid-mediated enzymes that confer resistance to oxyimino-B-
lactams such as cefotaxime, ceftazidime and aztreonam, antibiotics that were
designed to be effective against strains producing known plasmid-determined B-
lactamases. The first report of klebsiellae resistant to oxyiminocephalosporins came
fro Germany in 1983 [188]. Three unique clinical isolates from the university clinic
in Frankfurt produced a mutationally-altered SHV-1 B-lactamase, designated SHV-
2, that conferred resistance to cefotaxime [188,189]. The first major outbreak due to
ESBL producers, specifically isolates with TEM-3 B-lactamase, occurred around
Clermont-Ferrand in 1985-1987 [19,22] and was soon followed by outbreaks
elsewhere in France [190]. Strains producing ESBLs began to be reported in the
United States in 1989 to 1990 after which major outbreaks occurred [191]. Most
ESBLs are mutant class A oxyimino-B-lactamases derived from the widely prevalent
plasmid-determined TEM-1, TEM-2 and SHV-1 B-lactamases and a few are derived
from the plasmid-mediated OXA-10 B-lactamase [174]. Sixty-seven TEM
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(including the inhibitor-resistant enzymes), 11 SHV and four OXA variants have
been described [174]. The TEM- and SHV-derived ESBLs are commonest in
klebsiellae but occur also in other enterobacteria and the inhibitor-resistant TEM-
derived enzymes have been found in Escherichia coli. The OXA-derived ESBLs
have been found in Pseudomonas aeruginosa [174].
Many more plasmid-mediated B-lactamases including extended-spectrum class A
B-lactamases that are not related to TEM, SHV or OXA 13-lactamases, plasmid-
mediated class C 13-lactamases such as MIR-1 that confer high-level resistance to
cefoxitin and other 7-a-methoxy-B-lactams as well as oxyimino-B-lactams and
carbapenemases (both class B metallo-enzymes and unsequenced non-metallo-
enzymes) have been documented [170,174],
Against this clinical and scientific background, the aim of the present work was
to investigate the cefotaxime resistance mechanisms of AGNB isolated from the
surveillance flora of patients in the ITU undergoing SPEAR and to assess the
implications of such resistance for the continued use of this controversial
prophylactic regimen. The resistance mechanisms most worrying in this context
would be those involving chromosomal AmpC B-lactamase derepression and
plasmid-mediated ESBL production.
In practice the investigation would require the summation of the following
information for each isolate:
• its species identification
• whether it belonged to a chromosomal B-lactamase-inducible species or a
species more commonly associated with ESBL production
• its antibiotic sensitivity pattern
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its plasmid profile
whether its resistance to cefotaxime was transferable
whether any transferable resistance to cefotaxime was associated with the
transfer of a plasmid
whether the isolate produced one or more B-lactamases
the pi value(s) of the B-lactamase(s) produced by the isolate.
Chapter 2 Patients, Materials and Methods
2.1 Isolates and patients
2.1.1 The SPEAR isolates and their identification
As an integral part of SPEAR, the surveillance flora of ITU patients was screened
routinely by disk diffusion testing for resistance to any component of the regimen
(Figure 4). Over a period of two years and ten months (5/8/88 to 20/5/91), 200
consecutive isolates ofAGNB showing resistance to cefotaxime or tobramycin were
collected from throat swabs, tracheal aspirates, rectal swabs and faeces of ITU
patients and stored on nutrient agar slopes in darkness at room temperature. These
were termed the SPEAR isolates. The aim of the present work was to investigate the
cefotaxime resistance of these organisms. Of the 200 isolates in the collection 17
were excluded at the outset: 13 had been submitted from a patient in another ITU,
two isolates had not survived and the identification data for another two was
erroneous. Of the 183 remaining, ten had been recorded as resistant to tobramycin
but sensitive to cefotaxime. Cefotaxime sensitivity was confirmed in eight of these
isolates which were therefore removed from the study. As two of the ten
tobramycin-resistant isolates (although sensitive in vitro to cefotaxime) displayed
features suggestive ofESBL production they were included for full investigation
along with the 173 cefotaxime-resistant strains. Therefore 175 isolates were
investigated in this study.
Species identification was carried out using the API 20 E and 20 NE systems
(bioMerieux, Marcy-l'Etoile, France). Nine isolates - 13, 15, 18, 28, 29, 30, 31, 32
and 95 - grew optimally at 30°C rather than at 37°C. Disk diffusion tests, minimum
inhibitory concentrations (MICs) and transconjugation experiments were carried out
at 30°C on these organisms.
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Figure 4 The three components of SPEAR.
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2.1.2 The patients
The SPEAR isolates were collected from 92 patients aged from 17 to 83 years
(Appendix I) out of a total number of 969 patients admitted to a general
medical/surgical five-bedded ITU (Figure 5) over a period of 2 years and 10
months. The patients comprised 49 male patients (aged from 19 to 78 years) and 43
female patients (aged from 17 to 83 years). The length of time spent in ITU ranged
from 12 hours to 36 days but the mean duration of stay was 9.8 days. Admission to
ITU was for medical reasons in 26 patients and for surgical reasons in 66 patients.
Cefotaxime therapy before admission to ITU was recorded for only five patients (3,
13, 14, 31, and 51).
2.2 Antimicrobial susceptibility testing
2.2.1 Antibiotics
The following antibiotic disks were purchased from Oxoid (Basingstoke, UK):
amoxycillin 20 pg and clavulanic acid 10 pg "co-amoxyclav" (AMC 30); ampicillin
10 pg (AMP 10); azlocillin 75 pg (AZL 75); aztreonam 30 pg (ATM 30);
carbenicillin 100 pg (CAR 100); cefotaxime 30 pg (CTX 30); cefoxitin 30 pg (FOX
30); cephalexin 30 pg (CL 30); ceftazidime 30pg (CAZ 30); ciprofloxacin 5 pg
(CIP 5); erythromycin 15 pg (E 15); gentamicin 10 pg (CN 10); imipenem lOpg
(IPM 10); mecillinam 25 pg (MEL 25); meropenem 10 pg (MEM 10); oxacillin 1
pg (OX 1); penicillin G 10 units (P 10); piperacillin 100 pg (PRL 75); piperacillin
100 pg and tazobactam 10 pg "tazocin" (TZP 110); ticarcillin 75 pg (TIC 75);
ticarcillin 75 pg and clavulanic acid 10 pg "timentin" (TIM 85); trimethoprim 5 pg
(W 5). Temocillin 30 pg (TEM 30) disks were obtained from Mast Laboratories
Ltd. (Bootle, Merseyside, UK).
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Figure 5 The general medical/surgical ITU where the isolates were
collected from patients undergoing SPEAR.
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Adatabs (ampicillin, cefotaxime, ceftazidime, and nalidixic acid) for agar dilution
susceptibility testing were obtained from Mast Laboratories Ltd. (Bootle,
Merseyside, UK) and antibiotic powders were obtained as follows: rifampicin (R
3501, Sigma Chemical Co., Poole, Dorset, UK); Rifampicin BP (Marrion Merrell
Dow Ltd, Uxbridge, Middlesex, UK).
Etest® strips (AB Biodisks, Solna, Sweden) for the detection of ESBLs were
purchased from Cambridge Diagnostics Services Ltd, Cambridge, England).
2.2.2 Disk diffusion tests
Disk diffusion tests were carried out according to National Committee for
Clinical Laboratory Standards (NCCLS) criteria [192]. Organisms were grown
overnight on nutrient agar (CM271, Oxoid, UK) and checked for purity. The
inoculum was prepared by touching the tops of four separate colonies [193] of each
isolate with a sterile disposable loop (Technical Service Consultants Limited,
Heywood, Lancashire) and suspending in 0.85% sterile saline. The inoculum density
was adjusted immediately to match a 0.5 McFarland barium sulphate turbidity
standard and a sterile swab was dipped into the inoculum suspension. The swab was
rotated several times pressing on the inside wall above the fluid level to remove
excess inoculum. The dried surface of a Mueller-Hinton agar (CM337, Oxoid, UK)
plate was inoculated by streaking the swab over the entire agar surface three times
while rotating the plate to ensure an even distribution of inoculum (and a confluent
or almost confluent lawn of growth after incubation). The appropriate drug-
impregnated disks were then placed on the surface of the agar either with sterile
forceps or with disk dispensers (Oxoid, UK) and the plates incubated for 18 hours at
37°C or 30°C depending on the optimal growth temperature of the organism. Zones
of inhibition, including the 6 mm disk diameter, were measured to the nearest mm
using a ruler and recorded. The sizes of the zones of inhibition were interpreted
according to NCCLS guidelines [192],
-46-
2.2.3 Determination of cefotaxime MICs for SPEAR isolates
A standard agar dilution antimicrobial susceptibility test was used [194],
Doubling dilutions of cefotaxime (Adatabs, Mast Laboratories Ltd., Bootle,
Merseyside) ranging from 32 mg/L to 0.5 mg/L were prepared in molten Mueller-
Hinton agar (CM337, Oxoid, UK) at a temperature of approximately 50°C. Aliquots
of each dilution were poured into 85 mm diameter sterile plastic petri dishes
(Sterilin, UK), to a uniform depth of 3-4 mm on a level horizontal surface and the
agar allowed to cool and solidify at room temperature. Plates containing Mueller-
Hinton agar without antibiotic were prepared at the same time to act as growth
medium controls. The plates were used immediately or stored at 4°C and used
within 72 hr.
The purity of each isolate was verified by plating out for single colonies on
nutrient agar (CM271, Oxoid, UK) plates which were incubated aerobically
overnight at 37°C or 30°C according to the optimal growth temperature of the
organism. The inoculum was prepared by touching the tops of four separate colonies
[193] of each isolate and incubating in 10 mL Isosensitest broth (CM473, Oxoid,
UK) overnight at the appropriate temperature. Using a multipoint (19-pin) hand
inoculator and teflon inoculum pot (Mast Diagnostics, Merseyside) the inoculum
was applied in each case at about 3 x 104 cfu per inoculum spot to each of the
cefotaxime dilutions in the prepared plates which were incubated overnight at the
appropriate temperature. An identical preparation of a strain of Escherichia coli,
National Collection of Type Cultures (NCTC) accession number 101418 (Public
Health Laboratory Service, Colindale Avenue, London) was used to test the
consistency of the results with each set of test isolates. The next day the MIC of
cefotaxime for each isolate was read as the lowest concentration of the antibiotic
which had inhibited its growth [194] (Appendices II and IV).
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Isolates 133 and 140 {Klebsiella pneumoniae) were further tested by the methods
described above in a series of cefotaxime dilutions ranging from 2 mg/L to 0.0125
mg/L.
2.2.4 Etest® for ESBL detection
The Etest® (AB Biodisk, Solna, Sweden) for the detection of ESBLs was carried
out on all the SPEAR isolates. The Etest is based on the concepts of both dilution
and diffusion tests. As Etest MIC values are directly proportional to NCCLS
dilution results, NCCLS breakpoints are appropriate for susceptibility categorization
(AB Biodisk, Solna, Sweden). The Etest for ESBL detection consists of a thin, inert
and non-porous plastic strip carrying, at opposite ends, two predefined exponential
gradients of dried and stabilized antibiotics - TZ (ceftazidime 0.5-32 mg/L) and
TZL (ceftazidime 0.064-4 mg/L with clavulanic acid 4 mg/L). When the Etest strip
is applied to an inoculated agar plate the antibiotics are immediately released from
the carrier surface into the agar matrix. After incubation symmetrical inhibition
ellipses are seen unless the organism is resistant to the concentrations of antibiotics
used.
Each SPEAR isolate was plated out on nutrient agar (CM271, Oxoid, UK). After
appropriate incubation an inoculum suspension having a turbidity equivalent to a 0.5
McFarland standard was prepared from each isolate in a test tube containing 0.85%
sterile saline [192]. A sterile swab was dipped into each inoculum suspension and
excess fluid removed by rotating and pressing the swab firmly against the inside
wall of the test tube. The swab was then used to inoculate the entire surface of a
Mueller-Hinton agar plate (CM337, Oxoid, UK) with care to ensure an even
distribution of inoculum. The plates were allowed to sit for approximately ten
minutes so that their surfaces were completely dry before applying the Etest strips.
Escherichia coli NCTC 10418 was used as an ESBL-negative control and an SHV-
2-producing strain of Escherichia coli (kindly provided by Professor SGB Amyes)
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used as an ESBL-positive control. After overnight incubation at 37°C or 30°C
(depending on the optimum growth temperature of the isolate) the MIC values of
ceftazidime and ceftazidime with clavulanic acid for each isolate were read at the
point of intersection between the appropriate inhibition ellipse edge and the Etest
strip.
2.2.5 Ceftazidime MICs for SPEAR isolates
These were determined as an integral part of the Etest® for ESBL detection (AB
Biodisk, Solna, Sweden) as described above.
2.3 Plasmid analysis
2.3.1 Introduction
Most methods for detecting plasmids are variations on the theme of harvesting
bacterial cells, lysing the cells, centrifuging the lysate to remove cell debris,
purifying the resultant DNA and subjecting it to electrophoresis on agarose gels.
Following electrophoresis the gels are stained with ethidium bromide which
intercalates between adjacent base pairs in DNA and fluoresces under ultraviolet
light. DNA can be seen as bright orange bands in the gels with the use of a
transilluminator.
In plasmid preparations it is necessary to separate the plasmid DNA from the
large amount of bacterial chromosomal DNA which is also present in the cells. The
methods are based on the physical differences between plasmid DNA and
chromosomal DNA, the most obvious of which is size. The largest plasmids found
in bacteria are only about eight per cent of the size of the Escherichia coli
chromosome (4700 kb) and most are smaller. Techniques which separate small
DNA molecules from large ones can purify plasmid DNA to the extent required by
screening.
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The usual stage at which to attempt separation on the basis of size is during
preparation of the cell extract. If the cells are lysed under very carefully controlled
conditions then only a minimal amount of chromosomal DNA breakage will occur.
The bacterial cell is enclosed in a cytoplasmic membrane and surrounded by a rigid
cell wall. Gram-negative bacteria are enveloped by an outer membrane. These
barriers have to be disrupted to release the cell components. Chemical rather than
physical methods are most commonly used in DNA preparation. The chemicals that
are used depend on the species of bacterium involved. Weakening of the cell wall is
usually brought about by ethylenediaminetetraacetic acid (EDTA), lysozyme, or a
combination of both. EDTA removes divalent cations (magnesium Mg2+ and
calcium Ca2+) which help stabilize the membrane by combining with negative
charges of the phospholipids [195 {p63}] and are essential for preserving the overall
structure of the cell envelope, producing a non-specific increase in cellular
permeability [196,197]. EDTA, by chelating metal ions, also inhibits cation-
dependent nucleases which could degrade DNA [198]. Lysozyme is a protein which
breaks the B 1,4-glycosidic bonds between A-acetylglucosamine and N-
acetylmuramic acid in peptidoglycan.
The outer membrane ofGram-negative bacteria is disrupted by EDTA and this
allows lysozyme to degrade the peptidoglycan layer of the cell wall so that
sphaeroplasts are formed. In order to expedite a more controlled, gentle lysis these
reactions may be carried out in the presence of a sufficient concentration of sucrose
or other sugar to prevent immediate osmotic lysis of the sphaeroplasts [198]. Under
some conditions weakening of the cell wall with lysozyme or EDTA is sufficient to
cause the bacterial cells to lyse, but usually a detergent such as sodium dodecyl
sulphate (SDS) or Triton X-100 is also added. Detergent molecules disrupt
membranes by intercalating into phospholipid bilayers and solubilizing lipids and
proteins [199 {p582}]. Ionic detergents such as SDS contain a charged polar head.
They bind to the hydrophobic regions of proteins. They also alter the conformation
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of the hydrophilic regions and disrupt non-covalent bonds such as ionic and
hydrogen bonds. At high concentrations SDS completely denatures proteins.
Nonionic detergents such as Triton X-100 do not have a charged group. Usually
they solubilize biological membranes by forming mixed micelles of detergent,
phospholipid and integral membrane proteins. They generally do not denature
proteins [199 {p583}] and are thought to promote a more gentle lysis [200].
However some bacteria are not lysed by them.
At this stage the bacterial cell extract contains chromosomal DNA, plasmid
DNA, protein and ribonucleic acid (RNA). If the cells have been lysed under
carefully controlled conditions then only a small amount of chromosomal DNA
breakage will have occurred. The resulting chromosomal DNA fragments are still
much larger than the plasmids and are removed with the cell debris by
centrifugation, a clearing spin, of the crude cell extracts to leave a cleared lysate
consisting mainly of plasmid DNA [201 {p32}]. This process is aided by the fact
that the bacterial chromosome is physically attached to the cell envelope and
fragments are likely to sediment with the cell debris if these attachments are not
broken. A cleared lysate does, however, invariably retain some chromosomal DNA.
This is the reason why size fractionation on its own is insufficient if pure plasmid
DNA is required. Furthermore, if the plasmids are themselves large molecules then
they may also sediment with the cell debris.
In addition to size, plasmid and chromosomal DNA differ in conformation. This
refers to the overall spatial configuration of the molecule, with the two simplest
conformations being linear and circular. The bacterial chromosome is circular, but
during preparation of the cell extract the chromosome will always be broken to give
linear fragments. It is simplistic to say that plasmids have a circular conformation,
because double-stranded DNA circles can in fact take up one of two quite distinct
configurations. Most plasmids exist in the cell as supercoiled molecules.
Supercoiling occurs because the double helix of the plasmid DNA is partially
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unwound by DNA gyrase during the plasmid replication process. The supercoiled
configuration can be maintained only if both polynucleotide strands are intact and is
known as covalently closed circular (CCC) DNA. If one of the polynucleotide
strands is broken, then the double helix will revert to its normal relaxed state and the
plasmid will take on the alternative, open circular (OC), conformation.
Supercoiling is exploited in plasmid preparations because supercoiled molecules
can be separated from non-supercoiled DNA in crude cell extracts or cleared lysates
by such rapid methods as boiling or alkaline denaturation [202 {pi.25-1.30}] or the
very time-consuming, labour-intensive and expensive process of caesium chloride-
ethidium bromide density gradient centrifugation [202 {pi.42-1.46}]. The plasmid
DNA resulting from the last method is virtually pure whereas the rapid preparations
are invariably contaminated to a greater or lesser extent with chromosomal DNA.
However these rapid preparations are often in practice adequate for analysis with
restriction enzymes, for transformation and even in many cases for cloning [122
{pi4},200] without resorting to caesium chloride-ethidium bromide density gradient
centrifugation [202 {pi.23-1.24}].
Boiling or treatment with alkali disrupts base pairing, causing the linear
chromosomal DNA to denature. However the strands of CCC plasmid DNA are
unable to separate from one another because they are topologically intertwined.
When conditions are returned to normal, provided the exposure to heat or alkali has
not been prolonged, the strands of the plasmid DNA rapidly "fall into perfect
register" and completely native superhelical molecules are re-formed [202 {pi.22}].
An additional advantage of the alkaline denaturation procedure is that under
certain circumstances most of the protein and RNA will also become insoluble and
be removed by the centrifugation step [201 {p33}]. In the cases of the other rapid
procedures phenol or phenohchloroform extraction and ribonuclease treatment are
needed to remove protein and RNA [200,201 {p27}]. Following any of the rapid
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preparations the plasmid DNA can be concentrated finally by precipitation, usually
with ethanol [203 {pE.10 - E. 14}]
The choice of method for preparation of plasmid DNA is determined largely by
the aims of the investigator and depends on how pure the plasmid DNA has to be
and the quantity required. If the intention is to digest the DNA subsequently with
restriction enzymes or more especially to use it in cloning experiments then it is
essential to purify the DNA from clinical isolates.
2.3.1.2 Plasmid trapping
Cell density is the major parameter altered when preparing plasmid DNA from
different genera (DJ Piatt, personal communication). What exactly is the optimum
cell density? The process has not received much attention possibly because many
molecular biologists are working with small vector plasmids in Escherichia coli. In
the process of lysis and centrifugation, lysis releases cell contents including plasmid
and chromosomal DNA and the lysate becomes viscous. Centrifugation pellets cell
debris, including the majority of the chromosomal DNA except small linear shear-
fragments. However as this material travels to the bottom of the tube it can trap
plasmid DNA thereby reducing the yield. If this results in a final concentration of
plasmid DNA below the critical threshold for ethidium bromide detection, then false
negative results will be obtained.
Plasmid trapping may differ with genus because the properties of chromosomal
DNA differ (DJ Piatt, personal communication). The theory is that the genomes of
Klebsiella, Enterobacter and Serratia species are larger than that of Escherichia
coli. Whereas Escherichia coli would continue to give positive results at high cell
densities, strains of Klebsiella, Enterobacter and Serratia species would suffer from
excessive plasmid trapping by their large chromosomes at higher cell densities and
this would reduce the effective range of cell densities for these genera. A reduced
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cell density could be used in the preparation of the lysates but presumably there
would be a critical mass of cells below which plasmids would not be detected.
Are the chromosomes ofKlebsiella, Serratia and Enterobacter species larger than
that ofEscherichia coli ? Prior to 1970 the genome size of bacterial DNA was
known only for a very few species [204], With the application of the technique of
renaturation of single-stranded DNA substantial data became available [205]. The
sizes quoted for the genome ofEscherichia coli ranged from 2200 to 2980
megadaltons (MDa) [204,206,207]; for Klebsiella species 2360 to 2580 MDa
[204,206]; for Serratia marcescens 5020 to 5560 MDa [204] and for Pseudomonas
species 2530 to 6960 MDa [204,206]. A reference for genome size in Enterobacter
species was not found [204]. Modern sequencing methods [208] are now in progress
for the determination of bacterial genome sizes: that of Escherichia coli is reported
as 4600 kb (2921 MDa). Work on Klebsiella pneumoniae strain M6H 78578 is in
progress. There is no information yet on the genome sizes of Enterobacter or
Serratia species. The genome size of Pseudomonas aeruginosa strain PAOl is
reported as 5900 kb (3746 MDa).
Another way to approach the problem is not to reduce the cell density but to
emulsify the cells in electrophoresis buffer with additional EDTA, which has mild
detergent activities and prevents nuclease activity. The overall effect may be a
gentler lysis of the cells and protection of the supercoiling ofDNA with less
shearing of the chromosome. An additional factor in some genera is the fragility of
chromosomal DNA. In lower cell densities ofSalmonella, large plasmids can be
detected readily but plasmids < 30 kb are obscured because chromosomal shear-
fragments occupy a more extensive region of the track than is usual. This can be
overcome by using a higher cell density. It seems that in this situation a higher
concentration of chromosomal DNA protects against shear without significant
reduction in plasmid yield by entrapment (DJ Piatt, personal communication). The
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role of chromosomal trapping of plasmids may vary also with the size of the
plasmid: the larger the plasmid the more easily it is trapped.
2.3.2 Preparation of plasmid DNA
One of the aims of the present study was to determine whether the resistance of
any of the SPEAR isolates to cefotaxime was plasmid-mediated. It was necessary to
find out first whether the isolates actually carried plasmids and then to carry out
transconjugation experiments to determine whether the cefotaxime resistance could
be transferred to a recipient organism by transfer of a plasmid.
The method chosen for this work was based on that described by Piatt and
colleagues [209]. It had been designed to generate plasmid profiles from large
numbers of clinical isolates with speed and flexibility and to be applicable, with
minimal modifications, to diverse bacterial genera.
The purity of each isolate was checked by plating out for single colonies on
nutrient agar (CM271, Oxoid, UK) and incubating overnight at 37°C or 30°C. Using
a sterile disposable plastic loop (Technical Service Consultants Limited, Heywood,
Lancashire) 3 loopfuls of bacterial culture were transferred to a 1*5 mL eppendorf
tube (Treff, Scotlab, Paisley, Scotland) containing 300 pL of Tris-borate-EDTA
(TBE) electrophoresis buffer pH 8-3 comprising Trizma,
Tris(hydroxymethyl)aminomethane base 89 mM, boric acid 89 mM, and EDTA
1.25 mM (all Sigma Chemical Co., Poole, Dorset, UK). The pH of the TBE buffer
was measured using a Tris-compatible electrode [210 {p5-6}]. In certain
circumstances 50 pL EDTA (50 mM) were added to the 300 pL aliquot of TBE
electrophoresis buffer at this stage (see above). After thoroughly emulsifying the
bacterial cells in the buffer using a sterile wooden swab stick, 200 pL SDS (Sigma
Chemical Co., Poole, Dorset, UK) 10% weight/volume solution in TBE buffer, were
added to the eppendorf tube which was inverted two or three times very gently in
order to mix the contents and then incubated in a water bath at 50°C for five to ten
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minutes to aid bacterial cell lysis. On removal from the water bath the eppendorf
tube was centrifuged for 15 minutes at 11,600 g (MSE Micro-Centaur centrifuge,
MSE, Loughborough, Leicestershire, UK). The pellet of bacterial and chromosomal
debris was removed using a micropipette, leaving behind the supernatant containing
the plasmid DNA, i.e. the cleared lysate [201 {p32}].
2.3.2.1 Observations
The crucial step was the initial emulsification of the harvested bacteria in TBE
buffer and this seemed to depend greatly on the slime content of the cells. When this
was excessive fewer cells could be emulsified and the concentration ofDNA must
inevitably have been smaller. Attempts to emulsify too high a cell density resulted in
minimal or no supernatant (i.e. lysate) after the centrifiigation stage, i.e. everything
was entrapped by slime. This happened more often with isolates ofAcinetobacter
species and Pseudomonas species. Harvesting the bacteria in nutrient broth rather
than solid media, followed by several washes either in nutrient broth or in TBE
buffer followed by centrifugation did not improve emulsification in several strains
ofAcinetobacter and Pseudomonas species. Moreover, the practice of using TBE
buffer with additional EDTA as described above to minimise plasmid trapping was
not appropriate for certain mucoid isolates which emulsified even less easily in this
solution. In the case of very mucoid isolates it was helpful to use cultures after
approximately twelve hours of incubation when the slime production was less.
A modification of an alkaline extraction technique [211] was tried out only once
in conjunction with the method of Piatt and colleagues [209] on the Escherichia coli
strain 39R861 which carried four of the reference plasmids (bacterial strain and
plasmids to be described below). RNAase treatment of the resulting lysates was not
required, otherwise the results were not as good as those achieved using the method
of Piatt and colleagues [209] on its own.
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2.3.2.2 Reference plasmids
Six reference plasmids were used routinely for molecular weight determinations.
The largest of these, RTS 1 [212], contained in an Escherichia coli K12 host J53-1
was kindly provided by DJ Piatt, Department of Bacteriology, Glasgow Royal
Infirmary as a reference plasmid of 120 MDa. In transconjugation experiments
carried out in Escherichia coli hosts Ishihara and colleagues [213] found that RTS 1
gave rise to two kinds of deletion mutants with molecular weights of approximately
120 MDa and 100 MDa in co-sedimentation studies with known plasmids using
alkaline sucrose density centrifugation techniques. They reported the molecular
weight of the "original RTS 1" plasmid as 140 MDa [213]. However the RTS 1
plasmid, part of the Datta Collection [214 {pi}], had been donated to Dr Piatt by
Professor Datta as a plasmid of molecular weight 120 MDa "in her hands" (DJ Piatt,
personal communication). Piatt and colleagues [209] used RTS 1 as a reference
plasmid ofmolecular weight 120 MDa (174 kb) multiplying by a factor of 1*45 to
convert from MDa to kb. Throughout the present work the more recently
recommended conversion factor of 1.575 [203 {pC.3}] has been used. The
molecular weight of the RTS 1 reference plasmid was therefore designated 189 kb.
Strain 39R861 NCTC 50192, an Escherichia coli K12 construct (kindly provided
by DJ Piatt), was used as a molecular weight standard containing four reference
plasmids ofmolecular weights 98, 42, 23*9 and 4*6 MDa [215] i.e. 154*35 kb, 66*15
kb, 37*64 kb and 7*25 kb respectively.
The sixth and smallest reference plasmid was pUC9, molecular weight 2*68 kb,
in host strain Escherichia coli DS 941 donated by Professor D Sherratt,
Microbiology Unit, Department of Biochemistry, University of Oxford.
Cell lysates of the three bacterial host strains containing the reference plasmids
were prepared exactly as those of the test isolates. These reference plasmids were
included in each rim in order to check the technical acceptability of the system and
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to allow sizing of the test plasmids by comparing their distance ofmigration with
that of the reference plasmids.
DNA extracts of a very large plasmid pMG5 (491 kb), contained in the host
strain Pseudomonas aeruginosa PU21 (NCTC 50534), were also prepared as
described above and subjected to electrophoresis in order to determine whether the
system was capable of detecting such a large plasmid.
2.3.2.3 Preparation of cleared lysates for loading on to gels
A 45 pL volume of each lysate was transferred to a sterile eppendorf tube and
ribonucleic acid (RNA) was removed using Ribonuclease A (RNAase, Sigma
Chemical Company, UK), 1 pL of a lmg/mL solution in deionized water per 10 pL
of lysate. Prior to storage stock solutions (10 mg/mL) ofRNAase were boiled for 15
minutes to destroy any possible DNAase activity. Loading buffer consisting of
glycerol (Sigma Chemical Company, UK) 30% in deionized water and bromophenol
blue (Sigma Chemical Company, UK) 0.25% was added in volumetric ratio of 1 to
6 [202 {p6.12}] with the lysate to ensure that the preparation did not float out of the
well and to enable the sample to be visualized during electrophoresis. The total
sample volume routinely loaded was 45 pL.
2.3.3 Agarose Gel Electrophoresis
2.3.3.1 Introduction
Electrophoresis through agarose or polyacrylamide gels is the standard method
used to separate, identify and purify nucleic acids [202 {p6.2}]. DNA is negatively
charged by virtue of its phosphate groups. Electrophoresis is the procedure by which
charged molecules are allowed to migrate in an electric field [195 {pi89}], their rate
ofmigration or mobility depending on the strength of the field, on the net charge,
size and shape of the molecules and also on the ionic strength, viscosity and
temperature of the medium in which the molecules are moving. The gel is a
complex network of fibrils which acts as a molecular sieve and its pore size can be
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controlled by the way in which the gel is prepared. The nucleic acid molecules
migrate through the pores at rates dependent on their molecular weight and
molecular shape. Small or compact molecules migrate more rapidly than large or
loose molecules which are impeded to a greater extent by the gel matrix. DNA can
exist in various conformations, CCC, OC and linear forms and although this does
not affect charge, it does affect molecular sieving.
Agarose, a highly purified polysaccharide extracted from seaweed, is a linear
polymer whose basic structure consists of alternating D-galactose and 3,6-anhydro
L-galactose molecules [202 {p6.3}]. Agarose, which comes in powder form
dissolves when added to boiling liquid. It remains in a liquid state until the
temperature is lowered to about 40°C, at which point it gels. The gel is stable and
will not dissolve again until the temperature is raised back to about 100°C. Its pore
size may be predetermined by adjusting the concentration of agarose in the gel: the
higher the concentration, the smaller the pore size. Therefore agarose gels can be
poured in a variety of shapes, sizes and porosities and can be run in a variety of
configurations.
The most commonly used configuration is the horizontal slab gel [202 {p6.8}]
which is usually poured on a glass plate or plastic tray which can be installed on a
platform in the electrophoresis tank. Electrophoresis is carried out with the gel
submerged just beneath the surface of the buffer i.e. horizontal submarine gel
electrophoresis. The resistance of the gel to the passage of electric current is almost
the same as that of the buffer and so a considerable fraction of the applied current
passes along the length of the gel. Grinsted and Bennett [216] recommend horizontal
rather than vertical gel electrophoresis because horizontal gels are much easier to
prepare, use and process afterwards. However one advantage of vertical gels is that
the wells can be deeper and therefore that larger samples can be run.
Agarose gels are cast by melting the agarose in an appropriate buffer until a clear,
transparent solution is achieved. The melted solution is poured into a mould or gel
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tray and allowed to harden. On hardening, the agarose forms a matrix, the density of
which is determined by the concentration of the agarose. When an electric field is
applied across the gel, DNA, which is negatively charged, migrates towards the
anode [202 {p6.3}]. After a defined period of time ofmigration the locations of the
DNA molecules in the gel are assessed by making them fluorescent and observing
the gel with ultraviolet radiation.
Plasmids vary greatly in size from about 1 kb to greater than 400 kb [217]. The
problem is that natural isolates can contain multiple plasmids, both large and small,
which must be displayed on the same gel to give a plasmid profile [200].
The use of agarose gel electrophoresis for the detection and preliminary
characterization of CCC plasmid DNA in clinical isolates and laboratory strains of
Gram-negative bacteria was first reported in 1976 [218]. Prior to this Aaij and Borst
[219] had reported that the migration rates of purified bacteriophage and
mitochondrial CCC DNAs ranging from 3*4 x 106 to 10 x 106 daltons, i.e. 5 to 16
kb, were related inversely to the logarithm of their mass in 0*6% agarose gels.
Subsequently agarose gel electrophoresis was employed widely in the analysis of
restriction-endonuclease-generated fragments of plasmid and viral DNA [218].
However the migration properties of higher molecular weight CCC DNA had been
overlooked. Plasmids in a fresh preparation usually consist of double-stranded DNA
and are generally isolated as circular molecules in which each of the single strands is
a covalently closed circle [200]. A small amount of the OC form may be present
which increases as the preparation ages and sometimes even the linear form
eventually appears [200].
Meyers and colleagues [218] found agarose gel electrophoresis to be suitable for
the detection and estimation of plasmid DNA ofmolecular weight ranging from 0.6
x 106 to 95 x 106 daltons in partially purified whole-cell lysates. Expressed in kb
[220] this is a size range from approximately 0*9 to 150 kb, as 106 daltons are
equivalent to 1*575 kb [203 {pC.3}]. Meyers and colleagues [218] found that the
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migrations of these CCC plasmid DNA species were related inversely to their
molecular weights i.e. the larger the molecular weight the slower the migration.
Willshaw and colleagues [221] further investigated the problems encountered in
using agarose gel electrophoresis in the analysis of wild enterobacterial strains.
Using 0.75% agarose gels they obtained a reliable estimate of molecular sizes over a
wide range, 3 x 106 to 80 x 106 daltons (5-126 kb) for which molecular weight and
relative mobility were linearly related. Gels were calibrated using a plot of the
logarithm of relative migration of the DNA through the gel versus the logarithm of
plasmid molecular weight. Within the range quoted above, plasmid sizes determined
by electrophoresis were within 10% of the values determined by electron
microscopy and physical measurements. For large plasmids up to 144 x 106 daltons
(227 kb) the linear relationship was no longer valid and the resolution of plasmid
species was reduced. With 1% agarose plasmid mobility was a linear function of
molecular size from 3 x 106 daltons to 50 x 106 daltons (5 to 79 kb) and these
conditions were not used for the molecular weight determination of large plasmids.
Molecular weights in excess of 80 x 106 daltons (127 kb) could be determined on
0.65% gels but at this agarose concentration the mobilities of plasmids smaller than
10 x 106 daltons (16 kb) were less than would be predicted from a linear relationship
between molecular weight and relative mobility [221],
2.3.3.2 Observations
Meyers and colleagues [218] obtained partially purified plasmid DNA by ethanol
precipitation of phenol-treated cleared lysates. Willshaw and colleagues [221] used
"crude ethanol-precipitated DNA". Both Meyers and colleagues [218] and Willshaw
and colleagues [221] used vertical agarose gels of 15 cm length. Sample volumes
were 5, 10 or 25 pL [218] and 2-100 pL [221],
In the present work partial purification of plasmid DNA was carried out as
described by Piatt and colleagues [209] who used cleared lysates without further
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purification (i.e. without phenol treatment and ethanol precipitation). They used
large volumes (100 pL) of these "crude" lysates on vertical gels of 15 cm length
whereas in the present work commercial horizontal gel electrophoresis apparatus
was used with necessarily smaller (45 pL) volumes of lysates.
These observations raised a number of questions. Would the smaller volumes of
lysates reduce the sensitivity of horizontal gels? Would horizontal gels have to be
longer than vertical gels to compensate for "lack of gravity" and to allow time for
large plasmids to enter the gels before smaller plasmids had migrated off the ends?
Would large plasmids even enter horizontal gels? At what voltage should the gels be
run? Would a higher voltage be needed to drive large plasmids into horizontal gels?
When choosing electrophoresis conditions a balance has to be struck between
sharpness and separation [222]. In general, large DNA fragments are best resolved
by subjecting gels to electrophoresis for long times at low voltage gradients.
According to Sambrook and colleagues [202 {p6.6}] agarose gels should be run at
no more than 5 V/cm to obtain maximum resolution ofDNA fragments greater than
2 kb in size but the authors were referring to linear DNA fragments. According to
Sealey and Southern [222] smaller fragments diffuse faster and therefore band
sharpness is increased by using high voltage gradients for electrophoresis. These
authors describe analogous situations with regard to gel length and gel
concentration. The further that fragments migrate the greater is the separation
between them. However increasing the migration distance requires either longer
times or higher voltage gradients which may lead to increased diffusion of small
fragments or less separation of large fragments respectively. In general separation is
better on gels of higher concentration for equivalent distances migrated. However
large DNA fragments move so slowly in concentrated gels that lower concentration
gels must be used [222]. In order to encompass some of these variables, three
horizontal electrophoresis systems of different dimensions were used in the present
work to screen the SPEAR isolates.
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2.3.3.3 Materials and Methods
Three horizontal electrophoresis systems of different sizes were used (Figure 6):
the GNA-100 (Pharmacia Molecular Biology, Uppsala, Sweden) mini-gel, the
Horizon™ 11*14 medium-size (11 x 14 cm) gel and the Horizon™ 20*25 large (20 x
25 cm) gel (both Gibco BRL, Paisley, Scotland, UK). Each SPEAR isolate was
examined at least twice: once on a medium-length (14 cm) and once on a long gel
(25 cm) and often on multiple gels. Transconjugants from the control broth-mating
systems were examined on the mini-gel system and those from the additional
transconjugation studies were examined on both the mini- and medium-gel systems.
Ultra-pure electrophoresis grade agarose (Gibco BRL, Paisley, Scotland) was
weighed and transferred to a glass beaker. An appropriate volume of TBE buffer, as
described above in the preparation of plasmids, was added to give an agarose
concentration of 0*7%. The beaker was placed on a tripod stand over a Bunsen
burner and heated until the agarose dissolved in the boiling liquid and the solution
appeared clear. The mixture was swirled continuously around the container during
heating to prevent scorching. The molten agarose was then placed in a water bath at
50°C. Gels were prepared by pouring the molten agarose, cooled to 50°C, to a depth
of 5-6 mm on to the bubble-levelled ultraviolet light translucent trays of the GNA-
100 (Pharmacia Molecular Biology, Uppsala, Sweden) horizontal mini-, medium or
large gel electrophoresis systems.
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Figure 6 The power supply, mini-, medium and large gel tanks used in
agarose gel electrophoresis.
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Wells were formed in each gel according to the apparatus being used by the
positioning of one of a variety of Noryl® plastic (Pharmacia Molecular Biology,
Uppsala, Sweden) or Delrin® (Gibco BRL, Paisley, Scotland, UK) combs of
different sizes in the molten agarose and removing them when the agarose was
completely set (approximately 30-45 minutes at room temperature) by which time
the gel had assumed a slight "bloom" or opacity. Removal of the comb without
tearing the bottom of the wells was facilitated each time by very gently wiggling the
comb to free the teeth from the gel, slightly lifting up one side of the comb, then the
other.
TBE buffer (described above in the preparation of plasmid DNA) was used as the
running electrophoresis buffer. The same batch of TBE buffer was always used in
both the electrophoresis tank and the gel to prevent small differences in ionic
strength or pH creating fronts in the gel which might affect the mobility ofDNA
fragments [202 {p6.9}]. TBE buffer was poured into the gel tank until the gel was
submerged to a depth of no more than 1-2 mm to prevent drying of the gel and to
ensure an even voltage gradient across the gel bed. Submerging to a depth greater
than 2 mm is unnecessary and increases electrical current and heat. The prepared
lysates containing loading buffer were each carefully loaded, under the buffer, into
the wells using a micropipette and disposable 200 pL sterile plastic tips.
Each electrophoresis apparatus was fitted with a safety lid which could not be
removed while electrical current was flowing through the system. In each case
power was provided by a constant voltage Gene Power Supply (Figure 6), GPS
200/400 (Pharmacia LKB Biotechnology, Uppsala, Sweden). Routine running
parameters for each electrophoresis system were 100 V for 2.5 hours (GNA-100),
100 V for 3.5 hours (Horizon™ 11*14) and 150 V for 6.5 hours (Horizon™ 20*25).
All gels were run at room temperature.
Lambda DNA///md III fragments (Gibco BRL, Paisley, Scotland) were included
in many runs only because of familiarity with their optimum appearance in a
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technically satisfactory run. It must be emphasized that the digest markers in this
preparation consist of linear DNA and as such were NOT appropriate for
comparative sizing of plasmid DNA which is mainly supercoiled.
2.3.4 Analysis of gels after electrophoresis
2.3.4.1 Introduction
The most convenient way of visualizing DNA in agarose gels is staining with the
fluorescent dye ethidium bromide [223] which contains a planar group which
intercalates between the stacked bases ofDNA. The fixed position of this group and
its close proximity to the bases cause dye bound to DNA to display an increased
fluorescent yield compared to that of dye in free solution. Ultraviolet radiation at
254 nm is absorbed by the DNA and transmitted to the dye whereas radiation at 302
nm and 366 nm is absorbed by the bound dye itself. In both cases the energy is re-
emitted at 590 nm in the red-orange region of the visible spectrum. Small amounts
ofDNA can be detected in the presence of free ethidium bromide in the gel because
the fluorescent yield of ethidium bromide:DNA complexes is much greater than that
of unbound dye [202 {p6.15}].
2.3.4.2 Materials and methods
On completion of the run, the gel was removed from the tank and stained with
ethidium bromide (Sigma Chemical Co., Poole, Dorset, UK) at a concentration of
0.5 mg/L in TBE electrophoresis buffer for 45 min. The gel was then destained for
20 min in changes of TBE buffer and deionized water in order to reduce excessive
background fluorescence of the gels and improve photographic appearances.
Prolonged destaining can cause loss of DNA-bound dye.
In order to analyse the pattern obtained and to keep a permanent record,
photography of the gels was carried out in a darkroom using a Polaroid MP-4 Land
Camera (Polaroid Ltd, Ashley Road, St Albans, Hertfordshire,UK) and Polaroid
Type 667 black and white film ISO 3000 (Sigma Chemical Co, Poole, Dorset, UK)
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while the gels were transilluminated with ultraviolet light provided by either a short¬
wave (254 nm) or medium-wave (302 nm) transilluminator (UV Products Ltd,
Science Park, Milton Road, Cambridge, UK) depending on the availability of access
to equipment. Most of the photographs were taken using the medium-wave (302
nm) transilluminator. The fluorescent yield of ethidium bromide:DNA complexes is
considerably greater at 302 nm than at 366 nm and slightly less than at short-
wavelength (254 nm) light. However the amount of nicking of the DNA is much
less at 302 nm than at 254 nm [202 {p6.19}]. Therefore for general use illumination
at 302 nm is preferred [222]. Photographs were taken through filters: a Kodak 2B
Wratten ultraviolet-blocking filter (Sigma Chemical Co., Poole, Dorset, UK) was
used in conjunction with a Kodak 23A Wratten red gelatin filter (Sigma Chemical
Co., Poole, Dorset, UK) to provide the highest contrast. Using a filter frame holder
(Sigma Chemical Co., Poole, Dorset, UK) the filters were orientated so that the red
23A filter was adjacent to the camera lens and the ultraviolet filter was between the
light source and the red filter. In the photographs plasmids and chromosomes
appeared as white bands against the dark background of the gel.
2.3.5 Estimation of plasmid size in the SPEAR isolates
Unknown plasmid sizes were estimated by comparing their mobilities with those of
the reference plasmids which were included in each gel. Figure 7 shows a
photograph of gel 69 (a typical medium-size agarose gel) run on the Horizon™ 11*
14 electrophoresis equipment. Distances (mm) migrated by the plasmids from the
edge of the well to the leading edge of the band were measured in the middle of the
track on the Polaroid photographs viewed under an illuminated magnifier (Luxo,
Gibco BRL, Paisley, Scotland). These distances were measured to the nearest 0*5
mm using a steel engineer's ruler (No. 147, England, UK). A plot of migration
(distances in mm) against plasmid size (molecular weight in kb) for the reference
plasmids gave a curved line. As interpolation is much more accurate if a function
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can be found which gives a straight line [222], the natural logarithm ofmigration in
mm was plotted against the natural logarithm ofmolecular weight in kb using the
LINEST function [224 {p254}] in a spreadsheet designed for the purpose. The
LINEST function uses the least squares method to calculate a straight line that best
fits the data and returns an array that describes the line and provides regression
statistics such as r2 - the coefficient of determination. Calibration spreadsheets were
calculated for each gel and the sizes (kb) of unknown plasmids were determined by
applying the natural logarithms of their migration distances (mm) to the straight line
equation on the spreadsheet. Figure 8 shows the spreadsheet for gel 69. The r2
statistic, depicted in bold red italics in the LINEST array in Figure 8, compares
estimated and actual y-values and ranges from 0 to 1. If it is 1, there is a perfect
correlation in the sample i.e. there is no difference between the estimated y-value
and the actual y-value. At the other extreme, if the r2 statistic is 0, the regression
equation is not helpful in predicting a y-value [224].
2.4 Transconjugation experiments: test and control systems
2.4.1 Introduction
The aim of the transconjugation experiments was to determine whether resistance
of any of the SPEAR isolates to cefotaxime could be transferred to a recipient
organism by conjugation. Each SPEAR isolate would be regarded as a potential
donor organism in broth-mating experiments with a suitable recipient bacterium














Figure 7 Agarose gel 069: Lane B - four reference plasmids from
strain 39R861. Lane C - RTS 1 reference plasmid. Lane D -
pUC9 reference plasmid (the sizes of the reference plasmids
are shown on the left). Lane L - A.DNA/Hind III fragments.
Lanes A, E to K, M and N - plasmid bands from SPEAR
isolates 141, 100, 101, 102, 116, 121, 126, 134, 146 and
147.
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(loq mm) -0.382587698 4.396592196 2.391164271
189 11.0 5.24175 2.39790 0.007971507 0.030615325 2.468647563
154.35 12.0 5.03922 2.48491 0.99826649 0.030381545 2.792813301
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T 11.0 2.39790 5.22415 185.70
T 12.0 2.48491 4.99673 147.93
T 16.5 2.80336 4.16436 64.35
T 19.5 2.97041 3.72771 41.58
T 37.0 3.61092 2.05358 7.80
T 57.5 4.05178 0.90125 2.46
141 11.5 2.44235 5.10797 165.33
100 12.0 r 2.48491 4.99673 147.93
100 35.0 3.55535 2.19883 9.01
100 46.0 3.82864 1.48450 4.41
101 12.0 2.48491 4.99673 147.93
101 35.0 3.55535 2.19883 9.01
101 46.0 3.82864 1.48450 4.41
102 12.0 2.48491 4.99673 147.93
102 35.0 3.55535 2.19883 9.01
102 46.0 3.82864 1.48450 4.41
116 11.0 2.39790 5.22415 185.70
121 11.5 2.44235 5.10797 165.33
126 13.0 2.56495 4.78751 120.00
126 47.0 3.85015 1.42829 4.17
134 11.5 2.44235 5.10797 165.33
146 13.0 2.56495 4.78751 120.00
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Figure 8 Calibration of agarose gel 069 with a log - log least squares
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straight line fit using Microsoft Excel spreadsheet
functions 'LINEST' and 'TREND'. The 'r2 statistic' (in bold
red italics above) gives an indication of how well the
straight line equation explains the relationship between the
variables. Unknown plasmid sizes are then read off using
this equation.
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If resistance to cefotaxime were transferable from a SPEAR donor isolate to the
recipient bacterium then the cefotaxime-sensitive recipient bacterium would acquire
resistance to cefotaxime, becoming a cefotaxime-resistant transconjugant. Such a
transconjugant would be counterselected on a solid medium containing two
antibiotics: cefotaxime which would inhibit the growth of the recipient organism
and another antibiotic which would inhibit growth of the donor bacterium.
It would be necessary to confirm the identity of any putative transconjugant and
to distinguish it from spurious overgrowth of either the donor or recipient organism
on the selective plates. A transconjugant would be identical morphologically and
biochemically (API 20 E system) to the recipient bacterium but would be resistant to
cefotaxime. Finally the putative transconjugant would undergo agarose gel
electrophoresis as previously described in order to determine whether it had
acquired a plasmid from the donor SPEAR isolate to account for its resistance to
cefotaxime.
In order to carry out the transconjugation experiments a suitable recipient
bacterium had to be chosen which was sensitive to cefotaxime, with an MIC at least
fourfold less than each of the SPEAR isolates, but resistant to another antibiotic to
which all the SPEAR isolates were sensitive. For this purpose it was necessary to
determine for each SPEAR isolate, i.e. each potential donor isolate, the MICs of any
antibiotics which might be used to counterselect for transconjugants. The choice of
recipient bacterium lay between two strains of Escherichia coli: either DH5a
(kindly provided by Dr Russell Thompson, Institute of Virology, University of
Glasgow) derived from DH5a ™ Competent Cells (Gibco BRL, Paisley, Scotland,
UK) which was resistant to nalidixic acid or J62-2, a strain ofEscherichia coli SA
128 (kindly provided by Professor SGB Amyes) which was resistant to rifampicin.
Ideally the MIC of the chosen antibiotic (nalidixic acid or rifampicin) for the
recipient bacterium would be at least four times greater than that for each donor
isolate to minimize overgrowth on the selective plates.
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Cefotaxime MICs for Escherichia coli DH5a and Escherichia coli J62-2 were
<0.5 mg/L respectively by standard agar dilution antimicrobial susceptibility test
[194] as already described.
2.4.2.Determination of rifampicin and nalidixic acid MICs for all SPEAR
(potential donor) isolates and for the two potential recipient bacteria
A standard agar dilution antimicrobial susceptibility test was used [194] as
described already for the cefotaxime MICs in section 2.2.3. Doubling dilutions of
nalidixic acid (Adatabs, Difco, UK) ranging from 32 mg/L to 0.5 mg/L and
rifampicin (Sigma Chemical Co., Poole, Dorset, UK) ranging from 125 mg/L to 2
mg/L were prepared separately in Mueller-Hinton agar (CM337, Oxoid, UK) at a
temperature of approximately 50°C. Aliquots of each dilution were poured into
sterile 85 mm plastic petri dishes (Sterilin, UK) on a level horizontal surface to a
depth of 3-4 mm. Methanol was used as the solvent for the rifampicin powder [225]
to make up the stock solution (25 mg/mL) prior to agar dilution. Standard inocula
were prepared from the SPEAR isolates exactly as described before for the
cefotaxime MICs and applied this time to the nalidixic acid and rifampicin plates.
Escherichia coli NCTC 10418 was again used as the control organism and Mueller-
Hinton agar without antibiotic was used as the growth medium control. Nalidixic
acid and rifampicin MICs for each isolate were read as the lowest concentrations of
each antibiotic causing inhibition of visible growth after overnight incubation at the
optimal temperature (37°C or 30°C) for the organism [194].
Provided the MICs were appropriate the rifampicin-resistant Escherichia coli
J62-2 was favoured as the recipient organism rather than the nalidixic acid-resistant
strain for the following reasons. Nalidixic acid acts by inhibiting the action ofDNA
gyrase which is necessary for the supercoiling of chromosomal DNA in bacteria in
order to have efficient cell division [226]. Resistant cells must be able to overcome
this effect of nalidixic acid. Mutations in a number of chromosomal loci have been
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described, resulting in DNA gyrases that are resistant to nalidixic acid. Many of
these mutations involve the substitution of single amino acids at key enzymatic sites
that are involved in the generation of the DNA gyrase-bacterial complex [226,227].
These mechanisms might exert an excessive strain on the cells, making them less
likely to accept a plasmid. Also the DH5a nalidixic acid-resistant strain of
Escherichia coli grew less well at 30°C, the optimal growth temperature for nine of
the SPEAR isolates (isolates 13, 15, 18, 28-32 and 95). In fact the nalidixic acid
MIC for Escherichia DH5a was only 32 mg/mL at 30°C while that for the nine
SPEAR isolates which grew optimally at 30°C ranged from 16 to > 32 mg/L.
Therefore Escherichia coli DH5a would not have been a suitable recipient for use at
30°C whereas the rifampicin MIC for Escherichia coli J62-2 was not affected by the
lower temperature.
Using an extended range of cefotaxime dilutions from 1 mg/L to 0.015 mg/L the
cefotaxime MIC for Escherichia coli J62-2 was found to be 0.125 mg/L by the
method already described [194].
Using an extended range of rifampicin (Sigma Chemical Co., Poole, Dorset, UK)
dilutions from 2000 mg/L to 16 mg/L the rifampicin MIC for Escherichia coli J62-2
was determined by the method described in section 2.2.3 to be 1000 mg/L [194].
The results of the rifampicin, nalidixic acid and cefotaxime MICs for the SPEAR
isolates (potential donors) and the potential recipients, Escherichia coli J62-2 and
Escherichia coli DH5a indicated that rifampicin would indeed be suitable as the
counterselecting antibiotic and that the rifampicin-resistant Escherichia coli J62-2
would be satisfactory as the recipient bacterium in the transconjugation experiments
with the SPEAR isolates (Appendix II). Further testing of the nalidixic acid-resistant
Escherichia coli DH5a was not carried out.
Rifampicin was used at a concentration of 500 mg/L in the selective plates as
some of the rifampicin MICs for the SPEAR isolates were 62 mg/L. Rifampicin BP
with polysorbate and water solvent (Marion Merrell Dow Ltd, Lakeside House,
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Stockley Park, Uxbridge, Middlesex, England) was available from the hospital
pharmacy department in more appropriate amounts (600 mg vials) and much more
cheaply than that obtainable from the Sigma Chemical Co. (150 mg vials). As
standard parenteral preparations are not routinely recommended for susceptibility
testing [194] direct comparison ofMICs for Escherichia coli J62-2 and a laboratory
reference strain Escherichia coli NCTC 10418 was made using each source of
rifampicin in two standard agar dilution susceptibility tests [194] run in parallel.
Rifampicin BP was reconstituted using the polysorbate solvent provided (Marion
Merrell Dow Ltd) at a concentration of 100 mg/mL and rifampicin powder (Sigma
Chemical Co.,Poole, Dorset, UK) dissolved in methanol (25 mg/mL) as described
above. Dilutions ranged from 2000 mg/L to 2 mg/L for each source of rifampicin.
As the results for each organism were identical using either source of rifampicin,
Rifampicin BP (Marion Merrell Dow Ltd) was used in the preparation of the
selective plates for the transconjugation experiments.
2.4.3 Preparation of selective plates for the test transconjugation system
Selective plates were prepared by adding suitably reconstituted Rifampicin BP
(Marion Merrell Dow Ltd) and cefotaxime (Adatabs, Mast Laboratories, Bootle,
Merseyside) to molten Mueller-Hinton agar at about 50°C to give respective
concentrations of 500 mg/L and either 4 mg/L or 1 mg/L. Cefotaxime was used at a
concentration of 4 mg/L in all cases other than six in which SPEAR isolates 6, 58,
76, 82, 138 and 143 were the potential donors. As their cefotaxime MICs were 8, 8,
4, 8, 8 and 8 mg/L respectively cefotaxime was used at a concentration of 1 mg/L
for these isolates. The agar was then poured as quickly as possible to prevent
cooling and partial solidification in the mixing container into 85 mm diameter Petri
dishes on a level surface to a uniform depth of 3 to 4 mm. The agar containing the
antibiotics was allowed to solidify at room temperature and the plates were either
used immediately or stored at 4°C and used within 72 hours.
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2.4.4 Broth mating in the test transconjugation system
One hundred and seventy-three of the 175 SPEAR isolates were examined in the
test transconjugation system. A standard broth mating procedure was used
(Professor SGB Amyes, personal communication). In the test system the potential
donor was always one of the SPEAR isolates and the recipient was always
Escherichia coli strain J62-2. The purity of each isolate was checked by plating out
for single colonies on nutrient agar (CM271, Oxoid, UK) and incubating overnight
at the appropriate temperature which was either 37°C, or 30°C when the donor was
one of the twelve SPEAR isolates which grew optimally at the latter temperature.
Donor and recipient bacteria were grown separately overnight in 10 mL nutrient
(Isosensitest) broth (CM473, Oxoid, UK)at 37°C or 30°C according to the optimal
growth temperature of the SPEAR isolate. Then 0*1 mL of each donor broth was
added to 4*5 mL of sterile nutrient broth pre-warmed to 37°C or 30°C and 1 mL of
the recipient broth added to the same. Care was taken to avoid shaking the mating
mixtures which were incubated overnight at 37°C or 30°C. Fifteen mL sterile
phosphate buffered saline (PBS) pH 7.4 (Pharmacy Department, Western Infirmary)
were added to the broth-mating mixtures, whirlimixed and centrifuged at 10,000
rpm for 15 min in 30 mL polypropylene tubes (Centritubes, Eastmoor, Runcorn,
Cheshire) in an IEC Centra-3S bench centrifuge (Damon/IEC UK Ltd., Dunstable,
Bedfordshire).
Each of the resulting bacterial pellets was resuspended in 0*5 mL PBS. Selective
Mueller-Hinton agar plates containing rifampicin and cefotaxime as described above
were allowed to equilibrate at ambient temperature then dried in an incubator at
37°C for 15 min with their lids ajar. A 0.1 mL amount of each resuspended pellet
was spread over half of a selective plate then streaked out for single colonies using a
standard loop. The plates were then incubated overnight at 37°C or 30°C as
appropriate for the donor organism.
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Donor and recipient bacteria were each plated out on selective plates (on which
they were not expected to grow) and on Mueller-Hinton agar plates without
antibiotics to act as growth controls. These plates were incubated overnight at 37°C
and at 30°C. Following incubation any organism growing on the selective plates, i.e.
any putative transconjugant, was investigated to check its identity. The test
transconjugation system is depicted in Table 1(a).
2.4.5 The control broth transconjugation system
A control transconjugation system was devised to be run in parallel with every set
of test transconjugation experiments. The aim of the control transconjugation system
was to find out whether a control system donor, Escherichia coli CT 73, would
transfer its plasmid coding for ampicillin resistance to the rifampicin-resistant
recipient strain Escherichia coli J62-2, under the same general experimental
conditions as those of the test system, the latter consisting of a SPEAR isolate acting
as a potential donor with the same strain ofEscherichia coli J62-2 as recipient. The
control broth mating system was set up along with every set of test transconjugation
experiments, including those carried out at 30°C, in order to check the viability of
the procedure. The donor organism, Escherichia coli CT 73 (Figure 9), kindly
donated by Dr Chris Thomson, (Bayer pic, Newbury, UK) had been isolated from a
urinary tract infection. Escherichia coli CT 73 was able to transfer its plasmid-
mediated resistance to ampicillin readily (Dr Chris Thomson, personal
communication). The recipient strain Escherichia coli J62-2 (Figure 9) was the same
organism as that used in the test system. Ideally ampicillin MICs would be at least
fourfold less for the recipient than for the donor and rifampicin MICs would be at
least fourfold greater for the recipient than for the donor bacterium.
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Figure 9 a) The donor lactose-fermenting Escherichia coli CT 73
and b) the recipient non-lactose-fermenting Escherichia coli
J62-2 growing on MacConkey agar.
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Ampicillin MICs were determined for Escherichia coli CT 73 and for Escherichia
coli J62-2 by a standard agar dilution antimicrobial susceptibility method [194]
using Adatabs (Mast Laboratories Limited, Bootle, Merseyside) to prepare dilutions
of ampicillin ranging from 64 mg/L to 0.125 mg/L. The MIC of ampicillin for
Escherichia coli CT 73 was >64 mg/L and that for Escherichia coli J62-2 was 4
mg/L. The MIC of rifampicin for Escherichia coli CT 73 was 8 mg/L and that for
J62-2 was 1000 mg/L as determined by the method described in section 2.4.2. The
results showed that a control transconjugation system with these strains would be
possible using ampicillin and rifampicin for counterselection of transconjugants.
2.4.6 Preparation of selective plates for the control transconjugation system
It was decided to counterselect for transconjugants in the control system using
ampicillin at a concentration of 16 mg/L which would inhibit the growth of the
recipient, and rifampicin at a concentration of 500 mg/L which was greatly in excess
of that needed to inhibit the growth of the donor. Rifampicin could have been used
at a much lower concentration e.g. 32 mg/L in the control system, but in order to
make the control conditions as similar as possible to the test conditions, it was used
throughout at a concentration of 500 mg/L exactly as in the test system.
Plates for counterselection of transconjugants were prepared by adding suitably
reconstituted Rifampicin BP (Marion Merrell Dow Ltd, Uxbridge, Middlesex) and
ampicillin (Adatabs, Mast Laboratories, Bootle, Merseyside) to molten Mueller-
Hinton agar held at 50°C in a water bath to give respective concentrations of 500
mg/L and 16 mg/L The agar was then poured as quickly as possible to prevent
cooling and partial solidification in the mixing container into 85 mm diameter Petri
dishes on a level surface to a uniform depth of 3 to 4 mm. The agar was allowed to
solidify at room temperature and the plates were either used immediately or stored
at 4°C and used within 72 hours. Each time the same batches ofRifampicin BP and
Mueller-Hinton agar were used in the control and test systems.
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(a) Test transconj ugation system
RP 500mg/L CTX 4mg/L*
Potential donor SPEAR isolate S R
Potential recipient Escherichia coli J62-2 R S
Potential transconjugant R R
RP - rifampicin, CTX - cefotaxime, S - sensitive, R ■- resistant.
(b) Control transconjugation system
RP 500mg/L AMP 16mg/L
Potential donor Escherichia coli CT73 S R
Potential recipient Escherichia coli J62-2 R S
Potential transconjugant R R
RP - rifampicin, AMP - ampicillin, S - sensitive, R - resistant.
(* in 167 SPEAR isolates, 1 mg/L was used in 6 SPEAR isolates with MICs of 4 or 8 mg/L. Two
SPEAR isolates with MICs <0.5 mg/L were tested with ceftazidime in the additional test
transconjugation system)
Table 1 Donor, recipient and transconjugants in (a) the test systen
and (b) the control system.
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2.4.7 Broth mating in the control system
The methods were exactly as described above for the test system except that the
donor was always Escherichia coli strain CT 73. The recipient was Escherichia coli
strain J62-2 as in the test system. The control conjugation system was set up in
parallel with every test transconjugation experiment. Transconjugants were colonies
ofEscherichia coli strain J62-2 rendered resistant to ampicillin by acquisition of a
plasmid from Escherichia coli strain CT 73. The control transconjugation system is
depicted in Table 1(b).
Putative transconjugants on the selective plates were replated on MacConkey
agar (CM7, Oxoid, Basingstoke, UK) and incubated overnight at 37°C. Their
sensitivity to ampicillin and other antibiotics was tested by a standard disk diffusion
method as described previously [192] on Mueller-Hinton agar (CM337, Oxoid, UK)
and compared with that of the recipient strain Escherichia coli J62-2 and the donor
strain Escherichia coli CT 73. Antibiotic disks (Oxoid, UK), included: ampicillin 10
pg (AMP 10), oxacillin 1 pg (OX 1), cephalexin 30 pg (CL 30), erythromycin 15pg
(E 15), trimethoprim 5 pg (W 5) and penicillin G 10 units (P 10). Putative
transconjugants were identified by the API 20 E system and their biochemical
profiles compared with those of the donor and recipient strains.
2.4.8 Plasmid detection in transconjugants from the control transconjugation
system
Following antibiotic sensitivity testing and species identification as described
above, transconjugants obtained in the control mating system were plated out on
nutrient agar (CM271, Oxoid, UK) and incubated at 37°C along with purity plates of
the donor strain Escherichia coli CT 73 and the recipient strain Escherichia coli J62-
2. Preparations of plasmid DNA were made from the donor, the recipient and their
transconjugants and agarose gel electrophoresis in the GNA-100 mini-gel apparatus
carried out using methods described in detail in section 2.3.
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2.5 B-Lactamase analysis
2.5.1 Preparation of B-lactamases from test isolates
All SPEAR isolates were tested for the production of B-lactamases. Organisms
were checked for purity by plating out for single colonies on nutrient agar (CM271,
Oxoid, UK) and incubating overnight at 37°C or 30°C according to their optimal
growth temperature. The tops of four or five colonies of each isolate were then
touched with a sterile loop, inoculated on to nutrient agar slopes (CM271, Oxoid,
UK) in bijoux and incubated overnight at 37°C or 30°C. Bacterial cells on each
slope were removed with 1 mL of 10 mM sodium phosphate buffer [228] at pH 7*0,
transferred to a sterile polypropylene microfuge tube (Treff microtubes, Scotlab,
Bellshill, Scotland) and disrupted by sonication using an MSE Soniprep 150
Ultrasonic Disintegrator (© Sanyo Gallenkamp PLC, Meridian Business Park,
Leicester, UK) fitted with an exponential microprobe. In order to minimise loss of
B-lactamase activity due to temperature increase during sonication each microtube,
clamped in position, was immersed in a beaker of ice and water placed on the
adjustable platform of the sonicator. Sonication was carried out using two 30-second
pulses with a 30-second pause between pulses, after which the microtube was placed
in a bucket of ice. Debris was removed by centrifugation (MSE Micro-Centaur
Centrifuge, MSE, Loughborough, Leicestershire, UK) at 11,600 g for 15 minutes.
The supernatant, which contained the (3-lactamase, was then transferred to a sterile
microtube and subjected to isoelectric focusing or stored at minus 20°C.
2.5.2 Preparation of B-lactamases used as pi control standards
Control B-lactamases whose pis were known were prepared from their carrier
strains in exactly the same way as described for the test (SPEAR) isolates. These
control standards included TEM-1 (pi 5-4); TEM-2 (pi 5-6); SHV-1 (pi 7-6); OXA-
1 (pi 7*4); PSE-1 (pi 5*7); PSE-2 (pi 6-1) all kindly provided by Dr DM Livermore,
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Central Public Health Laboratory, Colindale Avenue, London and OXA-4 (pi 7*5)
kindly provided by Professor SGB Amyes, Department ofMedical Microbiology,
Medical School, University of Edinburgh. Carrier strains were Escherichia coli K12
J62-1 (TEM-1); Escherichia coli K12 J53-1 (SHV-1, OXA-1); Pseudomonas
aeruginosa PU21 (TEM-2, PSE-1, PSE-2) and Escherichia coli K12 (OXA-4).
2.5.3 Spot-testing of B-lactamase preparations with nitrocefin
In order to optimise the concentration of each B-lactamase preparation applied to
the gel spot-testing of each extract prior to loading on the gel was carried out using
the chromogenic cephalosporin 87/312 [229] as described previously, marketed
commercially as nitrocefin (Oxoid, UK). For this purpose nitrocefin was
reconstituted according to the manufacturer's instructions, then diluted 1 in 10 using
10 mM phosphate buffer at pH 7*0.
Using a micropipette a 20 pL drop of diluted nitrocefin was placed in a sterile
plastic Petri dish on a piece ofwhite paper. Using a fresh sterile pipette tip a 20 pL
drop of one of the B-lactamase preparations was added to the drop of nitrocefin and
mixed by drawing the material up and letting it down once or twice within the
micropipette tip. The transparent Petri dish was convenient because many
preparations could be tested in one dish and the colour change was easy to read
against the background of white paper.
A colour change in the nitrocefin from pale yellow to pink within 20 to 60
seconds indicated that the B-lactamase preparation could be used neat at a volume of
20 pL whereas a change of colour happening immediately or in less than 20 seconds
suggested that the preparation should be diluted. Dilutions of 1 in 2, 1 in 3 or 1 in 4
were carried out easily by placing a 20 pL drop of the 6-lactamase extract in a
sterile Petri dish and adding one, two or three 20 pL drops as required of 10 mM
[228] sodium phosphate buffer [203 {pB.21}] at pH 7*0 using a fresh sterile pipette
tip. A 20 pL drop of the appropriate dilution was then loaded on the gel (see below).
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If the colour change did not develop within 60 seconds then a larger volume of that
particular B-lactamase preparation was loaded on to the gel using two or at most
three sample application pieces stacked or laid end to end.
2.5.4 B-Lactamase induction
If preparations did not react in spot-testing, the isolates from which they were
derived were plated out on Mueller-Hinton agar (CM337, Oxoid, UK) and a 30 jig
cefoxitin disk (Oxoid, UK) applied [230]. After appropriate incubation the colonies




Isoelectric focusing [231] is a method of separation in which proteins align
themselves as sharp bands at their pis in an electrophoretically-produced pH
gradient. A high degree of resolution is obtained by the method because isoelectric
focusing is caused by forces that act against diffusion and proteins are therefore
concentrated during their separation.
In 1975 Matthew and her colleagues [156] first described the use of analytical
isoelectric focusing for detection and identification of B-lactamases. Isoelectric
focusing was carried out on sheets ofpolyacrylamide gel supported on glass plates
and B-lactamase was usually detected using a chromogenic cephalosporin as
substrate. This compound, 3-(2,4-dinitrostyryl)-(6R,7R)-7-(2-thienylacetamido)-
ceph-3-em-4-carboxylic acid, E-isomer, code number 87/312 [229] is one of a group
of related cephalosporins which undergo a distinctive colour change when
hydrolyzed by B-lactamases. The solid is yellow and it gives a yellow solution when
made up in water. It has an unusual absorption spectrum with an extra band of
absorption with its A.max at 386 run. This is attributed to the high degree of
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conjugation in the substituent in the 3-position and the further conjugation of this
group with the B-lactam ring and the double bond in the dihydrothiazine ring. This
conjugation is thought to make the B-lactam ring unusually reactive and the
compound thus rapidly breaks down in the presence of B-lactamases from a variety
of bacteria.
O'Callaghan and colleagues [229] reported that the disruption of the B-lactam
ring was accompanied by a change in colour from yellow to red. While
acknowledging that the rupture of the B-lactam ring in cephalosporins was always
accompanied by loss of the ultraviolet absorption in the 260 nm region they stated
that a change in the visible region was unusual. Other cephalosporins conjugated in
this way gave a similar effect, but if the 3-substituent did not carry a further
chromophore, in this case two nitro groups, then the change in the spectrum was not
visible and went undetected unless deliberately sought [229].
Following application of compound 87/312, focused bands with B-lactamase
activity appeared pink on a yellow background [156]. Enzymes that could not be
distinguished biochemically or immunologically could be differentiated by
analytical isoelectric focusing. Using this very sensitive technique the different
enzymes produced by various strains each appeared as a pattern of bands (usually a
group comprising a main band and satellites) which could be compared visually.
Chromosomal and R factor-mediated B-lactamases produced by a single strain
appeared as separate entities [156].
2.5.5.2 Materials and Methods
B-Lactamase preparations of all 175 SPEAR isolates were subjected to isoelectric
focusing even if B-lactamase had not been detected on spot-testing. In such cases the
maximum amount of B-lactamase preparation was loaded on to the gel.
Isoelectric focusing was carried out using a Multiphor II Electrophoresis System
with a Multidrive™ XL power supply (both Pharmacia LKB Biotechnology,
- 84-
Uppsala, Sweden) (Figure 10). The cooling plate was first positioned on the
Multiphor II unit which was then bubble-levelled by adjustment of the levelling feet.
Cold tap water was allowed to circulate through the cooling unit for 15 minutes
before the run and throughout the procedure. Ampholine® PAGplates (Pharmacia
LKB Biotechnology, Uppsala, Sweden), 1 mm thick polyacrylamide gels cast on a
plastic support film, were used throughout the work in the pH range 3*5-9*5. In each
case the gel was applied to the cooling plate with a uniform layer of non-charged
insulating fluid to ensure efficient heat transfer from the gel during electrofocusing.
To do this a few millilitres of 0.1% Triton X-100 non-ionic detergent solution were
pipetted towards one end of the cooling plate. Starting at one end, the gel support
was laid on the cooling plate over the detergent solution and gradually lowered to
the horizontal position. When air bubbles became trapped, the gel was raised just
enough to release the air then gradually lowered again on to the cooling plate. Any
excess solution was removed with a tissue.
The electrode strips were wet uniformly with the appropriate electrode solution.
The anode solution was 1 M H3PO4 stored in the dark at room temperature for up to
six months and the cathode solution was 1 M NaOH which was stored at room
temperature for up to one week only. To ensure that there were no dry spots caused
by trapped air in the paper, the electrode strips were laid on a glass plate and using a
pipette drawn along the strip, each one was wet with approximately 3 mL of the
appropriate electrode solution. The strips were blotted to remove any excess
electrode solution and each one laid approximately 2 mm from the edge of the gel at
the cathode and anode, making sure that they were applied with the correct polarity.
The ends of the strips were trimmed 2-3 mm short of the edge of the gel in order to
avoid a short-circuit of the current path.
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Figure 10 Power supply and electrophoresis equipment used in
isoelectric focusing.
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Samples were applied using sample application pieces (Pharmacia LKB
Biotechnology) which were suitable for the application of 15-20 pL volumes. The
dry pieces were applied with forceps to the Ampholine PAGplate surface
approximately 10 mm from the cathode, although they could have been applied at
any position in the pH gradient [156]. Using a micropipette and a fresh sterile
pipette tip for each sample, 20 pL volumes of sample solution, previously spot-
tested with nitrocefin as described above, were applied to each piece. When
applying larger volumes of samples which had given a very weak reaction or had
not reacted in the nitrocefin spot tests, two or at most three sample application
pieces, stacked or laid end to end, were used.
At one end of the gel two 1 pL spots of lysed blood (100 mL defibrinated horse
blood, E & O Laboratories, Bonnybridge, Scotland, lysed with 3 mL Saponin 20%,
BDH Laboratories, Poole, England) were applied directly to the gel surface,
opposite one another, approximately 10 mm from the cathode and anode
respectively, to act as timing markers for the run [228].
The electrode holder was placed on the unit. Correct orientation of the electrodes
with regard to polarity was checked. The electrodes were aligned with the centre of
the electrode strips then the electrode holder was lowered carefully so that the
electrodes rested on the electrode strips. After attaching the bridging socket to the
pin connector the safety lid was placed in position and the electrode leads connected
to the Multidrive™ XL power supply.
Running parameters set in the manual mode were 2000 V and 15 W constant
power for approximately 1 hr 45 min. Usually the two bands derived from each of
the spots of lysed blood met after approximately 80 min at which time the power
supply was disconnected and the sample application pieces removed with forceps.
The power supply was reconnected immediately and electrofocusing continued for a
further 20 -30 minutes until the two bands from each of the spots of lysed blood had
merged completely, then electrofocusing was stopped. The electrode strips were
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lifted from the gel which was then removed from the cooling plate and nitrocefin
applied as described below.
2.5.5.3 Detection of 13-lactamases and calculation of pi values
Nitrocefin (Oxoid, UK) made up as directed by the manufacturer was poured
undiluted on to the gel and spread with a glass spreader. Within a few seconds pink
bands began to appear. However as described by Matthew and colleagues [156] 13-
lactamase bands visualised by this method appear gradually and in some cases by
the time the weakest bands were visible the strongest bands had diffused. Therefore
a water-resistant template (Pharmacia LKB Biotechnology) was aligned directly on
the surface of the gel immediately after the application of nitrocefin and the position
of the pink bands denoting the 13-lactamases marked with a pencil as soon as they
appeared, as shown in Figure 11 for isoelectric focusing gel 9. After rinsing in tap
water and drying between paper towels the template was photocopied for purposes
ofmeasurement and permanent record.
The distances in mm from the cathode to the pis of the test and control 13-
lactamases denoted by the pencil lines on each photocopied template were measured
to the nearest mm using a steel engineer's ruler (No 147, England) and an
illuminated magnifier (Luxo, Gibco BRL, Paisley, Scotland). The distances (mm)
from the cathode to the pis of the control 13-lactamases were then plotted against
their known pi values using the Microsoft LINEST function [224] with unlogged
data in a spreadsheet designed for the purpose. This function was described in detail
in section 2.3.5 when it was used to determine plasmid sizes, except that
logarithm/logarithm plots using the natural logarithms of the numerical values gave
the best straight lines with the plasmid data.
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Figure 11 Water-resistant template placed on top of the isoelectric focusing
gel to record the B-lactamase bands directly as they developed
(gel 9).
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Calibration spreadsheets were calculated for each isoelectric focusing gel and the
pi value of each unknown 6-lactamase was determined by applying the distance
(mm) between the cathode and its pi to the straight line equation on the spreadsheet.
Figure 12 shows the calibration spreadsheet for gel 9.
In order to keep a direct record of the raw data, photography of the gels was
carried out using a Model QSP Quickshooter Camera fitted with a green filter and
Model QSP No 27 Hood (Model QSP Quickshooter Photosystem, IBI Ltd, Clifton
Road, Cambridge, UK). After application of nitrocefin each gel was
transilluminated with fluorescent light on a portable Whatman Lightbox (Labsales,
Maidstone, Kent, UK) and a photograph taken using Polaroid Type 665 black and
white film ISO 80 (Sigma Chemical Co, Dorset, UK). Because of the fugitive nature
of some of the bands it would have been necessary to take multiple serial
photographs of each gel to obtain a complete photographic record as shown in
Figure 13 for gel 9. Also for quantitative analysis it was more appropriate to record
the B-lactamase bands using the template method as described.
2.6 Additional transconjugation studies on four isolates which were positive
in the Etest for ESBL production
Additional transconjugation studies were carried out on the two SPEAR isolates
ofKlebsiella pneumoniae (isolates 133 and 140) and two Acinetobacter isolates
(132 and 137) which were positive in the Etest for ESBL production, using
ceftazidime rather than cefotaxime along with rifampicin for counterselection.
2.6.1 Preparation of selective plates for the additional transconjugation studies
First the ceftazidime MIC for the recipient strain Escherichia coli J62-2 had to be
determined by standard agar dilution antimicrobial susceptibility testing [194] as
described already for the cefotaxime MICs.
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(mm) -16.34427032 150.4850637 62.22600392
TEM-1a 5.4 62 0.485840444 3.17521382 58.95714985
TEM-2a 5.6 59 0.99560143 1.173511936 29.53746327
OXA-1a 7.4 29 1131.732386 5 27.90303624
OXA-4a 7.5 28 1558.54292 6.885651322 26.26860921
SHV-1a 7.6 27 57.32272282
PSE-1a 5.7 59 50.78501469
PSE-2a 6.1 49







TEM-1a 62 5.4 pi Gel No. 9
TEM-2a 59 5.6 pi Gel No. 9
OXA-1a 29 7.4 pi Gel No. 9
OXA-4a 28 7.5 pi Gel No. 9
SHV-1a 27 7.6 pi Gel No. 9
PSE-1a 59 5.6 pi Gel No. 9
PSE-2a 49 6.2 pi Gel No. 9
pi Gel No. 9
pi Gel No. 9
78 18 8.1 pi Gel No. 9
78 27 7.6 pi Gel No. 9
79 18 8.1 pi Gel No. 9
79 27 7.6 pi Gel No. 9
80 18 8.1 pi Gel No. 9
80 27 7.6 pi Gel No. 9
81 18 8.1 pi Gel No. 9
81 27 7.6 pi Gel No. 9
82 undetected undetected pi Gel No. 9
83 undetected undetected pi Gel No. 9
84 undetected undetected pi Gel No. 9
85 7 8.8 pi Gel No. 9
86 undetected undetected pi Gel No. 9
91 18 8.1 pi Gel No. 9
92 18 8.1 pi Gel No. 9
92 27 7.6 pi Gel No. 9
92 35 7.1 pi Gel No. 9
93 18 8.1 pi Gel No. 9
94 18 8.1 pi Gel No. 9
94 27 7.6 pi Gel No. 9
94 35 7.1 pi Gel No. 9
97 18 8.1 pi Gel No. 9
100 18 8.1 pi Gel No. 9
103 undetected undetected pi Gel No. 9
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Calculated pi
Figure 12 Calibration of isoelectric focusing gel 9 using a least squares
straight line fit with Microsoft Excel spreadsheet functions
'LINEST' and 'TREND'. The 'r2 statistic' (in bold red
italics above) gives an indication ofhow well the straight
line equation explains the relationship between the
variables. Unknown isoelectric points are read off this
equation.
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Figure 13 Photograph of isoelectric focusing gel 9
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This time ceftazidime Adatabs (Mast Laboratories Ltd., Bootle, Merseyside, UK)
were used to prepare doubling dilutions of ceftazidime ranging from 2 mg/L to
0.015 mg/L. The ceftazidime MIC for the recipient strain Escherichia coli J62-2 was
0.25 mg/L. Selective plates were prepared by adding reconstituted Rifampicin BP
(Marion Merrell Dow Ltd) and ceftazidime (Adatabs, Mast Laboratories, Bootle,
Merseyside) to molten Mueller-Hinton agar at about 50°C as described in section
2.4.3 to give rifampicin concentrations of 500 mg/L and ceftazidime concentrations
of both 4 mg/L and 1 mg/L.
2.6.2 Broth mating in the additional transconjugation studies
The SPEAR potential donor isolates 133 and 140 (both Klebsiella pneumoniae),
132 (Acinetobacter calcoaceticus var. anitratus) and 137 (Acinetobacter species)
were each grown in nutrient broth (CM271, Oxoid, UK), mated with recipient strain
Escherichia coli J62-2 and the putative transconjugant material prepared and
transferred to the selective plates containing rifampicin and ceftazidime. Donor and
recipient bacteria were each plated out on selective plates (on which they were not
expected to grow) and on Mueller-Hinton agar plates without antibiotics to act as
growth controls. These plates were incubated overnight at 37°C. Following
incubation any organism growing on the selective plates, i.e. any putative
transconjugant, was investigated to check its identity.
2.6.3 Plasmid detection in transconjugants from the additional
transconjugation studies
Plasmid preparations from transconjugants obtained in this additional test system
were made and subjected to agarose gel electrophoresis as described in section 2.3.3
using the mini-gel GNA-100 (Pharmacia Molecular Biology, Uppsala, Sweden) and
the Horizon™ 11*14 medium gel (Gibco BRL, Paisley, Scotland, UK) equipment.
After staining with ethidium bromide as described in section 2.3.4 plasmids were
visualised and photographed on a GDS 7500 Gel Documentation System
-93-
(Ultraviolet Products Ltd.) purchased from Genetic Research Instrumentation Ltd.,
Gene House, Rayne, Braintree, Essex, UK).
2.6.4 B-Lactamase detection in transconjugants from the additional
transconjugation studies
8-Lactamases were prepared from transconjugants obtained in this additional test
system. Isoelectric focusing and the calculation ofpi values were carried out using




One hundred and seventy-five of the 200 SPEAR isolates collected were
appropriate for inclusion in the study (Appendices I - V). They comprised
Acinetobacter calcoaceticus var. anitratus (27), Acinetobacter calcoaceticus var.
Iwoffii (3), Acinetobacter species (1); Citrobacterfreundii (10); Enterobacter
cloacae (49), Enterobacter species (2); Escherichia coli (2); Flavobacterium
odoratum (2); Hafnia alvei (4); Klebsiella pneumoniae (2); Morganella morganii
(9); Pseudomonas aeruginosa (49), Pseudomonas fluorescens(\), Pseudomonas
species (7) and Stenotrophomonas maltophilia (7). Of these 175 AGNB, 173 had
cefotaxime MICs of 4 mg/L or greater. Both isolates ofKlebsiella pneumoniae were
sensitive to cefotaxime but resistant to ceftazidime and gentamicin. They were
included in the study as possible ESBL producers.
3.2 Antimicrobial susceptibility testing
Results of agar dilution susceptibility tests (MICs) for cefotaxime and the disk
diffusion and Etests are recorded in Appendices II III and IV. The results were
interpreted (Table 2) according to NCCLS guidelines [192,194] apart from those for
mecillinam (MEL 25) which, on the advice of the manufacturer (Leo
Pharmaceuticals, Princes Risborough, Buckinghamshire, UK), were interpreted with
reference to the work ofMenday and Tybring [232]; those for temocillin (TEM 30)
which were interpreted as recommended by SmithKline Beecham Pharmaceuticals,
Welwyn Garden City, Hertfordshire, UK according to the work of Fuchs and
colleagues [233] and those for meropenem (MEM 10) which were interpreted










R I S R S
Amoxycillin/clavulanic acid (AMC 30) 20/10 pg <13 14-17 £18 £16/8 <8/4
Ampicillin (AMP 10) 10 pg <13 14-16 £17 £32 <8
Azlocillin <a> (AZL 75) 75 pg £17 — £18 £128 <64
Aztreonam (ATM 30) 30 pg £15 16-21 £22 £32 <8
Carbenicillin (a> (CAR 100) 100 pg £13 14-16 £17 £512 <128
Carbenicillin (b> (CAR 100) 100 pg £19 20-22 £23 £64 <16
Cefotaxime (CTX 30) 30 pg £14 15-22 £23 £64 <8
Cefoxitin (FOX 30) 30 pg £14 15-17 £18 £32 <8
Ceftazidime (CAZ 30) 30 pg £14 15-17 £18 £32 <8
Cephalexin (CL 30) 30 pg £14 15-17 £18 £32 <8
Ciprofloxacin (CIP 5) 5 pg £15 16-20 £21 £4 <1
Erythromycin (E 15) 15 pg not applicable not applicable
Gentamicin (CN 10) 10 pg £12 13-14 £15 £8 <4
Imipenem (IPM 10) 10 pg £13 14-15 £16 £16 <4
Mecillinam (MEL 25) 25 pg £12 13-17 £18 £32 <8
Meropenem (MEM 10) 10 pg £11 12-13 £14 £16 <4
Oxacillin (OX1) 1 M9 not applicable not applicable
Penicillin (P 10) 10 units not applicable not applicable
Piperacillin <a> (PIP 100) 100 pg £17 ... £18 £128 <64
Piperacillin <b> (PIP 100) 100 pg £17 18-20 £21 £128 <16
Piperacillin/tazobactam <a> (TZP 110) 100/10 pg £17 ... £18 £128/4 <64/4
Piperacillin/tazobactam <b> (TZP 110) 100/10 pg £17 18-20 £21 £128/4 <16/4
Temocillin (TEM 30) 30 pg £15 16-18 £19 £32 <16
Ticarcillin <a> (TIC 75) 75 pg £14 — £15 £128 <64
Ticarcillin <b> (TIC 75) 75 pg £14 15-19 £20 £128 <16
Ticarcillin/clavulanic acid <a> (TIM 85) 85 pg £14 — £15 £128/2 <64/2
Ticarcillin/clavulanic acid <b> (TIM 85) 85 pg £14 15-19 £20 £128/2 <16/2
Trimethoprim (W 5) 5 pg £10 11-15 £16 £16 <4
(a> when testing Pseudomonas aeruginosa




Table 2 Antibiotics, abbreviations and interpretative guidelines
for disk susceptibility tests.
R
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The results of the Etest for ESBL detection are also recorded in Appendix IV and
were interpreted according to the manufacturer's instructions. When an ESBL-
producing strain with a ceftazidime MIC equal to or greater than 1 mg/L is inhibited
by clavulanic acid the MIC of ceftazidime is reduced by three or more two-fold
dilutions when tested in the presence of clavulanic acid. A ratio of the MIC of
ceftazidime 0.5 - 32 mg/L (ESBLTZ) to the MIC of ceftazidime 0.064 - 4 mg/L
with clavulanic acid 4 mg/L (ESBL TZL) of less than 8 is a negative result whereas
a ratio equal to or greater than 8 may indicate the presence of an inhibitable ESBL
in certain Gram-negative bacteria (AB Biodisk, Solna, Sweden). When both MIC
values are below or above the test ranges, interpretation is not determinable. Positive
results were obtained for four isolates: 133 and 140 {Klebsiella pneumoniae) and
132 (Acinetobacter calcoaceticus var. anitratus) and 137 {Acinetobacter species).
Ceftazidime MICs (ESBL TZ) were recorded in Appendix IV as an integral part of
the Etest for ESBL detection. Figures 14a and b show isolates 140 and 137 growing
on nutrient agar and showing a positive result in the Etest for ESBL detection on
Mueller-Hinton agar.
3.3 Plasmid analysis
Seventy-eight agarose gels were analysed as described in section 2.3.5 for gel 69
(Figures 7 and 8). Plasmids ranging from about (c.) 2 kb to c.214 kb were detected
in 78 of the 175 SPEAR isolates. Forty-seven of the 78 isolates had multiple
plasmids. The number '0.99826649' depicted in bold red italics in Figure 8 is the r2
statistic, or coefficient of determination, as described in detail in section 2.3.5. The
r2 statistic ranged from 0.9915 to 0.9999 in 76 of the 78 gels. In only two of the gels
was the value below 0.9915 (0.9868 and 0.9713). The percentage error for each
reference plasmid was obtained by calculating the percentage of its actual size
represented by the difference between its estimated and actual size.
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Figure 14 a Isolate 140 ( Klebsiellapneumoniae) growing on nutrient
agar (left) and showing a positive result in the E test for









Figure 14 b Isolate 137 ( Acinetobacterspecies) g wing on nutrient
agar (left) and showing a positive result in the E test for
ESBL production on Mueller-Hinton agar (right).
-98-
The mean percentage error for each reference plasmid, determined by the
analysis of the data from all 78 gels, was as follows: RTS-1 (189 kb) - ± 5.0%; the
four reference plasmids from strain 39R861: 154.35 kb - ± 4.6%, 66.15 kb - ± 4.8%,
37.64 kb - ± 15.7%; pUC9 (2.68 kb) - ± 5.0%. The results of the plasmid analysis of
each SPEAR isolate are displayed on an isolate, plasmid and 13-lactamase matrix
(Appendix V). The very large plasmid pMG5 (491 kb) as described in section
2.3.2.2 was not run routinely, but it was detected on both mini- and medium gels
under the same conditions as the test isolates.
3.4 fi-Lactamase analysis
Twenty-nine isoelectric focusing gels were calibrated exactly as described
previously for gel 9 (Figures 11 and 12). The number '0.99560143' depicted in bold
red italics in Figure 12 is the r2 statistic, or coefficient of determination, as described
in detail in section 2.3.5. The r2 statistic ranged from 0.9690 to 0.9999 and only six
gel calibrations were below 0.9830. The error incurred for each control J3-lactamase
was obtained by comparing its calculated pi value from the spreadsheet for each gel
with its actual pi value. The mean error for each control 13-lactamase determined by
analysis of the data from all 29 gels was as follows: TEM-1 (pi 5.4) - ± 1.90%;
TEM-2 (pi 5.6) - ± 0.50%; SHV-1 (pi 7.6) - ± 0.04%; OXA-1 (pi 7.4) - ± 0.07%;
OXA-4 (pi 7.5) - ± 0.19%; PSE-1 (pi 5.7) - ± 0.11%; PSE-2 (pi 6.1) - ± 3.01%. 13-
Lactamases ofpi values ranging from 4.9 to 8.8 were detected in 147 of the 175
isolates and multiple enzyme bands were detected in 38 of these isolates. The results




3.5.1 Transconjugation in the test mating system
Mating experiments were set up between 173 of the 175 SPEAR isolates and
Escherichia coli J62-2 using rifampicin and cefotaxime as the counterselecting
antibiotics. Transferable resistance to cefotaxime was not detected in the test mating
system.
3.5.2 Transconjugation in the control mating system
The control mating system was set up in parallel with every batch of SPEAR
isolates in the test system. Transconjugants were obtained on the selective plates in
the control system on each occasion, at 37°C and at 30°C. Figure 15 shows
transconjugants growing on a Mueller-Hinton selective plate containing rifampicin
500 mg/L and ampicillin 16 mg/L. Transconjugants, like the recipient Escherichia
coli J62-2, were non-lactose-fermenters on MacConkey agar and gave an identical
biochemical profile to that of the recipient Escherichia coli J62-2 in the API 20 E
system. Figures 16a, b and c show respectively the recipient, the donor and their
transconjugants growing on MacConkey agar and on Mueller-Hinton agar with a
selection of antibiotics. The recipient Escherichia coli J62-2 (non-lactose-fermenter)
shows sensitivity to ampicillin, cephalexin and trimethoprim and of course
resistance to oxacillin, erythromycin and penicillin (Figure 16a). The donor
Escherichia coli CT 73 (lactose-fermenter) shows resistance to ampicillin,
cephalexin, trimethoprim, oxacillin, erythromycin and penicillin (Figure 16b). The
transconjugants (non-lactose-fermenters) show resistance to ampicillin, oxacillin,
erythromycin and penicillin but sensitivity to cephalexin and trimethoprim (Figure
16c). The zone sizes (mm) obtained in these disk diffusion tests are shown in Table
3. Transconjugants comprised the recipient Escherichia coli J62-2 made resistant to
ampicillin by acquisition of a plasmid from the donor Escherichia coli CT 73.
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Figure 15 Transconjugants from the control mating system growing on
Mueller-Hinton agar containing rifampicin 500 mg/L and
ampicillin 16 mg/L.
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Figure 16 a) The recipient Escherichia coli J62-2, b) the donor
Escherichia coli CT 73 and c) their transconjugants
growing on MacConkey agar (left) and showing their
individual sensitivity patterns on Mueller-Hinton agar
(right). Antibiotic discs: 1-ampicillin, 2-oxacillin, 3-
cephalexin, 4-erythromycin, 5-trimethoprim, 6-penicillin.
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3.5.3 Plasmid detection in transconjugants from the control transconjugation
system
Agarose gel electrophoresis of plasmid DNA prepared from the donor
Escherichia coli CT 73, the recipient Escherichia coli J62-2 and their
transconjugants is shown in Figure 17 for gel 127 and its calibration spreadsheet is
shown in Figure 18. The donor Escherichia coli CT 73 had three plasmids of c.62
kb, 6 kb and 2 kb. Plasmids were not detected in the recipient Escherichia coli J62-
2. Each transconjugant preparation had a plasmid band at the level of the largest
donor plasmid (c.62 kb). The transfer of this plasmid was associated with ampicillin
resistance in the transconjugants as described above.
3.6 Additional transconjugation studies on the two Klebsiella isolates and two
Acinetobacter isolates which were positive in the Etest for ESBL detection
3.6.1 Transconjugants
Transconjugants were obtained from the Klebsiella pneumoniae isolates 133 and
140 using rifampicin 500 mg/L and ceftazidime 1 mg/L as the counterselecting
antibiotics. Transconjugants were not detected when ceftazidime was used at the
higher concentration of 4 mg/L. Transconjugants were not obtained from the
Acinetobacter isolates at either ceftazidime concentration.
A useful practical feature in the transconjugation experiments was the distinctive
"flat" morphology of the recipient Escherichia coli J62-2. (Figure 19). The purity of
the putative transconjugants was rigorously checked, then antibiotic susceptibility
testing and identification by the API 20 E system (bioMerieux, Marcy l'Etoile,
France) were set up in each case. The biochemical profile of the transconjugants
matched exactly that of the recipient strain Escherichia coli J62-2 and differed from










































Figure 17 Agarose gel 127: Lanes A and B - reference plasmids from
strain 39R861. Lane C - pUC9 reference plasmid. Lane D-
RTS 1 reference plasmid (the sizes of the reference plasmids
are shown on the left). Lane E - donor Escherichia coli CT
73 showng three plasmid bands (highlighted □). Lane F -
recipient Escherichia coli J62-2 (no plasmids). Lanes G and
H - transconjugants each showing one plasmid band
(highlighted □) at the level of the largest plasmid (c. 62 kb) of
the donor representing transfer of this plasmid from the
donor Escherichia coli CT 73.
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(log mm) -0.353174496 4.347420706 2.496169346
189 12.0 5.24175 2.48491 0.007954153 0.030548674 2.567695751
154.35 13.0 5.03922 2.56495 0.997975168 0.030315403 2.866939746
66.15 18.0 4.19192 2.89037 1971.472835 3.066079861
37.64 21.0 3.62807 3.04452 1.811830194 0.003676095 3.647781511
7.25 40.0 1.98100 3.68888 3.999255357
2.68 53.0 0.98582 3.97029











12.0 2.48491 5.27364 195.12
13.0 2.56495 5.04700 155.55
18.0 2.89037 4.12558 61.90
21.0 3.04452 3.68911 40.01
40.0 3.68888 1.86463 6.45
53.0 3.97029 1.06783 2.91
CT73 18.0 2.89037 4.12558 61.90
CT73 41.0 3.71357 1.79472 6.02
CT73 52.0 3.95124 1.12176 3.07
J62-2 0.0 no plasmid no plasmid no plasmid
Trans 1 18.0 2.89037 4.12558 61.90
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Figure 18 Calibration of agarose gel 127 with a log - log least squares
straight line fit using Microsoft Excel® spreadsheet
functions 'LINEST' and 'TREND'. The 'r2 statistic' (in bold
red italics above) gives an indication of how well the
straight line equation explains the relationship between the
variables. The size of the transferred plasmid was then read
off using this equation and compared with the donor's
plasmids.
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Antibiograms for the donor Klebsiella pneumoniae isolate 140, the recipient
Escherichia coli J62-2 and their transconjugants are shown in Table 4. These results
are similar to those obtained for donor Klebsiella pneumoniae isolate 133 and its
transconjugants (not shown). Transconjugants from both donor isolates 133 and 140
were themselves positive in the Etest for ESBL detection. Ratios of ESBL TZ (MIC
of ceftazidime alone) to ESBL TZL (MIC of ceftazidime in the presence of
clavulanic acid) were 3/0.125 = 24 for transconjugants of isolate 133 and 6/0.25 =
24 for transconjugants of isolate 140. "Phantom" inhibition zones indicative of
ESBL production in the Etest were also recorded for transconjugants obtained from
isolates 133 and 140.
3.6.2 Plasmid analysis of the Klebsiellae transconjugants
Plasmid preparations of the donor Klebsiella pneumoniae isolates 140 and 133,
the recipient organism Escherichia coli J62-2 and their transconjugants were
examined along with reference plasmid preparations in the GNA-100 (Pharmacia
Molecular Biology, Uppsala, Sweden) mini-gel system as shown in Figure 21
(agarose gel 139). Figure 22 shows its calibrated spreadsheet. Bands representing
large plasmids (c. 160 kb) can be seen in preparations from both donor isolates 140
and 133. In the transconjugant preparation from isolate 140, only a band
representing a plasmid size of c.214 kb can be seen. Another band representing a
smaller plasmid (c.38 kb) can be seen nearer to the chromosomal band in each of the
donor isolates 140 and 133. Plasmid bands are not seen in the transconjugant
preparation from isolate 133. Similar results which are not shown were obtained in
repeat examinations using six different plasmid preparations of the same isolates.
The band representing the largest plasmid of isolate 140 varied in intensity between




















































































(*antibioticbbreviationcodesiT l2) Table4Antibiogramsfothed nor,recipi ntnde rtransco juga ts intheadditionalransconjugationstudies.
Figure 19 Donor isolate 140 {Klebsiella pneumoniae)and recipient
Escherichia coli J62-2 growing on MacConkey agar. The
distinctive morphology of the Escherichia coli J62-2 is
shown on the right.
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Figure 20 API 20 E biochemical profiles:
a) recipient Escherichia coli J62-2
b) donor Klebsiella pneumoniae (SPEAR isolate 140)
c) transconjugant (profile identical to that of the recipient).
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Various plasmid preparations of donor isolate 140 and its transconjugants were
examined in the Horizon™ 11*14 medium gel system (Gibco BRL, Paisley,
Scotland, UK) as shown in Figure 23 (agarose gel 140) and Figure 24 shows its
calibrated spreadsheet. Instead of one band representing a large plasmid in isolate
140, two bands can be seen representing plasmid sizes of c.214 kb and 160 kb
respectively. The band representing a much smaller plasmid of c.38 kb can be seen
nearer to the chromosomal band as before. A band representing a plasmid of c. 214
kb can be seen in two of the transconjugant preparations from isolate 140 and very
faintly (highlighted in Figure 23) in a third preparation which was more dilute. In
another transconjugant preparation a band representing a plasmid of c. 160 kb can be
seen (highlighted in Figure 23). As the antibiograms of all the transconjugants of
isolate 140 were identical, it may be that the plasmid band of c.214 kb represented
the OC form of the 160 kb plasmid rather than another larger plasmid.
3.6.3 B-lactamase analysis of the Klebsiella transconjugants
The results of isoelectric focusing of the donor Klebsiella pneumoniae isolates
133 and 140, the recipient strain Escherichia coli J62-2, their transconjugants and
controls are shown in Figures 25 (isoelectric focusing gel 33) and 26 (calibration
spreadsheet). Both donor Klebsiella pneumoniae isolates had a TEM-type enzyme
which aligned with the control TEM-1 enzyme and an SHV-type enzyme which
aligned with the control SHV-1 and SHV-2 enzymes. The recipient isolate
Escherichia coli J62-2 had a 13-lactamase ofpi 8.4 which was presumably
chromosomally-mediated. The transconjugants of both isolates 133 and 140 each
had the TEM-type enzyme ofpi 5.2 and also the 13-lactamase of pi 8.4 which
aligned with that of the recipient Escherichia coli J62-2 strain. They did not have











Figure 21 Agarose gel 139: Lane A - reference plasmids from strain
39R861. Lane B - RTS 1 reference plasmid. (the sizes of the
reference plasmids are shown on the left). Lane C - donor
Klebsiella pneumoniae isolate 140 with two plasmid bands
at c. 160 kb and 38 kb. Lane D - recipient Escherichia coli
J62-2 with no plasmids. Lane E - transconjugants of donor
isolate 140 with plasmid band at c.214kb (highlighted □).
Lane F - dilute preparation of transconjugants of donor
isolate 140 with no plasmid bands. Lane G - donor
Klebsiella pneumoniae isolate 133 with two plasmid bands
at c. 160 kb and 38 kb. Lane H - transconjugant of donor
isolate 133 with no plasmid bands.
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(log mm) -0.384491828 4.89670678 2.881297889
189 18.0 5.24175 2.89037 0.011465696 0.052418668 2.959166813
154.35 19.0 5.03922 2.94444 0.998224646 0.014921176 3.284945916
66.15 27.0 4.19192 3.29584 1124.536123 2 3.501744546
37.64 33.0 3.62807 3.49651 0.250368405 0.000445283 #N/A
#N/A











T 18.0 2.89037 5.21815 184.59
T 19.0 2.94444 5.07753 160.38
T 27.0 3.29584 4.16360 64.30
T 33.0 3.49651 3.64169 38.16
140 19.0 2.94444 5.07753 160.38
140 33.0 3.49651 3.64169 38.16
J62-2 0.0 no plasmid no plasmid no plasmid
140TC 17.0 2.83321 5.36681 214.18
133 19.0 2.94444 5.07753 160.38
133 33.0 3.49651 3.64169 38.16
133TC 0.0 no plasmid no plasmid no plasmid
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Figure 22 Calibration of agarose gel 139 with a log - log least squares
straight line fit using Microsoft Excel spreadsheet
functions 'LINEST' and 'TREND'. The 'r2 statistic' (in bold
red italics above) gives an indication ofhow well the
straight line equation explains the relationship between the
variables. The sizes of the plasmids of donor isolates 133
and 140 and of the transconjugants of isolate 140 were then









Figure 23 Agarose gel 140 showing plasmid transfer from the donor
Klebsiella pneumoniae isolate 140 in the additional test
transconjugation system: Lanes A and B - reference
plasmids from strain 39R861. Lane C - RTS 1 reference
plasmid (the sizes of the reference plasmids are shown on the
left). Lane D - recipient Escherichia coli J62-2 with no
plasmids. Lanes E and F - donor Klebsiella pneumoniae
isolate 140 with three plasmid bands c. 214 kb, 160 kb, 38
kb. Lane G - 140 TCI* with no plasmid bands. Lane H -
140 TC2* with one plasmid band c. 214 kb. Lane I - 140
TC3* with one plasmid band c. 214 kb (highlighted □). Lane
J - 140 TC4* with one plasmid band c. 160 kb (highlighted
□).
* TCI, TC2, TC3, TC4 - different plasmid preparations of
transconjugants of donor isolate 140.
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(log mm) -0.366020464 4.558957072 2.640370399
189 14.0 5.24175 2.63906 0.013157498 0.060153223 2.714498424
154.35 15.0 5.03922 2.70805 0.997422225 0.017122847 3.02462678
66.15 21.0 4.19192 3.04452 773.8629894 2 3.231010191
37.64 25.0 3.62807 3.21888 0.226890353 0.000586384 #N/A
#N/A











T 14.0 2.63906 5.24533 189.68
T 15.0 2.70805 5.05684 157.09
T 21.0 3.04452 4.13757 62.65
T 25.0 3.21888 3.66122 38.91
J62-2 0.0 no plasmid no plasmid no plasmid
140 14.0 2.63906 5.24533 189.68
140 15.5 2.74084 4.96726 143.63
140 26.0 3.25810 3.55407 34.96
140TC1 14.0 2.63906 5.24533 189.68
140TC2 14.0 2.63906 5.24533 189.68
140TC3 14.0 2.63906 5.24533 189.68
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Figure 24 Calibration of agarose gel 140 with a log - log least squares
straight line fit using Microsoft Excel® spreadsheet
functions 'LINEST' and 'TREND'. The 'r2 statistic' (in bold
red italics above) gives an indication ofhow well the
straight line equation explains the relationship between the
variables. The sizes of the plasmids of donor isolate 140 and
its transconjugants were then read off using this equation.
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Figure 25 Isoelectric focusing gel 33 and its template showing the 13-
lactamase bands from donors 133 and 140 (both Klebsiella
pneumoniae), the recipient Escherichia coli J62-2 and their
transconjugants (TC).

























(Haemoglobin marker bands seen at extreme left of the gel - highlighted □)
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(mm) -14.50735064 135.9903034 57.65060995
TEM-1a 5.4 60 0.768326162 5.135059681 54.74913982
TEM-2a 5.6 54 0.988904942 1.773541333 25.73443854
SHV-1a 7.6 26 356.5208831 4 28.63590866
OXA-1 7.4 29 1121.418205 12.58179543 47.4954645
PSE-2 6.1 45 25.73443854
SHV-2 7.6 26







TEM-1a 60 5.2 pl Gel No. 33 0.988904942
TEM-2a 54 5.7 pl Gel No. 33 0.988904942
SHV-1a 26 7.6 pl Gel No. 33 0.988904942
OXA-1 29 7.4 pl Gel No. 33 0.988904942
PSE-2 45 6.3 pl Gel No. 33 0.988904942
SHV-2 26 7.6 pl Gel No. 33 0.988904942
140 26 7.6 pl Gel No. 33 0.988904942
140 61 5.2 pl Gel No. 33 0.988904942
140 66 4.8 pl Gel No. 33 0.988904942
133 26 7.6 pl Gel No. 33 0.988904942
133 61 5.2 pl Gel No. 33 0.988904942
133 66 4.8 pl Gel No. 33 0.988904942
TEM-1 61 5.2 pl Gel No. 33 0.988904942
TEM-1 66 4.8 pl Gel No. 33 0.988904942
140TC1 14 8.4 pl Gel No. 33 0.988904942
140TC1 61 5.2 pl Gel No. 33 0.988904942
140TC1 66 4.8 pl Gel No. 33 0.988904942
133TC 14 8.4 pl Gel No. 33 0.988904942
133TC 61 5.2 pl Gel No. 33 0.988904942
133TC 66 4.8 pl Gel No. 33 0.988904942
J62-2 14 8.4 pl Gel No. 33 0.988904942
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Figure 26 The pis of the B-lactamases of the donor Klebsiella
pneumoniae isolates 133 and 140, the recipient Escherichia
coli J62-2 and their transconjugants were read off a least
squares straight line fit using Microsoft Excel® spreadsheet
functions 'LINEST' and 'TREND'. The 'r2 statistic' (in bold
red italics above) gives an indication ofhow well the





Thirty-one isolates belonging to the genus Acinetobacter were examined.
Twenty-seven were identified as Acinetobacter calcoaceticus var. anitratus, three as
Acinetobacter calcoaceticus var. Iwoffii (isolates 18, 46 and 123) and one (isolate
137) was identified satisfactorily to genus only. (More recently the genus
Acinetobacter has been reclassified into 17 genomic species ofwhich Acinetobacter
baumannii is the one most commonly isolated from clinical material). Sixteen of the
31 isolates were obtained from patients on their first day of admission to ITU.
Twenty of the 31 isolates contained plasmids ranging from c.3 kb to 142 kb. Most of
these (22 of 35 plasmids) were under 30 kb. Thirteen isolates each had one plasmid,
six had two plasmids and one had nine plasmids. 13-Lactamases with pi values
between 5.4 and 8.8 were detected in 26 of 31 isolates.
All 31 isolates were susceptible to the carbapenems (imipenem and meropenem).
Only one showed reduced sensitivity to ciprofloxacin and three were resistant to
gentamicin. All but three showed reduced sensitivity or were resistant to mecillinam
as expected and all but one were resistant to temocillin. Twenty-five of 31 isolates
were sensitive to carbenicillin, ticarcillin and piperacillin. Twenty-nine of 31
isolates showed reduced sensitivity or were resistant to aztreonam. Only two of the
31 isolates were resistant to ceftazidime by disk diffusion testing but in the Etest for
ESBL detection nineteen strains showed reduced sensitivity or were resistant to
ceftazidime (MICs equal to or greater than 8 mg/L). Twenty-seven of the 31 isolates
were resistant to cefoxitin by disk diffusion testing. Two isolates (132 and 137) were
positive in the Etest for ESBL detection. All isolates were resistant to ampicillin. Six
(3, 13, 18, 46, 88, 130) were resistant to amoxycillin/clavulanic acid and one (114)
showed reduced sensitivity.
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Isolates 3, 15, 18, 46 and 86 were resistant to carbenicillin and isolate 108
showed reduced sensitivity. Isolates 3, 18 and 46 were resistant also to ticarcillin
and strains 15 and 86 showed reduced sensitivity. Isolates 3 and 130 were resistant
to piperacillin and isolates 15, 46, 86. and 114 showed reduced sensitivity. However
isolate 114 gave good inhibition zones to carbenicillin and ticarcillin and isolate 130
was sensitive to carbenicillin. Although isolate 18 was resistant to
amoxycillin/clavulanic acid and ticarcillin it gave a good zone of inhibition with
ticarcillin/clavulanic acid.
The two isolates most resistant to the B-lactams were isolate 3 (Acinetobacter
calcoaceticus var. anitratus) and isolate 46 {Acinetobacter calcoaceticus var.
Iwojfii) both ofwhich showed reduced sensitivity to piperacillin/tazobactam and
were resistant to most of the other B-lactams: ampicillin, amoxycillin/clavulanic
acid, carbenicillin, ticarcillin, ticarcillin/clavulanic acid, aztreonam, cefoxitin and
ceftazidime. Isolate 46 showed reduced sensitivity to piperacillin and isolate 3 was
resistant. Isolate 3 was sensitive to temocillin and isolate 46 was resistant. Both
showed good zones of inhibition to mecillinam (unexpected for Acinetobacter
species which are usually resistant to mecillinam) and to the carbapenems imipenem
and meropenem and both were sensitive to ciprofloxacin and gentamicin. Isolate 3
had a small plasmid of c. 9 kb and a B-lactamase ofpi 8.3. Isolate 46 had two
plasmids of c.8 kb and 97 kb and a B-lactamase of pi 8.3. The two isolates were not
temporally or epidemiologically related.
Isolate 3 had been isolated from the tracheal aspirate of a 34-year-old patient
(patient 20) on her twelfth day in ITU with recurrent Guillain-Barre syndrome. Ten
days prior to her ITU admission she had begun treatment with benzylpenicillin for
pneumococcal pneumonia. SPEAR was started on admission to ITU, cefotaxime
being stopped after four days. Isolates ofAcinetobacter calcoaceticus var. anitratus
reported sensitive to cefotaxime had been grown from two tracheostomy site swabs
(clinical specimens) taken seven and ten days prior to this screening sample. It was
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not until nine months later that isolate 46 was grown from the throat swab of a 59-
year-old patient (patient 95) on his second day in ITU following a pneumonectomy
for infiltrating adenocarcinoma of the lung.
Seventeen of the 31 isolates each had one B-lactamase with a pi value between
8.0 and 8.9. Isolates 3, 46, 114 and 130 have already been mentioned. Isolate 106
was resistant to gentamicin; otherwise its antibiogram and those of the other twelve
isolates were unremarkable. Isolates 105,107, 115 and 120 (all Acinetobacter
calcoaceticus var. anitratus) each had a similar plasmid of c. 10 kb and an enzyme of
pi value 8.5, 8.0, 8.7 and 8.9 respectively. Isolate 120 differed from the other three
isolates in being resistant to gentamicin. Otherwise the antibiograms of the four
isolates were very similar and remarkably sensitive. There was no apparent
epidemiological connection. Isolates 105 and 107 had been isolated from throat
swabs taken from a 68-year-old patient (patient 23) on her first and third days in
ITU following cardiac surgery. Isolate 115 had been grown almost four weeks later
from a throat swab taken from a 54-year-old patient (patient 99) on his first day in
ITU following a hemicolectomy and transplant nephrectomy. Isolate 120 had been
obtained (almost four weeks after strain 115) from a rectal swab taken from a 62-
year-old patient (patient 67) on his fifth day in ITU following a coronary artery
bypass graft.
Isolates 191 (from patient 19) and 137 (from patient 81) each had two B-
lactamases. Those of isolate 191 were ofpi values 5.6 and 8.8 but its antibiogram
did not suggest the presence of a TEM-type B-lactamase in that it was sensitive to
carbenicillin, ticarcillin and piperacillin and it did not contain plasmids. Isolate 137
was positive in the Etest for ESBL production and is discussed in Chapter 4.
Isolates 13, 18 and 127 had a B-lactamase ofpi 7.8; isolates 111 and 196 had a B-
lactamase ofpi 7.7 and isolates 112 and 132 had a B-lactamase of pi 7.9. Isolate 18
(from patient 30) as previously mentioned was resistant to carbenicillin and
ticarcillin and borderline sensitive to piperacillin. It was resistant to ceftazidime and
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aztreonam as well as cefotaxime. It had a good zone of inhibition to
ticarcillin/clavulanic acid but had no zone of inhibition to amoxycillin/clavulanic
acid. It was resistant to cefoxitin. It contained nine plasmids. As it had a 8-lactamase
of 7.7 there is the possibility of an SHV-type enzyme. Isolate 132 from patient 81
was resistant to gentamicin and had no plasmids. However, like isolate 137, it was
positive in the Etest for ESBL detection and is discussed in Chapter 4. Although the
other five isolates had 6-lactamases of 7.7 or 7.8 and four of them contained
plasmids, their antibiograms were not typical of the presence of an SHV-type
enzyme as they showed sensitivity to carbenicillin, ticarcillin and piperacillin.
Isolates 111, 112 and 114 (all Acinetobacter calcoaceticus var. anitratus) each
contained two similar plasmids of c. 16 kb and 68 kb and had been isolated from
rectal swabs from 53-year-old patient (patient 4), taken on the third, sixth and eighth
days of his ITU admission following a road traffic accident. Isolates 111 and 112
had enzymes of similar pi (7.8 and 7.9) and almost identical antibiograms. Isolate
114 had a B-lactamase ofpi 8.7. Its antibiogram differed from that of isolates 111
and 112 in showing reduced sensitivity to amoxycillin/clavulanic acid and
piperacillin.
Isolates 132 and 137 were positive in the Etest for ESBL production. Plasmids
were not detected in isolate 132 (Acinetobacter calcoaceticus var. anitratus) which
had a B-lactamase of pi 7.9. In the Etest its ceftazidime MIC was > 32 mg/L
whereas its ceftazidime/clavulanic acid MIC was 0.38 mg /L. It had no zone of
inhibition to ampicillin but gave a substantial zone (26 mm) to
amoxycillin/clavulanic acid. It showed large inhibition zones to carbenicillin (26
mm), ticarcillin (27 mm), ticarcillin/clavulanic acid (30 mm), piperacillin (28 mm)
and piperacillin/tazobactam (36 mm). Isolate 132 was sensitive to ciprofloxacin and
resistant to gentamicin.
Isolate 137 (satisfactorily identified only to genus Acinetobacter) had three
plasmids of c. 5 kb, 6 kb and 51 kb and two B-lactamases of pis 7.9 and 8.6. In the
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Etest for ESBL detection its ceftazidime MIC, like that of isolate 132, was > 32
mg/L while its ceftazidime/clavulanic acid MIC was <0.125 mg/L. This isolate was
resistant to ampicillin (no zone of inhibition) but had a large zone to
amoxycillin/clavulanic acid (25 mm). It showed large inhibition zones to
carbenicillin (25 mm) and ticarcillin (24 mm) but gave a substantially larger zone
(36 mm) to ticarcillin/clavulanic acid. It had an inhibition zone to piperacillin of 23
mm and only a slightly larger zone to piperacillin/tazobactam (25 mm). It showed
reduced sensitivity to ciprofloxacin and was resistant to gentamicin.
3.7.2 Citrobacter freundii
Ten strains of Citrobacterfreundii were isolated. All strains were sensitive to the
carbapenems and mecillinam and all were resistant to cefoxitin. All were resistant to
ceftazidime and all but one were resistant to aztreonam. ESBL production was non-
determinable in the Etest for all isolates.
Isolate 4 showed borderline susceptibility to temocillin but was resistant to all
other B-lactams tested except the carbapenems and mecillinam. The isolate had a B-
lactamase ofpi 8.3 and plasmids were not detected. Isolate 5 was very similar
except that it was resistant to temocillin. Isolates 4 and 5 had been grown from rectal
swabs taken from patient 56, aged 61 years, on his first and third days in ITU with
respiratory and cardiac failure and possible adult respiratory distress syndrome
superimposed on chronic obstructive airways disease. Antibiotic treatment before
admission to ITU had not been recorded.
Isolate 9 was the most sensitive of the isolates of Citrobacterfreundii. It was
sensitive to carbenicillin, showed borderline susceptibility to ticarcillin and was
sensitive to ticarcillin/clavulanic acid, amoxycillin/clavulanic acid,
piperacillin/tazobactam, aztreonam and cefoxitin. It was resistant to ceftazidime
(MIC >32 mg/L) and piperacillin. The isolate had a B-lactamase ofpi 8.3 and a
plasmid of c. 125 kb. This isolate was grown from a rectal swab taken from patient
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1, aged 62 years, on her eighth day in ITU following cardiac arrest in a medical
ward. The patient had been found collapsed at home four weeks earlier and admitted
to the medical ward with a deep vein thrombosis, pulmonary embolism, congestive
cardiac failure and pneumonia. She had received amoxycillin and erythromycin
before her ITU admission at which time SPEAR was started and amoxycillin
stopped.
Isolate 97 was resistant to all the B-lactams tested other than the carbapenems and
mecillinam. It had a plasmid of c.8 kb and a B-lactamase ofpi 8.1. It was grown
from a 61-year-old patient (patient 70) on her fifth day in ITU with respiratory and
renal failure following a laparotomy for peritonitis. The patient had been transferred
from another hospital.
Isolates 118, 119 and 122 showed reduced sensitivity or resistance to all the B-
lactams tested other than the carbapenems and mecillinam. These isolates were
grown from rectal swabs taken from patient 87, aged 65 years, on her first, fourth
and sixth days in ITU. The patient had been transferred from another hospital in
septic shock following biliary bypass surgery. She had received perioperative
cefuroxime, gentamicin and metronidazole. B-Lactamase bands were detected as
follows: pi 8.7 (isolate 118), pi 8.5 (isolate 119), pis 7.9 and 8.7 (isolate 122).
Isolate 138 showed reduced sensitivity to cefotaxime (MIC 8 mg/L) and was
resistant to all other B-lactams tested other than the carbapenems and mecillinam.
Resistance to piperacillin was overcome by tazobactam. This isolate contained six
plasmids and had a B-lactamase ofpi 8.4. It had been grown from a rectal swab
taken from patient 66, aged 59 years, on his third day in ITU with respiratory and
renal failure.
Isolate 153 showed reduced sensitivity to piperacillin and was resistant to all
other B-lactams tested other than the carbapenems and mecillinam. It had a B-
lactamase ofpi 8.6. The strain had been isolated from a rectal swab taken from a 66-
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year-old patient (patient 38) on his fifth day in ITU with pancreatitis and respiratory
acidosis.
Isolate 165 was resistant to all B-lactams tested other than the carbapenems and
mecillinam. It had a B-lactamase ofpi 8.4. The strain had been isolated from a rectal
swab taken from patient 29, aged 74 years, on her ninth day in ITU with respiratory
failure and an acute exacerbation of chronic obstructive airways disease.
3.7.3 Enterobacter
Fifty-one isolates belonging to the genus Enterobacter were studied. Forty-nine
were identified as Enterobacter cloacae and two isolates (121 and 135) were
identified satisfactorily to genus only. All strains had cefotaxime MICs equal to or >
32 mg/L and 46 strains had ceftazidime MICs >32 mg/L. All isolates were negative
in the Etest for ESBL production. All were sensitive to the carbapenems imipenem
and meropenem and to mecillinam and ciprofloxacin. Eleven isolates were resistant
to gentamicin.
Isolates 7 and 8 were resistant or showed reduced susceptibility to all the B-
lactams other than the carbapenems, mecillinam and piperacillin. They contained a
similar plasmid of c.93 kb and had B-lactamases of pi 8.3. They had been grown
from rectal swabs taken from a 44-year-old patient (patient 93) on her first and third
days in ITU. She had been admitted from the cardiothoracic unit as a ventilatory
weaning problem following a tricuspid valve replacement and second mitral valve
replacement five days earlier. Antibiotic therapy prior to her ITU transfer was not
recorded. It is likely that isolates 7 and 8 had derepression of their chromosomally-
mediated B-lactamases.
Isolate 22 had two small plasmids and a B-lactamase of pi 7.9. It was resistant or
showed reduced susceptibility to all the B-lactams other than the carbapenems,
mecillinam and piperacillin. The organism had been grown from a rectal swab taken
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from a 56-year-old patient (patient 76) on his first day in ITU following bowel
resection and saphenous vein graft for a superior mesenteric artery thrombosis.
Isolate 26 had two plasmids of c.4 kb and 125 kb, a B-lactamase of 7.7 and an
antibiogram which showed resistance or reduced susceptibility to all the 6-lactams
except the carbapenems and mecillinam. The isolate had been grown from the throat
swab of a 63-year-old patient (patient 9) taken on the first day of her readmission to
ITU from the cardiothoracic unit having had a cardiac arrest. She had already spent
four days in ITU following a lobectomy seven days previously for a bronchogenic
carcinoma. Cefuroxime had been given perioperatively and SPEAR had been given
during her first 4-day ITU admission. Amoxycillin had been started the day before
her readmission to ITU.
Isolates 33, 34 and 35 were sensitive to the carbapenems and mecillinam and
showed borderline sensitive zones of inhibition with piperacillin. Otherwise they
were resistant or showed reduced susceptibility to the other B-lactams. These isolates
did not contain plasmids. Isolates 33 and 34 had two B-lactamase bands with pis of
8.1 and 8.7. Isolate 35 had B-lactamase bands with pis of 8.0 and 8.4 on a different
gel. The organisms had been isolated from rectal swabs taken from a 73-year-old
patient (patient 52) on his first, sixth and eighth days in ITU following repair of an
abdominal aortic aneurysm, renal failure and clinical sepsis. The patient had been
admitted to ITU from another hospital where amoxycillin had been given for
bronchitis.
Isolates 36 and 37 each had a plasmid of c. 125 kb and a B-lactamase of 8.1. They
were resistant or showed reduced susceptibility to all the B-lactams other than the
carbapenems, mecillinam and temocillin. These isolates had been grown from rectal
swabs taken from a 64-year-old patient (patient 16) on the first days of his second
and third admissions respectively to ITU, fourteen days apart. The patient suffered
from non-Hodgkin's lymphoma and had undergone splenectomy followed by an
overnight stay in ITU ten weeks previously. His second ITU admission followed
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resection of ischaemic bowel and his third followed breakdown of the anastomosis.
He had been receiving long-term flucloxacillin before his splenectomy for an
infected trephine biopsy wound. Unfortunately his history of antibiotic therapy
outwith the ITU was not available. The resistance patterns of isolates 36 and 37
were probably caused by chromosomally-mediated B-lactamase derepression
unrelated to SPEAR.
Isolates 39 and 40 each had six plasmids, five of which (c.6 kb, 18 kb, 31 kb, 53
kb and 125 kb) were similar and each had one (c. 11 kb in isolate 39) not observed in
the other (c. 102 kb in isolate 40). Isolate 39 had B-lactamase bands of pis 8.0 and
8.8 and isolate 40 had a B-lactamase band ofpi 8.3. These organisms had been
isolated from two rectal swabs taken from a 59-year-old patient (patient 60) on his
second day in ITU. He had been admitted for respiratory and cardiovascular
monitoring following coronary artery grafts and mitral valve annuloplasty. Their
antibiograms differed slightly. Isolate 39 showed borderline susceptibility to
piperacillin, aztreonam and temocillin while isolate 40 showed reduced
susceptibility to piperacillin and was resistant to aztreonam and temocillin. Both
were susceptible to the carbapenems and mecillinam.
Isolates 43 and 47 each gave rise to multiple B-lactamase bands with pis ranging
from 5.6 to 8.8. Isolate 43 contained two plasmids of c. 5 kb and 77 kb. Isolate 47
had three plasmids of c. 2 kb, 91 kb and 141 kb. The isolates were resistant or
showed reduced susceptibility to all the B-lactams other than the carbapenems and
mecillinam. Isolate 43 had been grown from a faecal sample from a 48-year-old
patient (patient 91) on the twelfth day of her admission to the ITU following surgery
for small bowel obstruction and division of adhesions. Isolate 47 was obtained from
the rectal swab of a 57-year-old patient (patient 75) taken on his first day in the ITU
following debridement of widespread necrotizing fasciitis, four weeks after the
previous patient's discharge.
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Isolates 50 and 51 were grown from the same rectal swab of a 50-year-old patient
(patient 41) on her second day in ITU after an aorta-superior mesenteric artery graft.
She had been transferred from another hospital with gangrene of the superior
mesenteric artery following cholecystectomy twelve days earlier. Isolate 50 had two
plasmids of c. 3 kb and 141 kb. Only the larger plasmid was detected in isolate 51. A
6-lactamase band ofpi 7.6 was detected in both isolates which showed resistance or
reduced sensitivity to all the B-lactams other than the carbapenems, mecillinam and
temocillin. Cefotaxime and metronidazole had been started prior to her ITU
admission but other details of antibiotic therapy were not available. Resistance was
possibly caused by chromosomally-mediated B-lactamase derepression not related to
SPEAR but perhaps to prior therapy the details of which were not available. The pi
value of 7.6 and the presence of the large plasmid raises the possibility also of an
SHV-type enzyme, either SHV-1 or an ESBL.
Isolate 52 was grown from the throat swab of a 63-year-old patient (patient 88)
on his first day in ITU after transfer, collapsed and septic, from another hospital. A
perforated duodenal ulcer had been oversewn eleven days earlier. A second
laparotomy following his collapse nine days later revealed several gastric ulcers.
Total gastrectomy and oesophago-jejunostomy were carried out. Isolate 52
contained a large plasmid of c. 163 kb and had a B-lactamase ofpi 7.6. It was
resistant to all the B-lactams other than the carbapenems and mecillinam.
Unfortunately the patient's antibiotic therapy prior to his ITU admission had not
been recorded. Isolate 52 was not apparently related epidemiologically to isolates 50
and 51 although the patients' stays in the ITU overlapped.
Isolates 53 and 54 had been grown from rectal swabs taken from a 17-year-old
patient (patient 5) on her first and third days in ITU after transfer from another
hospital with nephrotic syndrome. Metronidazole had been given prior to her ITU
admission. The isolates had a similar plasmid profile with multiple plasmids, the
largest being c.88 kb and a B-lactamase of pi 7.6. They were resistant to all the B-
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lactams other than the carbapenems and mecillinam. As with isolates 50 and 51
from patient 41 and isolate 52 from patient 88, resistance was possibly caused by
chromosomally-mediated B-lactamase derepression not related to SPEAR. The pi of
7.6 and the presence of the plasmids raises the possibility also of an SHV-type
enzyme, either SHV-1 or an SHV-derived ESBL. Isolates 53 and 54 were not
apparently related epidemiologically to isolates 50 and 51 or 52 and the plasmid
profiles were quite different, although the ITU stays of patients 5, 41 and 88
overlapped.
Isolates 61 and 62 and 64, 65 and 66 were grown from rectal swabs taken from a
53-year-old patient (patient 89) on his second, fourth, eleventh, fourteenth and
sixteenth days in ITU. He had been admitted with necrotizing fasciitis surrounding
his sternal wound following a coronary artery bypass graft. Flucloxacillin had been
started four days before admission to ITU. Plasmids were not detected in any of the
strains. Isolates 61 and 62 each had B-lactamases of pis 6.8 and 7.5, isolates 64 and
65 each had a B-lactamase of pi 7.6 and isolate 66 had B-lactamases ofpis 4.9 and
7.9 All isolates were resistant to all the B-lactams other than the carbapenems and
mecillinam.
Isolates 77-81 were grown from throat and rectal swabs taken from a 57-year-old
patient (patient 62) on her first and second days in ITU following a
polyagastrectomy. The isolates had identical plasmids of c.4 kb, 13 kb and 181 kb.
B-Lactamase bands were detected as follows: pi 7.6 (isolate 77); pis 7.6 and 8.0
(isolates 78, 79 and 81) and pis 6.8, 7.6 and 8.0 (isolate 80). Isolates 78 and 80 were
resistant to all the B-lactams apart from the carbapenems and mecillinam. Isolates 77
and 79 were different. Although their cefotaxime MICs were also > 32 mg/L they
showed susceptibility by disk diffusion to piperacillin, aztreonam and ceftazidime
and the ceftazidime MIC for each isolate was 2 mg/L. Isolate 81 had a cefotaxime
MIC of > 32 mg/L. It showed a reduced inhibition zone with piperacillin but was
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susceptible by disk diffusion to aztreonam and ceftazidime. Its ceftazidime MIC was
3 mg/L. All five isolates were resistant to gentamicin.
Isolates 92 and 94 were grown from rectal swabs taken from a 61-year-old
patient (patient 59) on his second and fourth days in ITU. He had been admitted in
respiratory and renal failure from another hospital. An elective inguinal hernia
repair twelve days earlier had been followed by intestinal obstruction, laparotomy
for division of adhesions and pneumonia. The isolates each contained three plasmids
of c.2 kb, 103 kb and 181 kb and each had J3-lactamases of pis 7.1, 7.6 and 8.1.
Their antibiograms showed reduced susceptibility to all the fi-lactams except the
carbapenems and mecillinam.
Isolates 100, 101 and 102 were grown from rectal swabs taken from a 79-year-
old patient (patient 51) on her first, second and fourth days in ITU with peritonitis
and decreasing renal function following repair of an anastomosis. She had
undergone a hemicolectomy twelve days earlier. Cefotaxime and metronidazole had
been started at that time and stopped after four days. Ampicillin was then given for
one day after which she was admitted to ITU and SPEAR started. The isolates each
had three plasmids of c.4, 9 and 162 kb; an extra 34 kb plasmid was found in isolate
101. Beta-lactamase bands were detected with the following pi values: 8.1 (isolate
100), 7.7, 8.1 and 8.5 (isolate 102), 8.3 and 8.5 (isolate 102). Their antibiograms
were almost identical and showed reduced susceptibility to all the G-lactams except
the carbapenems and mecillinam.
Isolate 116 carried three plasmids (c.5 kb, 11 kb and 214 kb) and had a 13-
lactamase of pi 7.9. It was sensitive to the carbapenems, mecillinam, aztreonam,
piperacillin and ceftazidime (MIC 3 mg/L in the Etest). It was resistant to cefoxitin.
A borderline susceptible zone of inhibition was observed with ticarcillin whereas
there was no inhibition zone with ticarcillin/clavulanic acid. The isolate was
resistant to gentamicin. It had been grown from a rectal swab taken from a 74-year-
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old patient (patient 61) on his fourth day in ITU with clinical sepsis following
bilateral axillo-femoral grafts and repair of an aortic aneurysm.
Isolate 126 had been grown from a rectal swab taken from a 22-year-old patient
(patient 40) on his third day in ITU following a second laparotomy to repair
stabbing injuries. The isolate contained three plasmids of c.4 kb, 13 kb and 120 kb.
Beta-lactamase bands ofpis 6.1, 6.5, 6.9 and 7.8 were detected. The isolate showed
reduced susceptibility to all the (3-lactamases except the carbapenems and
mecillinam.
Isolates 134, 135 (identified to genus only), 141 and 142 were resistant to all the
6-lactams except the carbapenems and mecillinam. They were resistant also to
gentamicin. The isolates were grown from rectal swabs taken from a 51-year-old
patient (patient 34) on her fifteenth and eighteenth days in ITU following surgery
for the repair of a large hiatus hernia. Beta-lactamase bands of pi 7.7 (isolate 134)
7.8 (isolate 135) and 8.0 (isolates 141 and 142) were detected. Each strain had a
large plasmid. Isolates 135 and 142 had identical plasmids of c. 198 kb. Isolates 134
and 141, examined on a different agarose gel, had identical plasmids of c. 165 kb.
However it is possible that the different sizes represented the same plasmid because
of the wide error margins already addressed.
Isolate 146 gave a borderline susceptible zone to temocillin but otherwise showed
reduced susceptibility or resistance to all the B-lactams except the carbapenems and
mecillinam, as did isolates 147 and 148. These strains were isolated from a 69-year-
old patient (patient 31) who had been transferred from another hospital with adult
respiratory distress syndrome and sepsis following a hemicolectomy nine days
earlier. Isolate 146 was grown from a rectal swab taken on her first day, and isolates
147 and 148 from throat and rectal swabs respectively, taken on her fifth day in
ITU. A 13-lactamase ofpi 8.0 was found in each of the isolates. Isolates 146 and 147
each had a large plasmid of c. 120 kb on the same gel. Although the plasmid in
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isolate 148 was found to be c. 113 kb on a different gel it could have been the same
plasmid because of the wide error margins already addressed.
Isolates 149 and 150 were obtained from a 26-year-old patient (patient 50)
transferred to ITU from another hospital in septic shock secondary to peritonitis.
The patient who suffered from Crohn's disease had had a large perianal abscess
drained five weeks earlier followed by ischaemia of the colon, faecal peritonitis and
a panproctocolectomy. Isolate 149 was grown from a throat swab and isolate 150
from a rectal swab taken on her third and twelfth days in ITU respectively. Both
isolates had plasmids of c.6. 22 kb and 46 kb and another plasmid of c. 171 kb was
detected in isolate 150 only. A B-lactamase ofpi 8.6 was detected in both isolates
whose antibiograms showed reduced susceptibility or resistance to all the B-lactams
apart from the carbapenems and mecillinam.
Isolate 161 was resistant to all the B-lactams apart from the carbapenems. A B-
lactamase ofpi 8.0 was observed. Plasmids were not detected. The isolate was
grown from a rectal swab taken from a 37-year-old renal transplant patient (patient
14) on his fourth day in ITU with Legionella pneumophila pneumonia. He had
started ampicillin and flucloxacillin the day before admission to ITU where
flucloxacillin was stopped. Ampicillin, erythromycin and SPEAR (cefotaxime and
SDD) were given for four days then ampicillin and cefotaxime were stopped and
ciprofloxacin substituted. Treatment with SDD, erythromycin and ciprofloxacin was
continued for eleven days.
Isolates 174, 178 and 184 were grown from rectal swabs taken from a 73-year-
old patient (patient 24) on his first, sixth and eighth days in ITU following a
possible respiratory arrest. Having sustained multiple injuries in a fall he had been
admitted to an orthopaedic ward fifteen days before his ITU admission. Isolates 174
and 178 had two identical small plasmids on the same agarose gel. Isolate 184 had
undergone electrophoresis on a different agarose gel. It had four small plasmids of
a similar size to those of isolates 174 and 178. B-Lactamase bands with the
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following pis were detected: 6.8 and 8.6 (isolate 174), 8.6 (isolate 178), 6.9 and 8.7
(isolate 184). Isolate 174 was resistant or showed reduced susceptibility to all the 13-
lactams except the carbapenems, mecillinam and temocillin. Isolate 178 was
sensitive to the carbapenems and showed borderline susceptibility to
piperacillin/tazobactam. It was resistant or showed reduced susceptibility to all the
other B-lactams including mecillinam and temocillin. Isolate 184 was sensitive to the
carbapenems, mecillinam, temocillin and piperacillin. Tazobactam did not enhance
the activity of piperacillin as it seemed to do in the case of isolate 178.
Isolate 197 was sensitive to the carbapenems and mecillinam but was resistant or
showed reduced sensitivity to all the other B-lactams. It had been grown from a
rectal swab taken from a 60-year-old patient (patient 22) on her first day in ITU
after transfer from another hospital. She had developed respiratory failure following
an endoscopic retrograde cholopancreatectomy. The isolate had a B-lactamase ofpi
8.6.
Isolate 199 was sensitive to the carbapenems and mecillinam but was resistant or
showed reduced sensitivity to all the other B-lactams tested. The organism had been
grown from a rectal swab taken from a 73-year-old patient (patient 71) on her
second day in ITU after drainage of a subphrenic abscess. She had undergone repair
of an aortic aneurysm six weeks earlier. Isolate 199 had a B-lactamase of 8.2. The
patient received ampicillin as well as SPEAR in ITU. Unfortunately details of
antibiotic therapy prior to her ITU admission were not recorded. Culture of the
subphrenic pus had yielded a strain ofEnterobacter resistant to cefotaxime, but the
rest of the antibiogram was not recorded.
Isolate 121 was sensitive to piperacillin, aztreonam, mecillinam, temocillin and
the carbapenems. It was resistant to cefotaxime (MIC > 32 mg/L), showed reduced
sensitivity to ceftazidime (MIC 4 mg/L) and was resistant also to gentamicin. It was
negative in the Etest for ESBL production. It had been grown from the rectal swab
of a 62-year-old patient (patient 67) on his fifth day in ITU with respiratory failure
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following a coronary artery bypass graft. It had a large plasmid (c. 165 kb) and a 13-
lactamase ofpi 7.9.
3.7.4 Escherichia coli
Two strains ofEscherichia coli were isolated. The Etest for ESBL detection was
negative for both strains and cefotaxime resistance was not transferred. Isolate 76
showed slightly reduced sensitivity to cefotaxime (MIC 4 mg/1) but was sensitive to
ceftazidime and aztreonam. It showed borderline susceptibility to temocillin and was
sensitive to cefoxitin. Except for the carbapenems it was resistant to the other 13-
lactams tested and resistant also to amoxycillin/clavulanic acid, ticarcillin/clavulanic
acid and piperacillin/tazobactam. The isolate contained two plasmids of c.73 kb and
92 kb and had two 13-lactamases of pis 5.4 and 7.4. This isolate had been grown
from a rectal swab taken from a 60-year-old patient (patient 98) on her fifth day in
ITU. She had suffered severe blood loss from a pathological fracture of her femur
secondary to myeloma.
Isolate 200 showed resistance or reduced sensitivity to all the 13-lactams tested
other than the carbapenems and mecillinam. The isolate contained three plasmids of
c.5 kb, 11 kb and 56 kb and had one J3-lactamase ofpi 8.5. This strain was isolated
from a rectal swab taken from a patient (patient 15) on his second day in ITU after
laparotomy for breakdown of a colonic anastomosis. He had undergone anterior
resection ten days earlier for rectal carcinoma.
3.7.5 Flavobacterium odoratum
Two strains of Flavobacterium odoratum were isolated. ESBL production was
not determinable by Etest in either strain. Isolates 89 and 90 were sensitive to
piperacillin and cefoxitin by disk diffusion testing but resistant to all other 13-lactams
tested including the carbapenems imipenem and meropenem. As expected for
Flavobacterium species the isolates were resistant also to gentamicin. They were
grown from throat swabs taken from a 70-year-old patient (patient 73) on his fourth
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day in ITU after an oesophagectomy for carcinoma. Plasmids were not detected in
either strain and a B-lactamase of pi 7.8 was detected in isolate 89 only.
3.7.6 Hafnia alvei
Four strains ofHafnia alvei were isolated. All were sensitive to the carbapenems
imipenem and meropenem. ESBL production was non-determinable in the Etest for
all four strains. Isolate 75 had two plasmids of c.42 kb and 119 kb and two 13-
lactamases with pi values of 7.4 and 7.8. The isolate was resistant to cefotaxime and
ceftazidime but was sensitive by disk diffusion testing to cefoxitin. Except for the
carbapenems and mecillinam it showed resistance or reduced sensitivity to the other
J3-lactams including the 13-lactamase inhibitor combinations. The isolate had been
grown from a throat swab taken from a 51-year-old patient (patient 86) on his first
day in ITU with respiratory failure. The patient had disseminated lymphoma and
diabetes and had been transferred from a medical ward.
Isolates 167, 168 and 169 were all grown from a 64-year-old patient (patient 43).
Isolates 168 and 169 were grown from a throat swab and rectal swab respectively
taken from the patient on her first day in ITU with renal failure following a
hemicolectomy four days earlier at another hospital. Isolate 167 was grown from a
rectal swab taken on her second day in ITU. A B-lactamase of 7.8 was detected in all
isolates. Six plasmids (c.5 kb, 6 kb, 11 kb, 14 kb, 51 kb and 59 kb) were observed in
isolate 167: plasmids similar to the first four of these were detected also in isolate
168 and plasmids similar to the first five in isolate 169. All three isolates were
resistant to cefotaxime and ceftazidime. Isolate 168 showed only borderline
sensitivity to aztreonam and was resistant to carbenicillin, ticarcillin piperacillin,
piperacillin/tazobactam and temocillin. Isolate 167 was sensitive to temocillin and
aztreonam but showed reduced sensitivity to carbenicillin, ticarcillin, piperacillin
and piperacillin/tazobactam. Isolate 169 was resistant to carbenicillin. It showed
borderline susceptibility to temocillin and reduced sensitivity to ticarcillin,
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piperacillin and piperacillin/tazobactam but was sensitive to aztreonam. All three
isolates were sensitive to cefoxitin and resistant to amoxycillin/clavulanic acid.
3.7.7 Klebsiella pneumoniae, ESBL production and transfer of ceftazidime
resistance
Two strains ofKlebsiella pneumoniae (133 and 140) were isolated. Although
both were sensitive to cefotaxime, isolate 140 was resistant to ceftazidime and
isolate 133 showed only borderline sensitivity by disk diffusion testing. Both were
resistant to gentamicin. For these reasons they were suspected of harbouring an
ESBL and were retained for further investigation. The Etest for ESBL detection was
positive for both isolates (Appendix IV). They had been grown from rectal swabs
taken from a 29-year-old patient (patient 81) on her sixth and eleventh days
respectively in ITU with respiratory failure. Hodgkin's disease had been diagnosed
four years earlier and she had undergone a bone marrow transplant six weeks prior
to her ITU admission. Ceftazidime had been started six days before she was
admitted to the ITU and was continued along with SDD throughout her ITU stay.
The patient had also received tobramycin.
Plasmid analysis of isolates 133 and 140 had originally been carried out on
different agarose gels. Isolate 133 had four plasmid bands of c. 5 kb, 10 kb, 54 kb
and 182 kb and two 6-lactamases of pis 5.4 and 7.6 suggesting a TEM-type and
SHV-type of enzyme respectively. The MIC of isolate 133 for ceftazidime was 8
mg/L and that for cefotaxime was <0.5 mg/L. By disk diffusion testing isolate 133
was sensitive to aztreonam and piperacillin/tazobactam but was resistant to
amoxycillin/clavulanic acid, carbenicillin, ticarcillin, ticarcillin/clavulanic acid and
piperacillin. It was sensitive also to cefoxitin, mecillinam, and the carbapenems and
resistant to gentamicin. Isolate 140 also contained four plasmids of c.5 kb, 12 kb, 48
kb and 168 kb and had two 6-lactamases of pis 5.3 and 7.6 suggesting a TEM-type
and SHV-type of enzyme respectively. Its antibiogram was similar to that of isolate
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133 except that its ceftazidime MIC was 32 mg/L. Although the isolates were
resistant to amoxycillin/clavulanic acid there was synergy between disks of
amoxycillin/clavulanic acid and ceftazidime.
In the additional transconjugation studies using ceftazidime rather than
cefotaxime along with rifampicin for counterselection, transconjugants were
obtained from both isolates at a ceftazidime concentration of 1 mg/L but not at the
higher ceftazidime concentration of 4 mg/L. Transconjugants from isolate 140 were
shown to have a large plasmid of c.214 kb but plasmids were not detected in
transconjugants from isolate 133 (Figures 21 and 22). However transconjugants
from both donor isolates 133 and 140 were shown to have the TEM-type B-
lactamase as well as the B-lactamase ofpi 8.4 of the recipient Escherichia coli J62-
2, but not the SHV-type enzyme of the donor Klebsiella organisms. Resistance to
ceftazidime in these isolates was almost certainly caused by an ESBL ofTEM-type.
The enzymes of pi 7.6 in both isolates were likely to be SHV-1 enzymes. Most
Klebsiella pneumoniae strains have chromosomally mediated SHV-1 B-lactamases
[98] which are constitutive and produced usually at low levels.
Isolates 133 and 140 were obtained from samples taken on the patient's sixth and
eleventh days in ITU and had ceftazidime MICs of 8 and > 32 mg/L respectively.
Both gave positive results in the Etest for ESBL production. Transfer of ceftazidime
resistance in both isolates was successful using the lower ceftazidime concentration
of 1 mg/L for counterselection, but not with the higher concentration of 4 mg/L.
Cefotaxime MICs for isolates 133 and 140 were 0.06 and 0.25 mg/L respectively.
3.7.8 Morganella morganii
Nine strains ofMorganella morganii were isolated from six patients. Plasmids
were detected in four of these isolates and G-lactamase bands were observed in all of
them. Isoelectric points ranged from 5.4 to 7.9. All of the isolates were sensitive to
the carbapenems imipenem and meropenem and all were resistant to ampicillin and
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amoxycillin/clavulanic acid. Resistance to cefotaxime was not transferred by any of
the isolates ofMorganella morganii and ESBL production was not determinable by
Etest.
Isolate 10 had a plasmid of c.71 kb and a B-lactamase of pi 7.4 which aligned
with OXA-1 on the same gel. However the isolate was sensitive to carbenicillin and
had a borderline inhibition zone with ticarcillin. It was resistant to cefotaxime,
ceftazidime and piperacillin but was sensitive to piperacillin/tazobactam, cefoxitin
and aztreonam. The isolate had been grown from a rectal swab taken from a patient
(patient 1) on her tenth day in ITU following cardiac arrest in a medical ward. The
patient had been found collapsed at home four weeks earlier and had been admitted
with a deep vein thrombosis, pulmonary embolism, congestive cardiac failure and
pneumonia. She had received amoxycillin and erythromycin before her ITU
admission.
Isolate 16 showed reduced sensitivity to cefotaxime and was resistant to
ceftazidime. It was sensitive by disk diffusion testing to aztreonam. It gave
borderline sensitive inhibition zones with ticarcillin, piperacillin and cefoxitin and
showed reduced sensitivity to carbenicillin. One B-lactamase of pi 7.9 was detected.
This isolate had been grown from a throat swab taken from a patient (patient 33) on
his first day in ITU with renal failure following an elective aorto-femoral bypass
three days earlier at another hospital. Morganella morganii was isolated also from
clinical samples.
Isolate 23 was grown from a rectal swab taken from a 59-year-old patient (patient
82) on her first day in ITU after desloughing of an old Caesarean section wound.
The isolate was resistant to all the B-lactams tested other than the carbapenems. It
had three plasmids (c.6 kb, 12 kb and 47 kb) and two B-lactamases of pis 6.5 and
7.8. Morganella morganii resistant to cefotaxime had been isolated also from
clinical specimens from this patient.
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Isolate 24 was grown from a rectal swab taken two days later from the same
patient (patient 82) as isolate 23. It had a plasmid profile identical to that of isolate
23, but had only one B-lactamase ofpi 7.7 and a slightly different antibiogram. It
was sensitive to ticarcillin (borderline inhibition zone), temocillin, aztreonam, and
cefoxitin. It showed reduced sensitivity to cefotaxime and was resistant to
ceftazidime. By disk diffusion testing it showed reduced sensitivity to carbenicillin
and was resistant to piperacillin but gave a good zone of inhibition to
piperacillin/tazobactam.
Isolate 25 was grown from a rectal swab taken on the first day of the above
patient's readmission to ITU fourteen days later following closure of a ventral
hernia. This isolate had two plasmids (c.6 kb and 15 kb) and B-lactamases of pis 6.5
and 7.9. It was sensitive to carbenicillin and ticarcillin (both borderline inhibition
zones), temocillin, aztreonam, cefoxitin and gentamicin. It showed reduced
sensitivity to cefotaxime and was resistant to ceftazidime and piperacillin but
sensitive to piperacillin/tazobactam.
Isolate 57 had B-lactamases ofpis 5.4 and 6.8 and was resistant or showed
reduced sensitivity to all the B-lactams tested other than the carbapenems. The B-
lactamase band of 5.4 was suggestive of a TEM-type enzyme although plasmids
were not detected. This isolate was grown from a rectal swab taken from a patient
(patient 42) on his fifteenth day in ITU after a second laparotomy for
cholecystectomy and drainage of a necrotic pancreas. Morganella morganii had
been isolated from multiple clinical specimens taken two days earlier. The patient
had received cefotaxime for the first three days of his ITU stay.
Isolate 58 was obtained from the same patient (patient 42) as isolate 57. It was
grown from a rectal swab taken on his twentieth day in ITU. This isolate had only
one B-lactamase ofpi 6.8 and was sensitive by disk diffusion to carbenicillin,
ticarcillin and piperacillin. Like isolate 57 it showed reduced sensitivity to
cefotaxime and was resistant to ceftazidime.
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Isolate 113 was resistant to cefotaxime and ceftazidime but sensitive to
aztreonam. It gave a substantial inhibition zone to carbenicillin and a borderline
sensitive zone to ticarcillin. It showed reduced sensitivity to piperacillin but was
sensitive to piperacillin/tazobactam and cefoxitin. Three B-lactamase bands ofpis
6.5, 7.3 and 7.9 were observed. The isolate was grown from a rectal swab taken
from a patient (patient 68) on his eighth day in ITU after transfer from another
hospital. He was suffering from an acute exacerbation of chronic obstructive
airways disease.
Isolate 157 was resistant to ceftazidime (MIC > 32 mg/1) although it gave a
sensitive inhibition zone by disk testing. The isolate showed reduced sensitivity to
cefotaxime and piperacillin but was sensitive to cefoxitin, carbenicillin, ticarcillin
and aztreonam. A B-lactamase band ofpi 6.8 was detected. The isolate was grown
from a rectal swab taken from a patient (patient 21) on his third day in ITU
following laparotomy for peritonitis. He had been given perioperative metronidazole
and gentamicin. On admission to ITU he received systemic tobramycin as well as
SPEAR. The patient had spent two days in ITU four weeks earlier following
hemicolectomy and splenectomy.
3.7.9 Pseudomonas
In the present study 57 pseudomonads were isolated. Of these, 50 were identified
as Pseudomonas aeruginosa, one as Pseudomonas fluorescens and six isolates were
satisfactorily identified to genus only. Cefotaxime MICs were 16 mg/L (three
isolates), 32 mg/L (thirteen isolates) and > 32 mg/L (forty-one isolates). Plasmids
were detected in only two isolates, 38 and 117, both Pseudomonas aeruginosa. B-
Lactamases were detected in 34 of the 57 pseudomonad isolates.
Isolate 38 had a plasmid of c.43 kb and B-lactamase bands representing pi values
of 7.9 and 8.8 were detected. Only one band occurred on each of two gels, the
higher pi being recorded on the more accurate gel. The antibiotic sensitivity pattern
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for the organism was unremarkable. These findings imply the basal production of a
chromosomally-mediated enzyme.
Isolate 117 had plasmids of c.l kb and 40 kb and a B-lactamase of pi 7.9. There
was complete resistance by disk diffusion to the third-generation cephalosporins
cefotaxime and ceftazidime, the carboxypenicillins carbenicillin and ticarcillin, the
ureidopenicillins azlocillin and piperacillin and the monobactam aztreonam. There
was a minimal zone of inhibition with ticarcillin/clavulanic acid but none with
piperacillin/tazobactam.
Isolate 27 had an antibiogram identical to strain 117 and a B-lactamase which
reacted immediately to nitrocefin spot-testing and banded strongly at pi 7.9.
Plasmids were not detected in this isolate, otherwise all the comments applied to
isolate 117 are pertinent to isolate 27.
Isolates 48, 49 and 103 had similar antibiograms to isolates 27 and 117. Beta-
lactamases of pis 8.2 and 8.7 were found in isolates 48 and 103 respectively; none
was detected in isolate 49 on three different gels.
Isolates 55, 93 and 103 showed resistance to carbenicillin, azlocillin and
ticarcillin by disk diffusion. Isolate 55 had a B-lactamase ofpi 7.8 which was
presumably a chromosomal type. Isolates 55 and 103 had enzymes ofpi 8.1 and 8.7
respectively, presumably chromosomal types.
Isolate 56 was resistant to carbenicillin and ticarcillin and to imipenem as well as
meropenem. However it was sensitive to azlocillin, piperacillin, ceftazidime and
ciprofloxacin. A B-lactamase ofpi 8.2, presumably chromosomally-mediated, was
detected.
Isolates 60, 71, 72, 73, 83, 84 and 85 had borderline or slightly reduced
sensitivities to carbenicillin but were otherwise unremarkable and B-lactamases were
not detected. Isolate 63 was resistant to carbenicillin and had a B-lactamase of 7.5
which could possibly have indicated an OXA-type enzyme.
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Isolates 139 and 163 were resistant to carbenicillin and strain 163 also showed
reduced sensitivity to ciprofloxacin. B-Lactamases were not detected in isolate 139
but B-lactamase bands of pi 7.4 and 7.9 were detected in isolate 163. It is possible
that the band ofpi 7.4 represented an OXA-type enzyme and that of 7.9 a
chromosomal enzyme.
Isolates 144, 152 and 162 showed reduced sensitivity to carbenicillin but were
otherwise unremarkable. All three had high pi enzymes probably of chromosomal
type.
Isolates 182, 183, 190 and 198 showed reduced sensitivity to carbenicillin but
were sensitive to ticarcillin by disk diffusion testing and clavulanic acid did not
particularly enhance the ticarcillin zones. B-lactamases were not detected in isolates
190 and 198. Isolate 182 had an enzyme ofpi 7.7. Isolate 183 had enzymes of 7.4
and 7.9.
Isolates 67, 68, 69 and 70 were identified to genus only. Isolates 67 and 68 had
reduced sensitivities to carbenicillin but were sensitive to ticarcillin. Clavulanic acid
seemed to have some effect in that larger zones of inhibition were exhibited with
timentin (ticarcillin/clavulanic acid) than with ticarcillin alone and both isolates
showed zones of inhibition around amoxycillin/clavulanic acid. However B-
lactamases were not detected.
Isolates 69 and 70 were resistant to carbenicillin and ticarcillin. Clavulanic acid
seemed to counteract the latter resistance suggesting the possible involvement of a
plasmid-mediated B-lactamase. Strain 69 had a B-lactamase of pi 7.6 but B-lactamase
bands were not detected in isolate 70.
Isolate 95, Pseudomonas fluorescens, was resistant to carbenicillin and ticarcillin.
The activity of the latter was unaffected by clavulanic acid. A B-lactamase of pi 8.3,
presumably of chromosomal type, was detected.
Isolates 17, 19, 20, 42 and 151 had ceftazidime MICs > 32 mg/L although all
isolates gave inhibition zones clearly denoting susceptibility to ceftazidime as well
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as piperacillin and aztreonam on disk diffusion testing. ESBL production was not
determinable by Etest on the five isolates. B-Lactamases of pis 8.2, 8.1, 8.3 and 8.4,
probably denoting chromosomal types, were found in isolates 19, 20, 42 and 151
respectively. None was detected in isolate 17. Plasmids were not detected in any of
the five isolates.
Isolate 17 was grown from a rectal swab taken from a 58-year-old patient on his
first day in ITU with renal failure following an aorto-femoral bypass at another
hospital. Isolates 19 and 20 were grown from a rectal swab taken from an 83-year-
old patient on her first day in ITU following a cataract extraction and lens implant.
Details of antibiotic therapy prior to ITU admission were not available for either of
these patients.
Isolate 42 was grown from a rectal swab of a 73-year-old patient (patient 64)
taken on his fourth day in ITU with renal failure following cholecystectomy at
another hospital. A rectal swab taken on the patient's first day in ITU yielded isolate
41 with a ceftazidime MIC of 8 mg/L, an unremarkable antibiogram, a B-lactamase
ofpi 8.3 (presumably chromosomal) and no plasmids.
Isolate 151 was grown from a rectal swab of a 67-year-old patient (patient 41)
taken on his first day in ITU following cardiac septal rupture. A rectal swab taken
from the same patient ten days later yielded isolate 152 with a ceftazidime MIC of 4
mg/L, an unremarkable antibiogram, B-lactamase bands of 8.2 and 8.4 and no
plasmids. Isolate 151 which was resistant to ceftazidime was grown from a sample
taken on the patient's first day in ITU while isolate 152 which was sensitive to
ceftazidime was isolated ten days later.
The remaining 21 pseudomonads had unremarkable antibiograms. B-Lactamases
were detected in 11 of these isolates. Nine had high pi enzymes of 7.9 and above,
which were probably chromosomally determined and one had a B-lactamase ofpi
7.7 probably also of chromosomal type. One had two bands of pi 7.4 and 7.9
respectively. Its cefotaxime MIC was > 32 mg/L but otherwise the antibiogram
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indicated a generally sensitive strain. It is likely that the enzymes of this isolate were
present in small amounts as they could be detected only after disk induction with
cefoxitin.
In summary the most noteworthy pseudomonads were isolates 117 and 27; isolate
49 which had a similar antibiogram but no detectable 13-lactamase band and isolate
56 which was resistant to both carbapenems imipenem and meropenem.
Isolate 117 had been grown from the rectal swab of a patient (patient 61) on his
fifteenth day in ITU following bilateral axillo-femoral grafts. Clinically he had
sepsis and acute renal failure. He had undergone SPEAR and had received in
addition flucloxacillin (for a bacteriologically confirmed Staphylococcus aureus
infection) and parenteral tobramycin.
Isolate 27 had been grown from the rectal swab of a patient (patient 58) with late-
onset asthma on her eighth day in ITU with a severe chest infection. She had
undergone SPEAR, except that cefotaxime was used as therapy rather than
prophylaxis in her case, doses and length of course being increased appropriately.
The patient had also received erythromycin and rifampicin. Isolates 27 and 117 were
obtained more than a year apart.
Isolate 49 had been grown from the rectal swab of a patient (patient 28) on his
sixteenth day in ITU following a road traffic accident in which he had sustained
multiple injuries. He underwent SPEAR, cefotaxime being continued for five days.
Strain 49 was isolated ten days after cefotaxime had been stopped. Isolates 49 and
27 were obtained more than four months apart.
Isolate 56 had been grown from the throat swab of a patient (patient 45) on the
first day ofhis admission to ITU. He had been transferred from another hospital for
management of sepsis, renal failure and a left pyopneumothorax following a left
hernia repair. Unfortunately no details of prior antibiotic therapy had been recorded.
Isolates 56 and 49 were obtained from samples taken over a month apart
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3.7.10 Stenotrophomonas maltophilia
Seven isolates of Stenotrophomonas maltophilia were investigated. Isolates 28,
29, 30, 31 and 32 were grown from rectal swabs from the same patient (patient 36)
taken on her first (isolates 28 & 29), third, sixth and eighth days in ITU respectively.
The patient was 75 years old, had a ruptured diverticulum, faecal peritonitis and
respiratory failure. Isolates 28, 30, 31 and 32 had cefotaxime MICs > 32 mg/L and
were resistant to all the antibiotics tested by disk diffusion other than ciprofloxacin
and ticarcillin/clavulanic acid. Isolate 29 differed slightly in showing reduced
sensitivity to ciprofloxacin and only a borderline zone of inhibition to
ticarcillin/clavulanic acid. Only weak B-lactamase activity was detected in nitrocefin
spot-testing of all five cell extracts even after disk induction with cefoxitin. On
isoelectric focusing a G-lactamase ofpi 6.1 was detected in all five isolates.
Isolate 99 was grown from the throat swab of a 79-year-old patient (patient 51)
on the second day of her ITU admission following repair of a colonic anastomosis,
peritonitis and deteriorating renal function. The antibiogram of this isolate was
similar to that of isolates 28 and 30-32, but 13-lactamases were not detected. There
was no temporal or epidemiological association between isolate 99 and the other
isolates.
Isolate 45 was grown from the throat swab of a 59-year-old patient (patient 95)
on his second day in ITU following a pneumonectomy for an infiltrating
adenocarcinoma of the lung. It was apparently more sensitive in vitro than the
strains isolated from the other two patients, showing large zones of inhibition to
ciprofloxacin, ceftazidime, ticarcillin/clavulanic acid and piperacillin/tazobactam. It
showed susceptibility also to carbenicillin, ticarcillin and azlocillin and borderline
sensitivity to piperacillin. Three small plasmids were detected in this strain, but B-
lactamases were not demonstrated. Again there was no temporal or epidemiological
link between isolate 45 and the other isolates.
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Chapter 4 Discussion
4.1 Aims of the study
The aims of the study were to investigate the cefotaxime resistance mechanisms
of 175 AGNB isolated from surveillance flora of ITU patients undergoing SPEAR
and to assess the implications of such resistance for the continuation of SPEAR.
This work was particularly concerned with the incidence of two mechanisms of
cefotaxime resistance in AGNB with the potential for dissemination in the ITU as a
result of the widespread use of cefotaxime as an integral part of SPEAR:
chromosomal B-lactamase derepression in the B-lactamase-inducible species such as
Citrobacterfreundii, Morganella morganii, Pseudomonas aeruginosa and
Enterobacter species and plasmid-mediated ESBL production, more common in
Klebsiella pneumoniae and Escherichia coli, but found also in many other AGNB
including the B-lactamase-inducible species. Findings of such resistance in
surveillance flora might be a portent of serious clinical resistance problems to come.
4.2 Plasmid analysis
4.2.1 Agarose gel size
Every isolate was screened for plasmids on at least one, and often multiple,
medium-length (14 cm) gels and at least one long (25 cm) gel. More plasmids were
detected on medium than on long gels in 54 of the 78 isolates which contained
plasmids. The same number of plasmids was detected on both medium and long gels
in 19 isolates and more plasmids were detected on long gels than on medium gels in
only five isolates. Twenty-seven plasmids > 100 kb were detected on medium but
not on long gels and only one large plasmid (171 kb) was detected on a long gel but
not on a medium gel. In this study sensitivity of horizontal agarose gel
electrophoresis was not improved by using the longer gel.
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4.2.2 Plasmid size
It is appreciated that only an estimate of plasmid size was obtained in the present
study. Agarose gel electrophoresis was not originally presented as a means for
precise plasmid characterization [218] and other investigators [221] have also
acknowledged the limitations of the method, because the logarithm/logarithm of
plasmid size versus mobility is not a straight line over all values. In the present
study the widest error margin occurred around the 38 kb size (section 3.3). Another
group [235] claimed greater accuracy for all plasmid sizes in an entire range from
1.76 MDa (2.7 kb) to 312 MDa (491 kb) using a more complex multiple regression
analysis. However throughout the present work the consistency of the experimental
technique was reflected in the proximity of the r2 statistic to '1'. If the results of
plasmid screening and transconjugation studies had suggested the presence of one or
more epidemic plasmids, then more accurate characterization would have been
carried out using restriction endonuclease analysis of appropriately purified cell
lysates [236].
4.3 Transconjugation experiments
Plasmids were detected in 78 of 175 isolates. In case any plasmids had not been
detected by agarose gel electrophoresis and in case transfer of cefotaxime resistance
might occur without plasmid transfer, transconjugation experiments were carried out
on all 175 isolates whether or not plasmid bands had been demonstrated.
Transferable resistance to cefotaxime was not detected in any isolate in this study
using standard broth mating methods at the optimal growth temperatures of the
organisms. Transferable resistance to ceftazidime was demonstrated in two isolates
which were sensitive to cefotaxime but resistant to ceftazidime. It might be argued
that some potential plasmid transfers were not expedited by the liquid mating
techniques used in this study and therefore that some plasmid-mediated ESBL
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production was not detected. Bradley and colleagues [237], studying plasmid
transfers between strains of Escherichia coli in 1980, showed that surface (plate)
mating was sometimes more efficient than liquid mating, especially in strains with
rigid pili. Also some plasmids are temperature-sensitive [237] and their transfer
might not have been detected in the present work as only those organisms which
grew better at 30° C were "mated" at that temperature. The phylogenetic origins of
the mating pairs must also be considered. The recipient organism was always
Escherichia coli whereas the potential donors were of various genera, usually not
Escherichia coli. Piatt and Sommerville [238] suggested that an intergeneric barrier
might limit genetic transfer between strains of different genera. Falkow and
colleagues [139] suggested that the divergent structure of the genetic material
affected chromosomal pairing and integration. However they did go on to describe
gene transfer between two strains of different genera with divergent DNA base
ratios.
4.4 Preparation of cell lysates
Slime production by mucoid organisms was mentioned as a problem in the
preparation of cell lysates. In order to overcome this problem Hibbert-Rogers and
colleagues [239] have since reported the use of snail acetone powder in the digestion
of bacterial cell wall polysaccharides prior to DNA extraction procedures.
4.5 Isoelectric focusing, antibiogram and prediction of B-lactamase type
Isoelectric focusing was carried out on all SPEAR isolates. As there are many
well-established relationships between B-lactamase activity and antibiogram [240]
the isolates were screened also for susceptibility to a battery of B-lactam antibiotics
chosen to facilitate the recognition of the resistance patterns associated with certain
B-lactamase types. For example, isolate 119 was identified as Citrobacterfreundii,
one of the species known to have inducible chromosomal B-lactamases. It was
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resistant to cefoxitin, cefotaxime, ceftazidime, piperacillin and
amoxycillin/clavulanic acid. It had a B-lactamase ofpi 8.5, plasmids were not
detected and cefotaxime resistance was not transferred. It therefore seemed
reasonable to infer that its resistance to cefotaxime was mediated by stable
derepression of a chromosomal AmpC enzyme. However prediction of B-lactamase
type using isoelectric focusing and antibiogram has limits. If hypothetically such an
isolate of Citrobacterfreundii also had a B-lactamase ofpi 7.6 it might mean that a
stably derepressed organism also produced a plasmid-mediated SHV-type ESBL or
simply a parental SHV-1 enzyme. In such a situation the antibiogram would not be
discriminatory and even a DNA probe would not distinguish between the latter two
enzymes, but the appropriate genetic experiments might detect the transfer of
genetic material. For this reason transconjugation experiments were performed on
all SPEAR isolates in the present study in order to look for transfer of cefotaxime
resistance. A further difficulty arises when the range of pis quoted for the
chromosomal B-lactamases of a B-lactamase-inducible species overlaps with the
range of pis for possible plasmid-mediated enzymes. This occurred with a number
of the Enterobacter isolates and is discussed in detail below. In such cases the
identity of the B-lactamase cannot be inferred from the antibiogram. Prediction of B-
lactamase type using isoelectric focusing and antibiogram is of limited value also for
organisms such as Acinetobacter species in which relationships between antibiogram
and B-lactamase profile are poorly established [240].
4.6 Chromosomal B-lactamases, their mode of production and contribution to
resistance
Chromosomal B-lactamases are almost ubiquitous in enterobacteria except for
salmonellae but vary greatly in amount, mode of production and therefore in their
contribution to resistance [155,173]. Some species have molecular class A types but
a greater number have molecular class C enzymes of Bush-Jacoby-Medeiros group
- 148-
1, also known as AmpC B-lactamases [169] whose expression may be inducible,
high-level constitutive or low-level constitutive, according to the species and the
strain. Chromosomal B-lactamases are ubiquitous also in non-fermenting AGNB and
as in enterobacteria are variable in amount and significance. The enzymes of
Pseudomonas aeruginosa and Stenotrophomonas maltophilia have been studied
extensively and their roles in resistance are well established; those ofAcinetobacter
and Flavobacterium species are less well understood according to Livermore in his
review [170]. Certain species ofAGNB, including Pseudomonas aeruginosa,
Enterobacter, Citrobacter and Morganella morganii, have inducible expression of
AmpC enzymes and show greater potential for resistance. B-Lactamase induction
has been the subject of confusion but is simply the transient elevation in B-lactamase
synthesis that occurs when a B-lactam drug is present. Enzyme synthesis returns to a
low level when the inducer is removed [241]. Individual B-lactam antibiotics differ
in their inducer power and lability (susceptibility to hydrolysis). First-generation
cephalosporins induce AmpC enzymes strongly and are labile to hydrolysis.
Consequently they cause their own destruction and lack activity against B-lactamase
inducible species [241], Ampicillin shows this behaviour for most species except
Citrobacterfreundii for which it is a weak inducer. Cefoxitin too is a labile strong
inducer for Pseudomonas aeruginosa, Citrobacterfreundii and Enterobacter
cloacae but is more stable to the AmpC enzymes ofSerratia marcescens and
Proteus species and remains active against these species. The carbapenems
imipenem and meropenem are strong inducers but are almost stable to AmpC [241].
They cause enzyme synthesis but are not destroyed and so remain active against B-
lactamase inducible species. Ureidopenicillins, monobactams and second- and third-
generation cephalosporins including cefotaxime are labile to AmpC enzymes but are
weak inducers [14,241], They remain active against B-lactamase-inducible species
because they fail to induce B-lactamase synthesis, not because they are stable to the
enzyme. The B-lactamase inducible species, particularly Pseudomonas aeruginosa
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and Enterobacter cloacae, segregate high frequency spontaneous mutants that
manufacture AmpC enzymes continuously at a high level. These mutants are termed
variously "constitutive", "stably derepressed" or "enzyme hyper-producers" and are
present naturally in inducible populations, usually at frequencies of 10"7 but
occasionally at up to 10"5 [242]. As they produce the B-lactamase independently of
induction they express resistance to the labile weak inducers but not to carbapenems
or to stable weak inducers such as temocillin. According to Livermore [241] when a
population of inducible bacteria containing, as it invariably does, a few derepressed
mutants is challenged with a newer cephalosporin, ureidopenicillin or monobactam,
the inducible cells fail to produce enough enzyme to inactivate the drug and are
killed whereas the derepressed mutants survive and may overgrow. This process
represents selection, not induction. Selection is favoured by labile weak inducers,
not as is often mistakenly thought, by strong inducers. Strong inducers, such as
imipenem and meropenem, retain equal activity against inducible and derepressed
organisms and so do not favour the latter mutants. Likewise weak inducers that are
stable, for example temocillin, are not selective [243]. Selections of stably-
derepressed mutants have been reported in vivo and in vitro with most of the third-
generation cephalosporins and with the monobactam aztreonam, more rarely with
ureidopenicillins, but not with carbapenems nor with the carboxypenicillins [14,15].
The AmpC enzymes are not sensitive to clavulanic acid and are only moderately so
to tazobactam [241], Overall AmpC enzyme derepression was inferred in 65 of the
175 SPEAR isolates.
It is worthwhile repeating that in the present study samples taken on a patient's
first day in ITU were taken within four hours of admission to ITU and before




It has been said that Acinetobacter species have B-lactamases and are resistant to
B-lactams [244], but it has also been said that the relationship between these bare
facts is unclear [170]. In the present study B-lactamases were detected in 25 of 31
isolates. After the first recognised outbreaks ofAcinetobacter infections reported in
1971 it was noted that isolates rapidly became resistant to aminopenicillins and the
first- and second- generation cephalosporins [244]. Indeed it had been stated that
Acinetobacter was intrinsically insensitive to most B-lactams, especially ampicillin
and cephalosporins [245]. However early studies reported in 1971 with ampicillin
and carbenicillin and later studies with ureidopenicillins such as piperacillin reported
in 1980, 1982 and 1985 showed that these compounds were active against 70-80%
ofAcinetobacter strains [244]. At a later stage, when Acinetobacter species became
resistant to early B-lactams, the third-generation cephalosporins, particularly
cefotaxime [246] and ceftazidime [246,247] were initially active. However within a
few years a rapid increase in resistance to carboxypenicillins and to a lesser degree
to ureidopenicillins and third-generation cephalosporins, led to the investigation of
the possible production of inactivating enzymes by Acinetobacter strains [244]. Both
TEM-1 and TEM-2 6-lactamases had been found previously in representative
isolates of epidemic strains and Joly-Guillou and colleagues [248] first demonstrated
the presence of a novel CARB-type enzyme ofpi 6.3 which they designated CARB-
5. These three enzymes belong to the group of constitutive plasmid-determined 8-
lactamases described by Medeiros [98] and Bauernfeind [249]. In the present study
the pi of 5.6 in isolate 191 suggested the presence of a TEM-type B-lactamase.
However this was not in keeping with the large zones of inhibition to carbenicillin
and ticarcillin on disk diffusion testing of the isolate.
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The rapid increase of resistance to third-generation cephalosporins reported in
1987 led several authors to investigate the possible presence of an inducible
cephalosporinase in Acinetobacter species [250]. Before the third-generation
cephalosporins became available in 1977 an initial study had demonstrated
production of an inducible Class I type B-lactamase in Acinetobacter species [251].
The enzyme closely resembled the enzymes produced by Proteus, Citrobacter and
Pseudomonas species in terms ofmolecular mass, sensitivity to inhibitors and
inducibility. Medeiros [98] described the "inducible" enzymes of "Acinetobacter
anitratum" as belonging to the "typical cephalosporinase group" of Sawai and
colleagues [252] which included inducible enzymes such as those produced by
Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens and
Pseudomonas aeruginosa. However according to Bergogne-Berezin & Joly-Guillou
in 1991 [244] no clear demonstration of an inducible cephalosporinase in
Acinetobacter species had been reported since that described by Morohoshi and
Saito in 1977 [251] and early claims that Acinetobacter species had inducible AmpC
enzymes were later discounted [253].
According to studies cited by Bergogne-Berezin and Joly-Guillou [244]
successive increases in the resistance of clinical strains ofAcinetobacter had been
reported periodically, high proportions of strains had become resistant to older
antibiotics and certain isolates were resistant to most commonly used antibacterial
drugs. Less than 50% of strains were inhibited by acceptable concentrations of
cefotaxime or even ceftazidime which was initially the most active of the
cephalosporins against Acinetobacter strains [244], It was postulated [244] that a
particular Acinetobacter isolate from a urine specimen might be an ESBL-producer
but apparently in general no convincing relationship has been established between
antibiogram and (3-lactamase production in Acinetobacter species [170].
Isoelectric points of 9.9 and 9.3 have been reported [169] for chromosomal
enzymes ofAcinetobacter species. In the present work B-lactamases were detected
- 152-
in 26 of 31 Acinetobacter isolates using conventional polyacrylamide gel
electrophoresis techniques of isoelectric focusing [156] and broad-range (pH 3.5-
9.5) ampholine PAGplates (Pharmacia, Uppsala, Sweden). One 6-lactamase had a pi
of 5.6; the others had pi values between 7.7 and 8.9. However the difficulties
associated with isoelectric focusing of the chromosomal 6-lactamases of
Acinetobacter species in conventional systems using broad-range ampholines and
the failure to focus enzymes of very high pi values and high molecular masses have
been described by Hood and Amyes [253].
Liu and colleagues [240] found in their survey of the prevalence of 6-lactamases
among one thousand Gram-negative bacilli that inhibition zone distributions for
Acinetobacter species were amongst the most complex and variable observed. They
found that even those Acinetobacter calcoaceticus var anitratus isolates that gave
substantial zones to ampicillin disks (> 20 mm) commonly gave 4-5 mm larger
zones to disks containing amoxycillin/clavulanic acid suggesting 6-lactamase
function. However isoelectric focusing resolved clear 6-lactamase bands in only a
few of their isolates. An alternative interpretation according to the authors [240] was
that these results might "reflect the inherent susceptibility ofmany isolates of
Acinetobacter spp. to clavulanate". The 6-lactamase inhibitors sulbactam and
tazobactam [254 {p210}, 221] rather than clavulanic acid are known to be
inherently active against Acinetobacter species. Sulbactam and tazobactam in
combination with ticarcillin and as single agents have been found to reduce
substantially the MICs of ticarcillin-resistant strains ofAcinetobacter species [244],
tazobactam being more active than sulbactam in both situations. Clavulanic acid
(tested in combination with ticarcillin but not as a single agent) was described as
causing a significant decrease in the MICs for the ticarcillin-resistant strains but not
a true reversion to susceptibility [244]. In the present study all Acinetobacter isolates
were resistant to ampicillin, 29 of 31 isolates having no zones of inhibition whereas
20 of 31 isolates gave substantial zones (23 mm or greater) to
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amoxycillin/clavulanic acid. Isolate 18 which showed no inhibition zones to
ampicillin, amoxycillin/clavulanic acid or ticarcillin gave a large zone of inhibition
to ticarcillin/clavulanic acid.
The responses of isolates 132 and 137 in the Etest for ESBL production and in
disk diffusion testing with clavulanic acid combinations might suggest ESBL
function or might indicate that these isolates were particularly sensitive to clavulanic
acid. The sensitivity of both isolates to carbenicillin, ticarcillin and piperacillin and
resistance to cefoxitin was not in keeping with ESBL production. Neither resistance
to cefotaxime nor to ceftazidime was transferred by transconjugation from these two
Acinetobacter isolates. Both isolates had been grown from rectal swabs taken from a
29-year-old patient (patient 81) on her sixth and eighth days in ITU with respiratory
failure. Hodgkin's disease had been diagnosed four years earlier and she had
undergone a bone marrow transplant six weeks prior to her ITU admission.
Ceftazidime had been started six days before she was admitted to the ITU and was
continued along with SDD throughout her ITU stay. The patient had also received
parenteral tobramycin. Interestingly this was the same patient (patient 81) from
whom the two isolates (133 and 140) ofKlebsiella pneumoniae which were positive
in the Etest for ESBL production and whose resistance to ceftazidime was
transferable had been grown from samples taken on her sixth and eleventh days in
ITU. However isolate 132 had an enzyme ofpi 7.9 and isolate 137 had enzymes of
pis 7.9 and 8.6 whereas the transferable B-lactamases from the Klebsiella isolates
133 and 140 had a pi of c.5.3.
Although chromosomal B-lactamase induction in general has been more or less
discounted in Acinetobacter species and ESBL production was not demonstrated in
this study, it could be argued that the widespread use of cefotaxime created a
selection pressure for Acinetobacter strains resistant to cefotaxime. However 16 of
the 31 Acinetobacter isolates were obtained from samples taken from 16 patients on
their first day in ITU and were unlikely to be related to SPEAR. From plasmid and
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6-lactamase profiles and antibiograms there was no evidence of an epidemic strain
among the 15 isolates obtained from samples taken on subsequent days from the
other seven patients.
4.7.2 Citrobacter freundii
Matthew and Harris [157] reported pis of c. 7.5 and 8.3 for chromosomally-
mediated B-lactamases of two strains of Citrobacterfreundii and a pi of 8.6 has been
described for a chromosomally-mediated 6-lactamase of Citrobacterfreundii
GN7391 [255]. Isoelectric points of 8.9 and 8.6 have also been recorded for
chromosomal enzymes of two other strains [169].
In the present study the results for nine of the 10 isolates of Citrobacterfreundii
suggested chromosomal AmpC (3-lactamase derepression possibly directly related to
SPEAR in four of the isolates. Regarding the other five isolates (isolates 4 and 5
from patient 56 and 118, 119 and 122 from patient 87) the resistant isolates were
first grown from samples taken on the respective patients' first days in ITU and were
therefore unlikely to be related to SPEAR. The resistance of isolate 9 to piperacillin
and the third-generation cephalosporins, the high pi (8.3) of the enzyme and the "not
determinable" result in the Etest for ESBL production allowed for the interpretation
of chromosomal AmpC 6-lactamase derepression, but the isolate's sensitivity to
cefoxitin, carbenicillin, ticarcillin, ticarcillin/clavulanic acid, piperacillin/tazobactam
and aztreonam was at variance with this theory.
4.7.3 Enterobacter species
In the present study the pis of the B-lactamases obtained from the Enterobacter
isolates ranged from 4.9 to 8.8. Matthew and Harris [157] reported a pi range
between 7.4 and 7.6 for chromosomally-mediated B-lactamases ofEnterobacter
cloacae. Different types of chromosomal B-lactamases have been described in
Enterobacter species. They have been designated type A, pi 8.8 and type B, pi 7.8
[256] and type B pi 7.9 [257], Other pi values of 8.25 [258], 8.2 [259], 8.4 [260]
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and 8.3 [261] have been published reflecting differences of methodology according
to Then and colleagues [257]. Other enzymes with pis of 6.9 and > 9.0 have been
recorded [259]. Enterobacter species have inducible B-lactamases and strains of
Enterobacter species with derepressed chromosomal B-lactamases show reduced
sensitivity to all B-lactams except carbapenems [170], mecillinam [262,263] and
temocillin [243]. Usually the B-lactamase inhibitors clavulanic acid, sulbactam and
tazobactam do not have sufficient inhibitory activity to potentiate their partner
penicillins against derepressed organisms.
Enterobacter species may also harbour plasmid-mediated 6-lactamases. The
widespread TEM-1, TEM-2 and SHV-1 plasmid-mediated enzymes attack narrow-
spectrum cephalosporins, cefoperazone and cefamandole and all the anti-Gram-
negative penicillins except temocillin. Aminothiazolyl cephalosporins (cefotaxime,
ceftazidime, ceftriaxone), cephamycins, monobactams and carbapenems are
considerably more stable. However much more worryingly they may harbour
ESBLs.
Isoelectric points for TEM enzymes including the parental enzymes TEM-1 and
TEM-2 and the TEM-derived ESBLs, range from 5.2-6.5 [169] and pis for the SHV
enzymes including the parental SHV-1 enzyme and the SHV-derived ESBLs range
from 7.0-8.2 [169]. The TEM- and SHV-derived ESBLs all have the ability to
attack most of the B-lactams including the extended-spectrum cephalosporins and
aztreonam. The carbapenems and cephamycins such as cefoxitin are stable and the
enzymes are inhibited by clavulanic acid.
Therefore an additional difficulty in the identification of Enterobacter B-
lactamases in the present study, especially as most of the isolates contained
plasmids, was the possibility of the coexistence of plasmid-mediated enzymes with a
derepressed AmpC enzyme. A TEM-1, TEM-2 or SHV-1 enzyme would not confer
resistance to cefoxitin or to the extended-spectrum cephalosporins or to aztreonam;
an ESBL on its own would not confer resistance to cefoxitin and would be likely to
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be detected in the Etest for ESBL production, but the effect on the antibiogram of
either or both of these would be masked by that of a derepressed chromosomal
ArnpC enzyme. The production of ESBLs in Enterobacter species has been
identified and is capable of producing clinically relevant resistance
[23,190,264,265],
Cefoxitin sensitivity and inhibition by clavulanic acid are properties used to help
identify ESBLs. However if an ESBL were produced by an isolate which also had
chromosomal 13-lactamase derepression neither cefoxitin testing nor the Etest for
ESBL production would be discriminatory. Although ESBLs are found most
commonly in klebsiellae and next in Escherichia coli they occur also in other
enterobacteria including Enterobacter species [23,190,264-266]. Kitzis and
colleagues [264] ascribed the high cefoxitin MICs of their ESBL-producing
Enterobacter, Citrobacter and Serratia species to cephalosporinase induction, not
derepression. De Champs and colleagues [23] commented that the frequency of
ESBL production in Enterobacter aerogenes strains in their study was probably
underestimated because detection of the synergy between cephalosporins and
clavulanic acid might have been hidden by production of the cephalosporinase.
D'Agata and colleagues [266] reported a range of cefoxitin MICs from equal to or
less than 2 mg/L to equal to or greater than 32 mg/L for their ESBL-producing
strains which included Enterobacter and Citrobacter species. The authors
commented that the differences in cefoxitin MICs probably reflected porin changes
associated with resistance, as described by Pangon and colleagues [267] in an
ESBL-producing strain ofKlebsiella pneumoniae.
Isolates 43 and 47 had multiple B-lactamase bands with pis ranging from 5.6-8.8.
The isolates each had one similar band ofpi 8.8 which most likely denoted a
chromosomally-mediated enzyme but the pis of the other bands were different in
each isolate. The isolates had different plasmid profiles and were not obviously
epidemiologically related. The fact that cefotaxime resistance was not transferred
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and the antimicrobial susceptibility pattern suggested chromosomal 13-lactamase
derepression as a cause of cefotaxime resistance. However with such a range of 13-
lactamases similar arguments pertain here as above regarding the possible presence
ofTEM or SHV enzymes.
Another five isolates ofEnterobacter species (77, 79, 81, 116 and 121) had an
unusual but similar antibiogram. Their ceftazidime MICs were 2, 2, 3, 3 and 4 mg/L
respectively and they were sensitive to aztreonam and piperacillin, but resistant to
cefoxitin, cefotaxime and gentamicin. The reason for this pattern of resistance was
not clear. Possibly it reflected changes in outer membrane permeability [261,268]
along with chromosomal 13-lactamase derepression and/or ESBL production. Isolates
77, 79 and 81 were from the same patient (patient 62) as isolates 78 and 80 which
were much more resistant to ceftazidime (MICs > 32 mg/L) and resistant to
aztreonam and piperacillin as well as cefoxitin, cefotaxime and gentamicin. ESBL
production was not determinable by Etest in any of the isolates. All had large
plasmids but cefotaxime resistance was not transferred. Isolates 77-81 had a 13-
lactamase ofpi 7.6 and isolates 78-81 also had a 13-lactamase ofpi 8.0. Isolates 116
and 121 from two other patients (patients 61 and 67) had J3-lactamase bands ofpi
7.9. There was no obvious clinical or epidemiological connection between patient 62
from whom isolates 77-81 were grown and the two other patients. Isolates 77-81
were obtained from samples taken from patient 62 on her first and second days in
ITU. Isolates 77 and 78 showing both patterns of resistance (isolate 77 being more
sensitive to ceftazidime and isolate 78 being much more resistant) were both isolated
on the patient's first day in ITU, which would argue against the implication of
SPEAR in their resistance (antibiotic therapy prior to admission to the ITU was not
recorded), whereas isolates 116 and 121 were obtained from samples taken from
patients 61 and 67 on their fourth and fifth days respectively in the ITU. There were
some similarities also between these isolates and a strain of Enterobacter aerogenes
from a patient described by Mellencamp and colleagues [269]. This strain had an
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unusual susceptibility profile in that it was resistant to ceftazidime but susceptible to
other third-generation cephalosporins and piperacillin in routine disk diffusion tests.
During therapy with piperacillin and amikacin the strain developed resistance to
multiple 13-lactam antibiotics in association with the loss of an outer membrane
protein. According to Sanders [270] hyperproduction ofAmpC B-lactamase in this
strain was not sufficient to confer resistance to multiple B-lactam agents until
coupled with a decrease in permeability. In the present study the resistance to
cefotaxime along with relative sensitivity to ceftazidime in isolates 77, 79, 81, 116
and 121 would seem more difficult to explain by limited chromosomal AmpC 13-
lactamase hyperproduction. As the diffusion rate of ceftazidime through the outer
membrane into the periplasm is slower than that of cefotaxime [92] a greater relative
increase in ceftazidime rather than cefotaxime resistance might be expected.
However the diffusion studies of Yoshimura and Nikaido [92] were performed in
Escherichia coli K-12 and may not pertain to clinical isolates ofEnterobacter
species. In 1979 Preheim and colleagues [271] reported the emergence of a type of
resistance in two patients during therapy with moxalactam that also conferred cross-
resistance to the aminoglycosides. In 1985 Sanders and Sanders [268] commented
that this type of cross-resistance between 13-lactams and aminoglycosides was
important but distinct from that associated with 13-lactamase induction and
derepression, was not associated with drug-inactivating enzymes and appeared to be
caused by changes in outer membrane permeability. The latter explanation might be
applicable to isolates 134, 135, 141 and 142 which were resistant to gentamicin and
all the J3-lactams (including ceftazidime) other than the carbapenems and
mecillinam. Their resistance may however be the result of a combination of
chromosomal AmpC 13-lactamase derepression and outer membrane permeability
changes.
Chow and colleagues [17] observed that in 40 case reports from various authors,
the duration of third-generation cephalosporin therapy before Enterobacter species
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resistant due to increased 13-lactamase production emerged at clinically infected
sites, ranged from 1 to 20 days. In the present study, samples taken on the patient's
first day in ITU were taken within four hours of the patient's admission to ITU and
before SPEAR had been started.
Multiresistance which includes resistance to extended-spectrum cephalosporins
and aminoglycosides also raises suspicion of the presence ofESBLs [265] in those
isolates with G-lactamases of appropriate pi values. As reported by Philippon and
colleagues [265] the TEM- and SHV- derived ESBLs are encoded by
multiresistance plasmids which are usually readily transmissible and which may
carry resistance to aminoglycosides. Outbreaks of infection caused by ESBL-
mediated resistant Enterobacter species have been noted predominantly in France.
Of the three most common ESBLs, CTX-1 (TEM-3), CAZ-5 (SHV-4) and CAZ-6
(TEM-24), detected in the Enterobacteriaceae between 1988 and 1989 in one
French hospital, 20% of the CTX-1 and 83% of the CAZ-6-producing isolates were
Enterobacter species [23,190,264,265]. These enzymes effectively hydrolyzed all 13-
lactams with the exception of the cephamycins and imipenem. Therefore acquisition
ofplasmid-encoded enzymes by Enterobacter species is possible [18].
In the present study an argument against ESBL production in these Enterobacter
isolates was the fact that cefotaxime resistance was not transferred from any of the
Enterobacter isolates to the recipient Escherichia coli. However in a study ofTEM-
10, TEM-12 and TEM-26, only 25 of 80 isolates transferred these 13-lactamase genes
by conjugation [239], Also Piddock and colleagues [272] in their UK survey of the
occurrence ofESBLs observed that it was exceptionally difficult to transfer the gene
encoding cephalosporin resistance to a new host and suggested that these genes
moved on to replicons which were incapable of easy conjugal transfer, but could
continue to move rapidly among bacterial species and strains leading to very
complicated epidemiological situations [272].
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In summary twenty-three Enterobacter isolates with resistance to cefotaxime
possibly directly related to SPEAR were isolated from twelve patients.
Chromosomal AmpC derepression was likely in twenty-one isolates (39, 40, 43, 50,
51, 61, 62, 64, 65, 66, 92, 94, 126, 134, 135, 141, 142, 149, 150, 161 and 199) from
seven patients. There was the possibility of coexisting plasmid-mediated 13-
lactamase production in four isolates (43, 92, 94, and 126) from another three
patients because of the pi values and plasmid profiles, although cefotaxime
resistance was not transferred. It was difficult to explain satisfactorily the
antibiogram of isolates 116 and 121 from patients 61 and 67.
It is unlikely that the reduced susceptibility to cefotaxime of the other twenty-
eight Enterobacter isolates obtained from another thirteen patients was directly
related to SPEAR. Fourteen of these isolates were grown from samples taken on the
first day of admission to the ITU and the others from samples taken on subsequent
days. In eight cases where more than one isolate was obtained from the same patient
the isolates appeared similar according to plasmid and 13-lactamase profiles and
antibiograms. The inference from the available data was that chromosomal AmpC
derepression was the most likely cause of the reduced susceptibility to cefotaxime
except for isolates 77, 79, 81 (patient 62), 47 (patient 75), 116 (patient 61) and 121
(patient 67).
4.7.4 Escherichia coli
Isolate 76 had a cefotaxime MIC of 4 mg/L but was sensitive to ceftazidime and
cefoxitin. Cefotaxime resistance was not transferred and the isolate was negative in
the Etest for ESBL production. Other than temocillin it was resistant to all the
penicillins and the inhibitor combinations, amoxycillin/clavulanic acid,
ticarcillin/clavulanic acid and piperacillin/tazobactam. It had B-lactamases of pis 5.4
and 7.4 the latter aligning with OXA-1 on the isoelectric-focusing gel. Escherichia
coli isolates usually have only insignificant levels of uninducible AmpC enzymes
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[172,173] and resistance to B-lactams, unless due to impermeability or failure to
bind to PBPs, is most often caused by acquisition of secondary B-lactamases
[240,273]. It is possible that isolate 76 had an inhibitor-resistant TEM mutant
enzyme along with an OXA-type enzyme. The classical TEM-1 and TEM-2 G-
lactamases segregate mutants which are resistant to G-lactamase inhibitors and ten
variants have been described [274-277]. Resistance to inhibitor combinations is
often caused by high-level production of classical TEM-1 enzymes themselves
[278,279] and such resistance is commoner with clavulanic acid than with
tazobactam combinations. Neither the classical TEM nor the inhibitor-resistant
mutant TEM enzymes should compromise cefotaxime sensitivity. The OXA-1
enzyme has been said to hydrolyze cefotaxime at a significant rate [280] although in
his review in 1995 Livermore [170] stated that extended-spectrum cephalosporins
were spared by OXA-1 G-lactamase. The OXA- enzymes 4-7 have been reported to
be active against cefotaxime [98]. By disk diffusion testing isolate 76 was totally
resistant to mecillinam which binds exclusively to PBP-2.
Isoelectric points for chromosomally-mediated G-lactamases of Escherichia coli
have been recorded as 8.6 [157], 8.3 and 8.1 [155], 9.2 [167], 8.5, 8.7 and 8.8 [169],
Isolate 200 more closely resembled those occasional isolates ofEscherichia coli
which do produce copious amounts of the chromosomally-mediated AmpC enzyme
and are more resistant to antibiotics [172]. Such isolates show reduced susceptibility
to all B-lactams except carbapenems, temocillin and mecillinam [170], Isolate 200
was resistant also to temocillin. According to Livermore [170] AmpC
hyperproducers account for less than 2% of all Escherichia coli isolates in most
surveys. Such mutant isolates of Escherichia coli resemble derepressed Enterobacter
species in phenotype but not in genetic organization and their G-lactam MICs are
usually lower than those of G-lactamase derepressed Enterobacter species. The
reason for their rarity is the fact that AmpC hyperproduction in Escherichia coli
requires two separate mutations [281] and the selection of such mutants during
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therapy has not been described [241]. One B-lactamase band of pi 8.5 was detected
in isolate 200, cefotaxime resistance was not transferred and the isolate was negative
in the Etest for ESBL production.
4.7.5 Flavobacterium odoratum
Flavobacterium species are found in the hospital environment and are commonly
resistant to many antimicrobial agents including cefotaxime, aztreonam, the
carbapenems and gentamicin. It was therefore no surprise that isolates 89 and 90
were resistant to most of the antibiotics tested. A chromosomal class B (zinc) B-
lactamase ofpi 5.8, active against carbapenems as well as penicillins and
cephalosporins and resistant to clavulanic acid, has been reported in Flavobacterium
odoratum [282]. In this study a B-lactamase band of pi 7.8 of unknown identity was
detected in isolate 89, but not in isolate 90 from the same patient (patient 73).
Plasmids were not detected in either isolate, cefotaxime resistance was not
transferred and ESBL production was not determinable by Etest.
4.7.6 Hafnia alvei
A pi of 7.1 has been published for the chromosomal B-lactamase of a strain of
Hafnia alvei 1094E [155,157] but the genus Hafnia is not mentioned in some more
recent classifications and reviews [167,169,170]. Piddock and colleagues [272]
described an enzyme ofpi 7.9 in three of seven strains ofHafnia alvei resistant to
cefotaxime and ceftazidime and inferred that this enzyme might be chromosomal in
view of negative polymerase chain reaction results with SHV primers. Two of these
strains also had enzymes with pis > 8 [272].
As cefotaxime resistance was not transferred in the present study and ESBL
production was not determinable by Etest in the four Hafhia isolates it is possible
that the enzyme ofpi 7.8 in all four isolates was chromosomal and that
hyperproduction caused resistance to the third-generation cephalosporins. The
cefoxitin sensitivity of the isolates is an argument against this theory, although
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cefoxitin has been reported to be almost stable to the B-lactamases of some inducible
species, namely Serratia, Providencia and Morganella [170]. Isolate 75 from patient
86 had another enzyme of pi 7.4 which was possibly an SHV-type or OXA-type 13-
lactamase. The patient's therapy prior to ITU admission was not recorded but the
isolate was obtained from a sample taken on his first day in ITU and was therefore
unlikely to be related to SPEAR. Isolates 167, 168 and 169 were obtained from a
different patient (patient 43) on her first and second days in ITU and were therefore
also unlikely to be related to SPEAR. This patient had received only a first-
generation cephalosporin prior to her ITU admission.
4.7.7 Klebsiella pneumoniae and ESBLs
The cefotaxime MICs for isolates 133 and 140 were 0.06 mg/L and 0.25 mg/L
respectively but their ceftazidime MICs were 8 mg/L and >32 mg/L respectively.
Both isolates were positive in the Etest for ESBL production. Ceftazidime resistance
was transferable from both isolates to the recipient organism Escherichia coli 362-2
and associated with this resistance a 13-lactamase of calculated pi 5.2 (although it
aligned with the control TEM-1 J3-lactamase of known pi 5.4) was detected in the
transconjugants from both isolates in addition to the 13-lactamase ofpi 8.4 which
was already present in the recipient organism. Transfer of a large plasmid, perhaps
two large plasmids, was demonstrated in the transconjugants from isolate 140, but
plasmids were not detected in transconjugants from isolate 133. The genetics may be
complex [239] but it is very likely that isolates 133 and 140 harboured one or more
TEM-derived ESBLs. Although synergy was demonstrated between disks of
amoxycillin/clavulanic acid and ceftazidime, the donor isolates 133 and 140 showed
reduced sensitivity to amoxycillin/clavulanic acid by disk diffusion testing. This
might seem unusual as TEM- and SHV-derived 13-lactamases are said to be inhibited
well by clavulanic acid [169]. In their review Philippon and colleagues [265] stated
that ESBLs remained susceptible to 13-lactamase inhibitors, although they pointed
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out that the effect of the inhibitor might be reduced in a strain which made TEM-1
as well as an ESBL [264], However since then it has been reported that MICs of
clavulanic acid combinations for ESBL-producers are often high [190,283]. The
transconjugants obtained from isolates 133 and 140 in the present study were both
borderline sensitive to amoxycillin/clavulanic acid (i.e. more sensitive than the
donor strains) by disk diffusion testing.
Most ESBLs are mutants of TEM-1, TEM-2 and SHV-1 enzymes and over 25
different variants have been claimed and are numbered TEM-3 to TEM-27 and
SHV-2 to SHV-7. The earliest documented ESBL-producing isolate in the world is
now recognized to be that recovered in Liverpool in 1982 [284]. Extended-spectrum
B-lactamases have been responsible for a number of incidents where bacteria
resistant to third-generation cephalosporins have caused therapeutic problems in
hospitals around the world [170,190,285].
It is probable that the widespread use of third-generation cephalosporins has
provided selective pressure promoting emergence of this type of resistance [265].
Payne and Amyes [285] suggested that the degree of control in the use of later
generation cephalosporins would probably determine whether ESBLs remained a
minor inconvenience or emerged as a major threat. However there are studies in
which prior exposure to third-generation cephalosporins was found not to be a risk
factor for colonization by ESBL-producers [266,286]. There is also evidence that
carriage ofAGNB that express resistance to third-generation cephalosporins is far
more common than infection caused by such bacteria, suggesting that the evolution
of resistance to third-generation cephalosporins may be largely cryptic [239]. Patient
81 in the present study from whom isolates 133 and 140 were grown was an
oncology patient who had been treated with ceftazidime and tobramycin for a
number of days prior to her ITU admission. This therapy, along with the SDD
component of SPEAR, was continued during her stay in ITU. Tobramycin was also
a component of SDD. The organisms were isolated from samples taken on days six
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and eleven in ITU. It is possible that the ceftazidime and tobramycin instituted in the
oncology ward, along with the general selection pressures prevalent in the ITU as
well as the specific selection pressures of SDD all contributed to her ESBL carriage.
Typically ESBLs are recognised by the unusual antibiotic resistance they provide
in their hosts, conferring the ability to attack extended-spectrum cephalosporins and
monobactams as well as narrow-spectrum cephalosporins and anti-Gram-negative
penicillins, but in some isolates an intermediate or even susceptible phenotype can
result [265]. The enzymes vary considerably in the level of resistance conferred to
cefotaxime, ceftazidime and aztreonam. Some enzymes do not increase the
cefotaxime MIC at all with a conventional bacterial inoculum [190]. Recognizing
that a classification scheme for ESBLs based entirely on structure was unhelpful,
Payne and Amyes [285] proposed a categorization scheme by which TEM- and
SHV- derived ESBLs were assigned to Groups 1 to 4 according to their relative
efficiencies of hydrolysis of cefotaxime and ceftazidime. In 1995 Du Bois and
colleagues [287] proposed an additional group (Group 0) to accommodate enzymes
with activities almost indistinguishable from TEM-1 or TEM-2. One of the most
important problems in the detection of ESBLs in clinical strains is the possibility of
a low expression of the enzyme [288] which may occur even in different isolates of
the same epidemic strain and may not be differentiated easily from susceptible
strains by disk diffusion testing [288]. In this study isolate 133 appeared sensitive to
ceftazidime by disk diffusion testing. As described by DAgata and colleagues [266]
not all ESBL producers appear resistant to all cephalosporin and penicillin
antibiotics even when MICs are performed. Yet while ESBL-producers may fail to
reach the pharmacological breakpoints for resistance favoured by the NCCLS [194]
they may have biological resistance that will cause treatment failure with
significantly increased mortality [287,289,290].
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4.7.8 Morganella morganii
It was impossible to predict enzyme identity in this B-lactamase inducible species
from the antibiograms and range of pi values obtained. Matthew and Harris [157]
reported a pi value of 7.3 for a chromosomal B-lactamase of a strain ofMorganella
morganii and pis of 8.7 and 7.2 have been recorded for the chromosomal enzymes
of two other strains [169]. According to work reviewed by Livermore [170] the
levels ofAmpC B-lactamase in Morganella strains are in general about tenfold
below those in derepressed Enterobacter species and Citrobacterfreundii.
Apparently cefoxitin is almost stable to the Morganella enzyme and is moderately
active against both B-lactamase-inducible and -derepressed strains, whereas it is
inactive against both inducible and derepressed strains of Enterobacter species and
Citrobacterfreundii. All isolates other than 23, 57 and 58 in this study were
sensitive to cefoxitin by disk diffusion testing. Isolates 23 and 57 showed no zones
of inhibition to cefoxitin and isolate 58 gave only a small zone. According to Akova
and colleagues [291] tazobactam inhibits the Morganella morganii AmpC B-
lactamase sufficiently to potentiate piperacillin against derepressed strains whereas it
has little effect against the AmpC enzymes ofEnterobacter species and Citrobacter
freundii. In the present study all isolates other than 23, 57 and 58 were fully
sensitive to piperacillin/tazobactam by disk diffusion testing. Isolates 10, 58, 113
and 157 gave large zones of inhibition with carbenicillin by disk diffusion testing
although isolates 10 and 113 were resistant to piperacillin and isolate 157 showed
reduced susceptibility. Cefotaxime resistance was not transferred and ESBL
production was not determinable by Etest in all isolates. It was tempting to infer that
resistance to cefotaxime and ceftazidime was caused by AmpC derepression but
difficult to explain the apparent carbenicillin sensitivity of five isolates.
Cefotaxime resistance was possibly directly related to SPEAR in four isolates of
Morganella morganii, 57 and 58 (patient 42), 113 (patient 68) and 157 (patient 21)
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but unlikely to be so in isolate 16 which was obtained from patient 33 on his first
day in the ITU. It was difficult to know what was happening with isolates 23, 24 and
25 grown from samples taken from patient 82 on her first, third and first day of
readmission to the ITU respectively. Isolates 23 and 24 had identical plasmid
profiles while isolate 25 differed slightly but had been examined on a different gel.
Isolates 23 and 25 each had two enzymes of pis 6.5 and 7.8 and isolate 24 had one
enzyme ofpi 7.8. In general isolate 23 was much more resistant than isolates 24 and
25.
4.7.9 Pseudomonas aeruginosa
It was no surprise that many isolates ofPseudomonas aeruginosa in the present
study showed reduced sensitivity or resistance to cefotaxime which is not used
clinically as an anti-pseudomonal agent. According to reports cited by Kucers and
colleagues [254 {p321}] most strains are moderately resistant (MICs 16-32 mg/L).
Some studies have found approximately 20% to be highly resistant (MICs 64 mg/L
or higher) while others have noted the majority of strains to be highly resistant.
Some strains may have intrinsic resistance to cefotaxime in the form of low outer
membrane permeability [292]. Most strains are susceptible to ureido- and
carboxypenicillins, ceftazidime, aztreonam, imipenem and meropenem. Increased
resistance to cefotaxime and resistance to the other agents can arise by various
mechanisms, including mutational derepression of the AmpC chromosomal 13-
lactamase, acquisition of secondary plasmid- or transposon-mediated J3-lactamases,
reduced permeability, multi-drug efflux or, in the case of imipenem, loss of the D2
porin [293].
Pseudomonas aeruginosa has an inducible AmpC enzyme similar to that of
Enterobacter species. This chromosomal AmpC enzyme is universally present in
Pseudomonas aeruginosa and is normally, without induction, expressed weakly
[293]. As with Enterobacter species ampicillin and narrow-spectrum cephalosporins
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are labile to hydrolysis and induce the enzyme strongly, destroying their own
activity, whereas ureidopenicillins and extended-spectrum cephalosporins are labile
but induce weakly and so are active against inducible strains but not against
derepressed mutants [170]. Carbapenems are strong inducers that are marginally
labile (imipenem) or are effectively stable (meropenem) [170]. Derepression in
Pseudomonas aeruginosa is often only partial, such that the uninduced enzyme level
is higher than is normal for the species but substantial inducibility is retained
[273,294] whereas derepression in Enterobacter species is almost always total [170].
Even a small degree of derepression compromises ureidopenicillins, whereas only
total derepression noticeably compromises carbenicillin [294]. Selection of totally or
partially derepressed mutants can occur during anti-pseudomonal therapy with labile
weak inducers. Extended-spectrum cephalosporins, ureidopenicillins (mezlocillin
and azlocillin) and piperacillin, have been widely reported to select for these
mutants in Pseudomonas aeruginosa infections [14,295].
Isoelectric points for the chromosomally determined AmpC (Sabath and
Abraham's) B-lactamase of Pseudomonas aeruginosa have been reported to range
from 7.4 to 7.9 [296], 7.2 to 8.15 [157] and 7.4-8.8 [294,297],
Plasmid-mediated and other secondary B-lactamases (i.e. enzymes encoded by
chromosomal inserts) have been reported widely in Pseudomonas aeruginosa but
are much rarer than in enterobacteria according to Livermore in his review [170].
Secondary B-lactamases were found in multicentre surveys in the United Kingdom
in 2.5% of 1,866 Pseudomonas aeruginosa isolates collected in 1982 [294] and
0.7% of 1,991 isolates collected in 1993 [293]. It has been suggested that the limited
transmissibility ofmany plasmids into and within Pseudomonas aeruginosa has
acted to restrict the enzyme dissemination [294]. Plasmid-mediated PSE-1, PSE-2,
PSE-3 and PSE-4 enzymes are well known [175,294,298] and numerous OXA types
have been recorded [293,294,298] as have various obscure types such as NPS-1 and
LCR-1 [170]. PSE-1 and PSE-4 enzymes are said to predominate mainly because of
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clonal selection of producers rather than because of plasmid spread [170]. TEM and
SHV types do occur but are rare compared with their predominance in
enterobacteria [170].
In the present study plasmids were detected in only two of forty-nine isolates of
Pseudomonas aeruginosa and in none of the other eight Pseudomonas species. No
enzymes with pis suggestive of PSE-1, 2, 3 or 4 were detected. Isolates 163 and 183
had enzymes of 7.4 as well as 7.9. However the enzymes ofpi 7.4 were unlikely to
be OXA-type enzymes as the isolates showed good zones of inhibition to ticarcillin,
azlocillin and piperacillin. There was no apparent epidemiological or temporal
connection among the 22 isolates which showed reduced sensitivity to carbenicillin
and or ticarcillin. In eleven out of the fifteen patients involved the organism had
been isolated from a sample taken on the first day of admission to the ITU; the
patients had come from a variety ofwards and sometimes different hospitals. From
the other four patients such isolates had been grown from samples taken on days 10,
2, 5 and 3 of their ITU admissions. None of the fifteen patients' stays overlapped.
Carbenicillin is not inactivated by the chromosomally mediated AmpC 6-lactamase
of Pseudomonas aeruginosa isolates. Resistance to carbenicillin in Pseudomonas
aeruginosa may be plasmid-mediated or intrinsic [254 {pi45}]. Intrinsic resistance
may result from an alteration of cell wall permeability or a marked decrease in the
affinity of PBPs. In some strains highly resistant to carbenicillin both of these
mechanisms of intrinsic resistance may be involved together with the production of
plasmid-mediated 13-lactamases. Ticarcillin is consistently at least twice and
sometimes four times as active as carbenicillin against Pseudomonas aeruginosa but
strains of all bacteria including Pseudomonas aeruginosa that have become resistant
to carbenicillin are also ticarcillin-resistant [254 {pl46}].
Twelve isolates of Pseudomonas aeruginosa (17, 19, 20, 27, 42, 48, 49, 103,
117, 151, 171, 182) were resistant to ceftazidime (MIC >32 mg/L). All were non-
determinable in the Etest for ESBL production. In contrast to cefotaxime, a high
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degree of activity against Pseudomonas aeruginosa is one of the most important
properties of ceftazidime and the main mechanism of resistance seems to be an
increased production of chromosomally mediated AmpC B-lactamase [254 {p322}].
Three of the ceftazidime-resistant organisms in this study (isolates 27, 49 and 117)
were resistant also to azlocillin, piperacillin and aztreonam and two (isolates 48 and
103) were resistant to azlocillin and aztreonam. Four had B-lactamases of pi equal to
or greater than 7.9 and in one (isolate 49 from patient 28) B-lactamases were not
detected. Isolate 27 was grown from a sample taken from patient 58 on her eighth
ITU day and isolate 117 from a sample taken from patient 61 on his fifteenth ITU
day. Isolates 48 and 49 were obtained from samples taken from patient 28 on his
eleventh and sixteenth days in ITU. Isolate 103 was grown from a sample taken
from patient 51 on her seventh day in ITU and its antibiogram was quite different
from that of the much more sensitive isolate 98 which was grown from the same
patient on her first day in ITU. It was likely that the resistance pattern of the five
isolates (27, 117, 48, 49, 103) was caused by chromosomal AmpC derepression.
One of these isolates (isolate 48) showed reduced sensitivity and three (isolates 27,
49 and 117) were resistant to carbenicillin by disk diffusion testing. Carbenicillin is
reported to be stable to and a potent inactivator of Sabath and Abraham's B-
lactamase [299] but it can be compromised by total derepression of the enzyme
[294]. It is possible also that porin deficiency could have contributed to the
resistance in these isolates. As the other seven ceftazidime-resistant isolates gave
large zones of inhibition to aztreonam and to piperacillin which is compromised by
even a small degree ofAmpC derepression [294], it is unlikely that their resistance
was caused by AmpC derepression. Another organism (isolate 124) showed reduced
sensitivity to ceftazidime (MIC 12 mg/L) and resistance to aztreonam by disk
diffusion but otherwise was a fairly sensitive strain. It is noteworthy that seven of
the 12 ceftazidime-resistant (MIC >32 mg/L) isolates were sensitive by disk
diffusion testing: five of the seven had inhibition zones of 30 mm diameter i.e. 12
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mm greater than the minimum interpreted as sensitive (18 mm) by NCCLS criteria
(Table 2). Occasional misleading results of disk susceptibility tests have been found
in other studies with other third generation cephalosporins: moxalactam [300] and
cefoperazone [301],
Isolate 56 was resistant to imipenem and to meropenem. In a study of resistance
mechanisms in Pseudomonas aeruginosa reported in 1995 [293] it was found that
resistance to imipenem was largely dissociated from that to other B-lactam agents
and probably reflected loss ofD2 porin, whereas resistance to meropenem was
mostly associated with intrinsic resistance to penicillins and cephalosporins.
Thirty-seven of the isolates were negative in the Etest for ESBL production but
twelve were not determinable. Five of the latter (isolates 19, 20, 27, 117 and 182)
had J3-lactamases with pis between 7.6 and 8.2 and theoretically might have
produced an SHV-type ESBL although cefotaxime resistance was not transferred
from any of the Pseudomonas isolates and two small plasmids (c. 7 kb and 40 kb)
were detected in isolate 117 only. The production ofESBLs would have been
unlikely in isolates 19, 20 and 182 as they gave large zones of inhibition with
azlocillin, piperacillin and aztreonam disks. In keeping with chromosomal AmpC
derepression, resistance to ticarcillin and piperacillin was not inhibited even to a
small extent by clavulanic acid or tazobactam in isolates 27 and 117.
As twenty-three of the forty-nine Pseudomonas isolates were grown from
samples taken from patients on their first day in ITU, resistance to cefotaxime was
unlikely to be related to SPEAR. At worst the general selection pressures created by
SPEAR may have contributed indirectly to the isolation of the other twenty-six
pseudomonads, only five of which probably had derepression of their chromosomal
AmpC 13-lactamases directly related to the use of cefotaxime in SPEAR.
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4.7.10 Stenotrophomonas maltophilia
Stenotrophomonas maltophilia has become a focus of interest because of the
increasing frequency of its isolation and its broad-spectrum antimicrobial resistance.
Severe infections may be caused by this organism in seriously ill or
immunocompromised patients. Susceptibility tests for these organisms vary
enormously with the test medium and method used [302,303]. All isolates in the
present study were tested at the same time, using the same methods and the same
batches of media. Few antimicrobial agents are effective against this opportunistic
pathogen which is notorious for its resistance to B-lactam antibiotics, including
carbapenems. It has been suggested that low outer-membrane permeability and
production of two chromosomally-mediated inducible B-lactamases, L-1 and L-2,
contribute to this resistance [304]. L-l is a class B zinc enzyme, broadly active
against penicillins, carbapenems and many cephalosporins but not against
aztreonam. L-2 is an unusual cephalosporinase which can hydrolyze those
cephalosporins and monobactams that escape L-l [305]. Cefotaxime is a potent
inducer of these B-lactamases [305] and because of the high level of hydrolytic
activity ofL-l for cefotaxime [306], this compound is inactivated quickly by
induced enzyme and overproduction of enzyme does not further increase the high
resistance of inducible strains. Therefore cefotaxime does not exert a selection
pressure for such strains. This contrasts with the behaviour seen with the inducible
chromosomal AmpC B-lactamases typical of Pseudomonas aeruginosa and some
enterobacteria [14]. The pis of the chromosomally-mediated B-lactamases L-l and
L-2 have been recorded respectively as 6.9 and 9.2 [168], 6.5 and 8.5 [304] and 6.9
and 8.4 [169].
Isolates 28-32 in the present study were from the same patient (patient 36) and a
B-lactamase ofpi 6.1 was detected in all five isolates on two different isoelectric
focusing gels. What did this B-lactamase band ofpi 6.1 represent? Isolates 28 and 29
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were grown from samples taken on the patient's first day of admission to ITU (and
therefore unlikely to be related to SPEAR), isolate 30 on the third day and isolates
31 and 32 on her sixth and eighth days respectively. Isolate 45 was grown three
months later from a sample taken from another patient (patient 95) on his second
day in ITU and isolate 99 was grown seven months after that from yet another
patient (patient 51) on her second day in ITU but not on subsequent days. B-
Lactamase bands were not detected in isolates 45 and 99. Plasmids were not
detected in any of the isolates, cefotaxime resistance was not transferred and ESBL
production was not determinable by the Etest. The antibiograms of all seven isolates
were in keeping with combined L-l and L-2 production, even showing sensitivity to
ticarcillin/clavulanic acid by disk diffusion testing. Apparently ticarcillin is only a
weak substrate for, or is stable to, the L-l B-lactamase and clavulanic acid protects
ticarcillin against the L-2 enzyme [303], However it has been shown that even
laboratory mutants lacking both L-l and L-2 enzymes remain resistant to many B-
lactams at breakpoint [304], Perhaps, at worst, the selection pressures of SPEAR in
general, but not specifically the cefotaxime component, contributed to the isolation
of five Stenotrophomonas maltophilia isolates from three patients who were not
temporally or epidemiologically related.
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Chapter 5 Conclusions and Recommendations
During the course of two years and ten months 173 isolates ofAGNB from the
surveillance flora of 92 patients, 26 medical and 66 surgical in a general
medical/surgical ITU, were found to be resistant or to show reduced sensitivity to
cefotaxime. Another two isolates from one of these patients did not show
pharmacological resistance to cefotaxime but they produced ESBLs which caused
resistance to multiple B-lactams and would have compromised the in vivo
effectiveness of cefotaxime.
5.1 Percentage of patients carrying cefotaxime-resistant AGNB
As 969 patients were treated in the ITU during the time that the isolates were
being collected, 9% (92 of 969) of patients carried AGNB which had reduced
susceptibility or resistance to cefotaxime. This represented a substantial pool of
resistant organisms with the potential for dissemination.
5.2 Cefotaxime resistance unlikely to be related to SPEAR
In 30 of the 92 patients carrying such AGNB, the organisms were grown only
from surveillance flora sampled on the patients' first day in ITU. As these samples
were obtained within four hours of admission to ITU and before SPEAR had been
started it was unlikely that the reduced susceptibility to cefotaxime was related to
SPEAR in the isolates from these patients.
5.3 Cefotaxime resistance directly related to SPEAR
In another 38 of the 92 patients who carried AGNB showing reduced
susceptibility or resistance to cefotaxime, the organisms were isolated from samples
taken on the patients' second and subsequent days in ITU, but not on the first. There
was evidence of chromosomal AmpC B-lactamase derepression in the AGNB
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(Citrobacterfreundii four isolates, Enterobacter cloacae 21 isolates, Morganella
morganii two isolates, Pseudomonas aeruginosa three isolates) of 18 of these 38
patients, one of whom (patient 14) had received cefotaxime therapy during the four
days preceding his admission to ITU. Therefore chromosomal AmpC enzyme
derepression directly related to SPEAR was inferred in the AGNB of 17 patients i.e.
1.8% of patients treated in the ITU over two years and 10 months.
5.4 Cefotaxime resistance indirectly related to SPEAR
In the remaining 21 patients of the above group (including the patient from
whom the ESBL-producing AGNB were grown) and in a further 24 patients from
whom AGNB with reduced susceptibility or resistance to cefotaxime were isolated
on their first and subsequent days in ITU, it is likely that the general selection
pressures imposed by SPEAR contributed to their continuing colonization with such
organisms. Therefore in 45 patients the cefotaxime-resistance of their AGNB was
inferred to be indirectly related to SPEAR.
5.5 Chromosomal B-lactamases
There was evidence of chromosomal AmpC B-lactamase derepression in 65 of the
175 SPEAR isolates. It was thought to be directly related to SPEAR in thirty (24%)
of the 124 isolates belonging to the B-lactamase-inducible species (Enterobacter,
Citrobacter, Morganella, Pseudomonas) but there was no evidence of the
emergence of an epidemic strain.
5.6 ESBLs
Strong evidence for ESBL-production was shown in two isolates ofKlebsiella
pneumoniae from one patient only (patient 81), although it was a possibility in two
Acinetobacter isolates from the same patient. However this study highlighted the
difficulties in predicting B-lactamase identity in certain isolates of the B-lactamase-
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inducible species, even with the knowledge of their antibiograms, plasmid profiles
and the pi values of their enzymes. ESBL detection in these organisms poses an
even greater problem than in Klebsiella species and in Escherichia coli. Presently
the only way of conclusively identifying an ESBL is to sequence the appropriate
gene which is usually plasmid-borne. However transposon and chromosomal
integration are thought to be common, with resultant wide dissemination and
stability of resistance even in the absence of selective pressure. ESBL-production
was first detected in the AGNB from patient 81 on her sixth day in the ITU.
Although ceftazidime therapy had been instituted 16 days prior to her admission to
ITU it is probable that ESBL selection was at least indirectly related to SPEAR.
5.7 Practical recommendations for the future
• Microbiological screening must continue
It is essential that microbiological screening of surveillance flora of ITU patients
should continue in order to identify resistance trends and the emergence of epidemic
strains which may herald resistance in clinical isolates. A dedicated ITU bench and
data-base showing results of both screening and clinical samples for all patients each
day 'at a glance' are helpful in expediting this process. All isolates should be
identified to species level and antibiotic susceptibility tests recorded quantitatively
i.e. diameters of zones of inhibition should be measured and recorded. Staffmust be
alert to 'suspicious' patterns of resistance such as combined third-generation
cephalosporin and aminoglycoside resistance and ceftazidime resistance in an
apparently cefotaxime-sensitive isolate. The limitations of pharmacological
breakpoints for resistance used by the NCCLS should be recognized and the concept
of biological resistance understood.
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• Cefotaxime alone should not be used to screen for ESBLs
Isolates should be tested initially for sensitivity to ceftazidime as well as
cefotaxime. Most ESBLs show resistance to ceftazidime but many are apparently
sensitive to cefotaxime as was the case in the present study. If cefotaxime alone is
used many ESBL-producers will be missed. Etests for ESBL production (using both
cefotaxime and ceftazidime ) might then be performed on resistant isolates.
However none of these tests is discriminatory for most ESBL-producing members
of the 13-lactamase-inducible species. Epidemiological vigilance may be the best
practical option for their detection so far.
• Rigorous standards of hand-washing and hygiene are the mainstay of
infection control
That there was no evidence of dissemination of an epidemic strain can largely be
attributed to the high standards of hand-washing and hygiene in this ITU.
• SPEAR should continue
The final conclusion is that SPEAR should continue at this location, but only
within the context of intensive microbiological monitoring and rigorous hygienic
precautions. The guiding principle must always be "primum non nocere" - "first of
all to do no harm". The challenge is to know when harm is being done.
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Postophemicolectomy/transplantnephrectomy




Minimum inhibitory concentration (mg/L)
cefotaxime rifampicin nalidixic acid
2 Acinetobacter calco var anitratus 16 16 16
3 Acinetobacter calco var anitratus 16 31 4
4 Citrobacter freundii 16 31 8
5 Citrobacter freundii 16 62 8
6 Acinetobacter calco var anitratus 8 8 4
7 Enterobacter cloacae >32 31 4
8 Enterobacter cloacae >32 62 8
9 Citrobacter freundii 32 16 8
10 Morganella morganii 16 16 4
13 Acinetobacter calco var anitratus 32 8 16
15 Acinetobacter calco var anitratus >32 16 32
16 Morganella morganii 32 16 4
17 Pseudomonas aeruginosa 32 62 >32
18 Acinetobacter calco var iwoffii 16 4 4
19 Pseudomonas aeruginosa 32 31 >32
20 Pseudomonas aeruginosa 32 31 >32
21 Pseudomonas aeruginosa >32 62 >32
22 Enterobacter cloacae 32 31 8
23 Morganella morganii >32 16 4
24 Morganella morganii 16 16 4
25 Morganella morganii 16 16 4
26 Enterobacter cloacae 32 31 16
27 Pseudomonas aeruginosa >32 31 >32
28 Stenotrophomonas maHophHia >32 16 16
29 Stenotrophomonas maItophilia >32 16 16
30 Stenotrophomonas maItophilia >32 16 16
31 Stenotrophomonas maltophilia >32 16 16
32 Stenotrophomonas maltophilia >32 16 16
33 Enterobacter cloacae 32 31 4
34 Enterobacter cloacae 32 31 4
35 Enterobacter cloacae 32 31 8
36 Enterobacter cloacae >32 31 4
37 Enterobacter cloacae >32 31 8
38 Pseudomonas aeruginosa >32 62 >32
39 Enterobacter cloacae >32 31 4
40 Enterobacter cloacae >32 31 4
41 Pseudomonas aeruginosa 32 62 >32
42 Pseudomonas aeruginosa 32 62 >32
43 Enterobacter cloacae 32 31 4
45 Stenotrophomonas maltophilia >32 16 8
46 Acinetobacter calco var Iwoffii 32 4 8
47 Enterobacter cloacae 32 31 8
48 Pseudomonas aeruginosa >32 62 >32
49 Pseudomonas aeruginosa >32 62 >32
50 Enterobacter cloacae 32 62 8
51 Enterobacter cloacae 32 62 4
52 Enterobacter cloacae >32 31 8
53 Enterobacter cloacae >32 31 8
54 Enterobacter cloacae >32 31 4
55 Pseudomonas aeruginosa >32 62 >32
56 Pseudomonas aeruginosa >32 62 >32
57 Morganella morganii 16 31 4
58 Morganella morganii 8 16 4
59 Pseudomonas aeruginosa >32 62 >32
60 Pseudomonas aeruginosa 32 62 >32
61 Enterobacter cloacae >32 31 8
62 Enterobacter cloacae >32 31 8
63 Pseudomonas aeruginosa >32 31 >32
64 Enterobacter cloacae >32 31 16
65 Enterobacter cloacae >32 31 8
66 Enterobacter cloacae >32 31 8
67 Pseudomonas species 32 8 >32
68 Pseudomonas species 32 8 >32
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Minimum inhibitory concentration (mg/L)
cefotaxime rifampicin nalidixic acid
69 Pseudomonas species 32 8 >32
70 Pseudomonas species 16 8 >32
71 Pseudomonas aeruginosa >32 31 >32
72 Pseudomonas aeruginosa >32 31 >32
73 Pseudomonas aeruginosa >32 31 >32
75 Hafnia alvei 32 62 4
76 Escherichia coli 4 16 4
77 Enterobacter cloacae >32 31 8
78 Enterobacter cloacae >32 31 8
79 Enterobacter cloacae >32 62 8
80 Enterobacter cloacae >32 31 8
81 Enterobacter cloacae >32 31 8
82 Acinetobacter calco var anitratus 8 8 32
83 Pseudomonas aeruginosa >32 62 >32
84 Pseudomonas aeruginosa >32 31 >32
85 Pseudomonas aeruginosa >32 31 >32
86 Acinetobacter calco var anitratus 32 8 16
87 Pseudomonas aeruginosa >32 31 >32
88 Acinetobacter calco var anitratus 16 16 16
89 Flavobacterium odoratum 32 <2 8
90 Flavobacterium odoratum 32 4 8
91 Pseudomonas aeruginosa >32 31 >32
92 Enterobacter cloacae >32 31 4
93 Pseudomonas aeruginosa >32 31 >32
94 Enterobacter cloacae >32 31 8
95 Pseudomonas fluorescens >32 31 >32
96 Acinetobacter calco var anitratus 32 8 16
97 Citrobacter freundii >32 31 8
98 Pseudomonas aeruginosa >32 31 >32
99 Stenotrophomonas maltophilia >32 8 8
100 Enterobacter cloacae >32 31 8
101 Enterobacter cloacae >32 62 8
102 Enterobacter cloacae >32 31 32
103 Pseudomonas aeruginosa >32 31 >32
104 Pseudomonas species >32 62 >32
105 Acinetobacter calco var anitratus 16 31 32
106 Acinetobacter calco var anitratus 16 8 32
107 Acinetobacter calco var anitratus 16 16 16
108 Acinetobacter calco var anitratus 16 16 >32
109 Pseudomonas aeruginosa >32 62 >32
110 Pseudomonas aeruginosa >32 31 >32
111 Acinetobacter calco var anitratus 32 8 16
112 Acinetobacter calco var anitratus 32 8 16
113 Morganella morganii 32 16 32
114 Acinetobacter calco var anitratus 32 62 16
115 Acinetobacter calco var anitratus 16 16 32
116 Enterobacter cloacae >32 62 32
117 Pseudomonas aeruginosa >32 31 >32
118 Citrobacter freundii 32 62 8
119 Citrobacter freundii 32 62 8
120 Acinetobacter calco var anitratus 32 62 16
121 Enterobacter species >32 32 8
122 Citrobacter freundii >32 32 8
123 Acinetobacter calco var Iwoffii 16 8 8
124 Pseudomonas aeruginosa >32 62 >32
125 Pseudomonas aeruginosa >32 32 >32
126 Enterobacter cloacae >32 31 16
127 Acinetobacter calco var anitratus 16 8 16
128 Pseudomonas aeruginosa >32 16 >32
129 Pseudomonas aeruginosa 16 31 >32
130 Acinetobacter calco var anitratus 32 4 16
132 Acinetobacter calco var anitratus 16 8 16
133 Klebsiella pneum pneumoniae <0.5 31 4
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Minimum inhibitory concentration (mg/L)
cefotaxime rifampicin nalidixic acid
134 Enterobacter cloacae >32 31 8
135 Enterobacter species >32 31 8
137 Acinetobacter species 16 8 8
138 Citrobacter freundii 8 8 4
139 Pseudomonas aeruginosa >32 31 >32
140 Klebsiella pneum pneumoniae <0.5 31 4
141 Enterobacter cloacae >32 31 32
142 Enterobacter cloacae >32 31 8
143 Acinetobacter catco var anitratus 8 8 8
144 Pseudomonas aeruginosa >32 31 >32
145 Pseudomonas aeruginosa >32 31 >32
146 Enterobacter cloacae >32 31 >32
147 Enterobacter cloacae >32 31 >32
148 Enterobacter cloacae >32 31 >32
149 Enterobacter cloacae >32 31 4
150 Enterobacter cloacae >32 31 4
151 Pseudomonas aeruginosa >32 31 >32
152 Pseudomonas aeruginosa >32 31 >32
153 Citrobacter freundii 32 62 8
154 Acinetobacter calco var anitratus 16 8 16
157 Morganella morganii 16 16 4
158 Pseudomonas aeruginosa >32 31 >32
160 Pseudomonas aeruginosa >32 31 >32
161 Enterobacter cloacae >32 31 >32
162 Pseudomonas aeruginosa 16 31 >32
163 Pseudomonas aeruginosa >32 31 >32
165 Citrobacter freundii >32 31 16
166 Pseudomonas aeruginosa >32 31 >32
167 Hafnia alvei >32 31 4
168 Hafnia alvei >32 31 4
169 Hafnia alvei 32 62 4
170 Pseudomonas aeruginosa 32 31 >32
171 Pseudomonas aeruginosa >32 31 >32
172 Pseudomonas aeruginosa >32 31 >32
173 Acinetobacter calco var anitratus >32 8 >32
174 Enterobacter cloacae >32 31 16
177 Pseudomonas aeruginosa >32 31 >32
178 Enterobacter cloacae >32 16 16
182 Pseudomonas aeruginosa 32 62 >32
183 Pseudomonas aeruginosa 32 62 >32
184 Enterobacter cloacae >32 16 8
190 Pseudomonas aeruginosa 32 31 >32
191 Acinetobacter calco var anitratus 16 8 16
195 Acinetobacter calco var anitratus 16 8 8
196 Acinetobacter calco var anitratus 16 8 16
197 Enterobacter cloacae >32 31 8
198 Pseudomonas aeruginosa >32 62 >32
199 Enterobacter cloacae >32 62 >32
200 Escherichia coli 32 31 8
201 CT 73 Escherichia coli N/A 8 N/A
202 J62-2 Escherichia coli SA 128 0.125 1000 N/A
203 DH5a Escherichia coli <0.5 N/A >32
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8.9
196
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11.25
7.7
197
Enterobactercl a ae
8.6
198
Pseudomonasaeruginosa
199
Enterobactercl a ae
8.2
200
Escherichiaoli
4.93
11.25
55.45
8.5
K)
U)
